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ABSTRACT 
Polymer micro- and nanofluidic systems, with their critical dimensions, offer a potential to 
outperform conventional analysis techniques and diagnostic methods by enhancing speed, 
accuracy, sensitivity and specificity. In this work, applications of microfluidics have been 
demonstrated to address the existing challenges in stroke diagnosis, by mRNA expression 
profiling from whole blood within <20 min. A brief overview of various biomarkers for stroke 
diagnosis is given in chapter 1 followed by design and testing of individual microfluidic modules 
(chapter 2 and 3) required for the development of POC diagnostic strategy for stroke. We have 
designed and evaluated the performance of polymer microfluidic devices for the isolation of 
leukocyte subsets, known for their differential gene expression in the event of stroke. Target cells 
(T-cells and neutrophils) were selected from with greater purities, from 50 µl whole human 
blood by using affinity based capture in COC devices within a 6.6 min processing time. In 
addition, we have also demonstrated the ability to isolate and purify total RNA by using UV 
activated polycarbonate solid phase extraction platform. 
Polymer-based nanofluidic devices were used to study the effects of surface charge on the 
electrodynamic transport dynamics of target molecules. In this work, we report the fabrication of 
mixed-scale micro- and nanofluidic networks in poly(methylmethacrylate), PMMA, using 
thermal nanoimprint lithography using a resin stamp and surface modification of polymer 
nanoslits and nanochannels for the assessment of the associated electrokinetic parameters – 
surface charge density, zeta potential and electroosmotic flow. This study provided information 
on possible routes that can be adopted to engineer proper wall chemistry of polymer 
nanochannels for the enhancement or reduction of solute/wall interactions in a variety of relevant 
single-molecule studies. 
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CHAPTER 1.BIOMARKERS FOR POINT-OF-CARE DIAGNOSIS OF 
STROKE: A LITERATURE REVIEW 
 
1.1 Stroke Introduction 
Stroke is a major cause of neurological disability and mortality affecting more than 15 
million people worldwide. It is the third leading cause of death in the United States after 
coronary heart disease and all cancers combined. In the United States alone, 795,000 cases are 
reported annually with approximately 75% being classified as incident cases.
1, 2
 It is predicted 
that the mortality rate of stroke will almost double by 2020 simply because, the ageing 
population is more susceptible to stroke.
3
 Mortality due to stroke and their higher incidence may 
be linked to a number of factors which are classified into modifiable and non-modifiable risk 
factors.  Modifiable risk factors include high blood pressure, diabetes mellitus, cardiac diseases 
(such as atrial fibrillation, heart failure), high cholesterols, cigarette smoking, alcohol 
consumption, obesity, sedentary lifestyle, and unhealthy dietary habits which account for 60% of 
all strokes.
4
 The other 40% of stroke cases are mediated by non-modifiable risk factors such as 
age, gender, ethnicity and genetics.  
Strokes are classified as diseases of the brain vasculature that share a clinical syndrome, 
which exhibits the rapid onset of a focal cerebral disturbance. The World Health Organization 
defines clinical stroke syndrome as “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent 
cause other than that of vascular origin.”5 This definition includes stroke both due to infarction 
and hemorrhage. Stroke accounts for 16% of all cardiovascular diseases (see Figure 1.1) and 2-
4% of the healthcare costs worldwide,
6
 and has a devastating impact on public health. Hence, it 
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is imperative to identify early risk factors of stroke to predict the recurrence of the disease and 
for primary prevention. 
 
Figure 1.1 Deaths from cardiovascular diseases, U.S, 2010 (Adapted from National Heart, Lung 
and Blood Institute, Disease Statistics)  
 
1.2 Subtypes of Stroke and Pathophysiology 
Stroke can be broadly classified into two subtypes, ischemic and hemorrhagic (see Figure 
1.2). Both forms of stroke are neurological deficits causing impairment of language, motor 
function, cognition, vision and affect and are caused by interruption of cerebral blood flow 
resulting in a temporary or permanent change in one or more regions of the brain. The functional 
changes associated with or resulting from (termed as pathophysiology) both subtypes are 
different and complex depending on the nature of the lesion (area of damaged brain tissue). 
Therefore, it is crucial to understand the biochemical mechanisms involved, to clearly delineate 
the type, diagnosis, and prognosis of stroke.  
1.2.1 Ischemic Stroke (IS) 
Ischemic stroke accounts for 84% of all strokes.
7
 IS can be further categorized into i) 
intracranial thrombosis (large vessel and small vessel types, see table 1.1) primarily caused by 
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impairment of blood flow to the brain due to blockage of cerebral arteries and ii) extracranial 
embolisms caused due to blockage of blood vessels resulting from a clot (embolus).  
 
Figure 1.2 Subtypes of stroke. (A) Image of brain showing ischemic stroke. Blue area indicates 
deprivation of blood supply and the inset shows blockage of blood vessels due lack of blood flow 
to the affected area. (B) Hemorrhagic stroke showing an area of bleeding (in red). Inset shows 
the leakage of blood caused by rupture of blood vessels. Reproduced with permission from 
(www.alilamedicalmedia.com) 
 
Table 1.1 Etiology of stroke 
 
 
 
 
 
The onset of ischemic stroke initiates a series of neurochemical events, which are referred to as 
an ‘ischemic’ cascade shown in Figure 1.3.  
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Figure 1.3 (A) Summary of neurochemical changes that trigger the initiation of ischemic cascade 
(B) Ischemic penumbra : a brain region of low perfusion in which cells have lost their membrane 
potential terminally (‘core’) is surrounded by an area in which intermediate perfusion prevails 
(‘penumbra’) and cells depolarize intermittently (‘peri-infarct depolarization’). Reproduced with 
permission from reference [8, 9]. 
 
During ischemia, brain damage or neuronal death is caused by the failure of energy 
producing compounds, like adenosine triphosphate (ATP), thereby causing a lack of glucose and 
oxygen to the brain; thus, cellular homeostasis is not supported. The inadequate energy 
production also affects the functioning of the ion gradient by the loss of potassium ions causing 
cytotoxic edema (neuronal swelling). Numerous other complex mechanisms are involved in the 
brain tissue causing ischemic stroke (see Figure 1.3A). They include the release of glutamate and 
aspartate neurotransmitters in the brain, calcium channel dysfunction, and production of reactive 
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oxygen species or oxygen radicals activating proteases and lipases that damage cellular and 
extracellular elements.
9, 10
  All these processes result in either the immediate death of a part of 
the brain parenchyma (core) or partial injury (penumbra) with the potential of recovery with 
therapeutic intervention (see Figure 1.3B). The duration, severity, and location of ischemia are 
the main factors which determine the extent of brain damage.  
1.2.2 Hemorrhagic Stroke (HS) 
Hemorrhagic stroke, which is responsible for about 16% of stroke cases, occurs due to a 
ruptured aneurysm (abnormal bulging on the wall of arteries)  in the brain causing blood leakage 
into the surrounding tissue.
11
 Hemorrhage due to ruptured brain arteries is of two types, 
intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH).
12
 ICH originates from the 
rupture of weakened cerebral vessels; most commonly, small arteries or arterioles causing a 
blood leakage within the parenchymal cerebral space. This forms a localized hematoma (cavity 
filled with blood) building up the pressure. The primary cause of ICH can be attributed to 
hypertension. SAH on the other hand, is triggered by bleeding of the ruptured arteries into the 
subarachnoid space further leaking into cerebral spinal fluid (CSF) blocking its circulation. This 
causes extensive damage to brain cells and therefore, SAH is the most deleterious type of stroke. 
The treatment for this type of stroke usually requires medications, which reverse the bleeding 
that has occurred and might even require surgical drainage in some cases. A report from 
Andersen et al. demonstrated the higher severity of stroke and mortality rates associated with HS 
(49.2%) when compared to IS (25.9%).
13
  
Stroke mimics (SMs) are non-stroke conditions (false positives) that present symptoms 
similar to stroke and therefore, SMs are most often confused with stroke. SMs are defined as 
diseases caused by neurologic symptoms which resemble a stroke, and their frequency varies 
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from 1.2 to 25%
14, 15
 depending on the clinical evaluation. They are reversible with no significant 
brain damage. The most common type of stroke mimics are migraine,
16
 demyelinating disease, 
tumors,
17
 meningitis,
14
 glucose level abnormalities like hypoglycemia, non-cerebrovascular 
diseases such as epilepsy
18
 (caused by focal dysfunction), dementia,
19
 and transient global 
amnesia.
20
 Misdiagnosis of stroke has serious ramifications and therefore SMs must be excluded 
for proper identification of stroke subtype and treatment management. A recent prospective 
study of more than 300 patients with suspected stroke found 31% had SMs at the time of final 
diagnosis.
21
  Libman et al. were able to correctly identify and diagnose stroke in 81% cases, 
finding 19% to be SMs.
22
 The possibility of a stroke in case of SMs are ruled out by 
neuroimaging methods, discussed in the next sections. 
Transient ischemic attacks (TIAs), also known as mini-strokes, are defined as events caused 
by transient interruption of blood flow to a part of brain and can be typically resolved within a 24 
h time window. Unlike an actual stroke event, there is no severe damage to the brain cells in 
TIAs. However, it is likely that the occurrence of stroke is preceded by a TIA, and studies show 
that 35% of TIA patients have a chance of stroke within five years.
23, 24
 Also, the presence of 
TIA conditions leads to recurrent strokes. Therefore, confirming the probability of stroke or TIA 
versus SMs is extremely important. 
1.3 Clinical Diagnosis of Stroke 
The longer the treatment for stroke is delayed, the lesser the benefits from it. Hence, the 
phrase “time is brain.” One of the most critical elements in stroke diagnosis is the time of onset. 
In most cases, the arrival of the patient to the hospital is delayed due to the limited awareness of 
signs and symptoms of the disease. Rapid assessment of patients suspected with stroke is 
therefore highly crucial to accommodate the therapeutic treatment for any subtype of stroke by 
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excluding SMs within a fairly short time window. Incidents of acute myocardial infarction are 
also noticed in some of the stroke patients and as a part of the initial evaluation; 
electrocardiography should be performed in such cases. The major challenges associated with 
stroke diagnosis are the lack of imaging resources, lack of neurologic training in emergency 
clinicians, exclusion of SMs and misdiagnosis, and the limited time window for effective 
treatment. 
1.3.1 Stroke Assessment Scales 
Stroke scales are evaluation tools used to provide quick and quantitative assessments of the 
severity of neurologic deficits including motor, sensory, visual and cognitive impairment, 
functional outcome, global outcome due to stroke condition.
25
 These scales also provide 
prognostic information and serve as a baseline to compare the progress or deterioration. Pre-
hospital stroke scales are therefore critical for early recognition ultimately saving valuable time 
in triage (priority of the treatment based on severity) and treatment of the patient.  
Initial attempts were made to develop a unified scale but due to the complex nature and 
heterogeneity of stroke, separate scales were developed.
26
 Based on the type of information 
collected about the patient, they are divided into the following sub-categories. i) Global outcome 
scales such as the modified rankin scale, and the glasgow outcome scale, which provide a broad 
overview about the neurologic disability ii) Physical deficit scales, such as the National Institutes 
of Health Stroke Scale (NIHSS), which provides information about the deficit with the result 
scores attached to severity based on the neurologic examination iii) Activities of daily living scales, 
such as the barthel index , which measure the functional outcome and recovery useful in studies of 
rehabilitation.
27-30
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Stroke scale chosen must be simple, easily and expeditiously administered, and sensitive to a 
patient’s condition.31 Although currently, existing scales do not satisfy all the criteria, NIHSS is 
considered to be the best scale and is widely used in most stroke studies as it is a highly 
reproducible numeric scale that can be completed within 5-8 minutes. It can be used both by 
neurologists and non-neurologists. Higher scores in this 15-point assessment scale indicates 
greater deficit. Compared to other scales, this scale has proven intrarater and interrater reliability 
and has predictive validity for stroke outcome.
32-34
 
It should be noted that these scales cannot be used in isolation in order to reach a decision 
about the treatment method. The important metrics for the use of these scales in diagnosis are 
validity and reliability. The diagnostic accuracy of most of these scales is about 80%, although 
their sensitivity and specificity differ to some extent. It is important to understand that clinical 
sensitivity and specificity differ from analytical sensitivity and specificity. Clinical sensitivity 
refers to the percentage of people with the disease, identified positive for the disease by a given 
assay whereas clinical specificity provides negative predictive value of the disease as determined 
by the assay.
35
 Majority of these scales are used to measure severity and predict stroke outcome, 
but they are not capable of distinguishing stroke subtypes. They might provide better results 
when used in conjunction with brain imaging or blood biomarkers. 
1.3.2 Neuroimaging Methods 
Neuroimaging has become an invaluable tool for the initial and accurate diagnosis of stroke 
and its subtypes. The advent of various imaging techniques have enabled clinicians to understand 
the cause of the disease (etiology) and functional changes associated with the disease 
(pathophysiology) of stroke and guide future therapy and provide the utmost benefit to the 
patient by confirming the diagnosis. Stroke imaging serves two purposes: first to diagnose or 
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confirm the occurrence of stroke by ruling out SMs and, second, to assess the location and 
amount of potentially salvageable brain tissue and irreversibly infarcted tissue.  
1.3.2.1 Computed Tomography (CT) 
The most commonly used modality for imaging is CT because of its wide availability in most 
clinical settings and quick acquisition times compared to other imaging methods. CT is the 
“criterion standard” for stroke evaluation and the primary diagnostic test to detect ischemic 
lesions and rule out ICH. Types of CT include noncontrast head CT (NCCT), CT angiogram of 
the head and neck (CTA), and perfusion CT (PCT).
36
 NCCT is usually performed to identify 
early signs of stroke and also exclude or confirm hemorrhages. It’s wide availability and the 
speed of image acquisition makes it useful for initial evaluation of suspected stroke patients.
37
 
The limitation of an NCCT scan is that subtle signs due to the disease are missed in the first few 
hours of stroke, resulting in about 40% false negative rates.
38
 The utility of CT for stroke has 
been enhanced by the advent of newer generation CT scanners such as  for CTA and PCT.
39
 
CTA provides information about vessel occlusion such as the site and length of the occlusion, 
and gives a clear picture of cerebral blood vessels.
40
 PCT requires a rapid injection of 
intravenous contrast and repeated imaging of sections of the brain. Based on the total amount and 
speed that blood flows to different vascular territories of the brain this technique can help in the 
assessment of potential areas of salvageable tissue in the ischemic penumbra.
41, 42
 Ezzedine et al. 
demonstrated the improvement of diagnostic accuracy by combining these two neuroimaging 
modalities when compared to the use of NCCT alone.
39
 
However, the limitations of CT are exposure to ionizing radiation, side effects associated 
with the use of intravenous contrast agents, inability of the scanners to image entire brain for 
perfusion imaging as current scanners are limited to 2-4 cm wide area of the brain.
41, 43 
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1.3.2.2 Brain Magnetic Resonance Imaging (MRI) 
MRI is another widely used neuroimaging method for the evaluation of stroke. This method 
is associated with high cost, limited availability, and lengthy image acquisition times, but, 
considered to be extremely sensitive in detecting ischemic lesions. MRI can also detect or 
exclude ICH with  an accuracy comparable to CT.
44
 It has also been shown that the sensitivity of 
MRI is 83% and that of CT is 26% for the diagnosis of any stroke subtype.
45
 Diffusion weighted 
imaging (DWI), perfusion weighted MRI (PWI), magnetic resonance angiography, and fluid 
attenuated inversion recovery, are some of the imaging techniques under the MRI umbrella.
46
  
Images from DWI give information about the onset of ischemia, which may not be 
sometimes seen using NCCT. Once a hemorrhagic stroke has been excluded by CT, DWI 
improves stroke detection from 50% to more than 95%.
47, 48
 PWI helps in the identification of 
hypoperfused regions of the brain by using a contrast agent and like PCT, it can identify the 
ischemic penumbra. Perfusion imaging of the entire brain is one of the main advantages of 
PWI.
48
 DWI/PWI mismatch values detect the tissue subjected to infarction by subtracting the 
volume of tissue restricted to diffusion from DWI and the volume of tissue that is poorly 
perfused from PWI. Information about penumbra from DWI/PWI mismatch helps to identify 
patients in need of tissue plasminogen activator (tPA), a clot buster drug or thrombolytic agent 
(also known IV rt-PA or alteplase, usually given through a catheter inserted into a vein in the 
arm).
49-51
 Despite significant advances in MRI techniques, implementation of MRI becomes 
difficult due to longer scanning times, high costs, non-applicability in patients with 
claustrophobia, and also impracticality in an emergency setting. 
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1.4 Therapeutics for Stroke 
Neurons in the low blood flow area of the penumbra are at a greater risk with elapsing time 
leading to neuronal cell death. This is linked to the short therapeutic time window which refers to 
time between the onset of symptoms and the treatment. For ischemic stroke, one therapeutic 
measure is the restoration of cerebral blood flow to the affected region (reperfusion) to limits the 
neurologic deficit. The most common therapy is thrombolytic therapy, which restores blood flow 
to the damaged ischemic tissue by dissolution of the clot and reduce the neuronal tissue 
damage.
52
 Another approach is neuroprotection, which involves the use of drugs to protect the 
brain against neuronal dysfunction; their efficacy is limited due to the associated side effects, and 
additional trials are still ongoing.
8
 However, the combination of thrombolysis and 
neuroprotectants may offer more advantages in the clinical management of stroke.
53
  
1.4.1 Recombinant Tissue Plasminogen Activator (rt-PA) 
Currently, the only FDA (Food and Drug Administration) approved drug for ischemic stroke 
is recombinant tissue plasminogen activator (rt-PA). It works by attaching to the fibrin in the 
blood clots, and then activates the production of plasmin, which causes the clots to disintegrate. 
This unblocks the blood vessel and restores the blood flow. The findings of a National Institutes 
of Neurological Disorders and Stroke trial have shown a complete neurologic recovery in about 
31 – 50% of patients treated with rt-PA in three months.54 However, rt-PA must be administered 
within a narrow time window of 3-4 h from the onset of stroke symptoms. As large number of 
patients arrive after the currently approved 3 h time window, administering a proper treatment 
remains difficult. Therefore, some studies have been conducted on the expansion of the effective 
therapeutic time window, but the results showed that increasing the time length between 
symptom onset and treatment from 4-6 h made the rt-PA treatment less beneficial compared to 
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treatment within 3 h.
55-57
 Moreover, this thrombolytic therapy (rt-PA) is contraindicated in HS 
patients which might lead to threating outcomes. While the phenomenon about the increased risk 
of hemorrhage with rt-PA administration is yet to be clearly elucidated, a CT scan must be 
performed to check for the possibility of HS before administering rt-PA and patients with the 
risk of HS are excluded. Due to this delay, the treatment can only reach 3-5% of patients with IS 
in the United States.
58,
 
59
 So far, there is no FDA approved treatment for hemorrhagic stroke. 
Other treatment methods for IS include perfusion enhancing approaches such as administration 
of aspirin and heparin,
60
 use of anticoagulants (warfarin), antiplatelet agents, antihypertensive 
agents and telemedicine.
61
  
1.5 Role of Blood Brain Barrier (BBB) in Brain Injury 
Understanding the physiology of the BBB is very crucial in developing an effective 
diagnostic and therapy for several brain diseases, especially stroke. The BBB plays an essential 
role in brain homeostasis. The BBB is a dynamic barrier, which protects the central nervous 
system (CNS) from unwanted and neurotoxic substances circulating in blood and allows for the 
transport and permeability of required nutrients. Any disruption or leakage of this barrier causes 
brain dysfunction and stimulates natural immune or inflammatory responses.
62, 63
 The BBB is 
comprised of endothelial cells forming the capillaries of the brain with tight junctions Fthat 
restrict the movement of molecules into the brain and maintain the cell polarity (which refers to 
diversification of cell shapes through asymmetric cell divisions of stem cells that are crucial 
proper functioning of differentiated cell types
64
).  Other components of the BBB include 
pericytes, astrocytes, and microglia, which support the permeability of this barrier and are 
involved in the immune responses of the central nervous system (see Figure 1.4).
65
 All these 
together form a complex neurovascular unit. The BBB plays a major role in the immune system 
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of the brain and any changes in the brain’s microenvironment caused by diseases like stroke 
generates inflammatory responses due to activation of microglial cells and programmed cell 
death (apoptosis) occurs.
66, 67
  
 
Figure 1.4 Cellular constituents of the blood–brain barrier. The barrier formed by capillary 
endothelial cells, surrounded by basal lamina and astrocytic perivascular endfeet. Astrocytes 
provide the cellular link to the neurons. The figure also shows pericytes and microglial cells 
which form the important components of a neurovascular unit. Reproduced with permission from 
reference [65].  
 
Breakdown of the BBB and damage of endothelial cells following brain injury increases the 
permeability of the barrier and allows for the passage of biomarkers from the neurons and glial 
cells (neuron supporting cells) into peripheral blood.
68
 There is also evidence of leukocyte 
infiltration into circulation in humans 48-72 h after stroke, and it has been hypothesized that the 
accumulation of these leukocytes is the primary cause of tissue damage and prevents blood flow 
after restoration.
69
 Specifically, neutrophil penetration into brain tissue causes significant damage 
due to the release of oxygen free radicals and proteolytic enzymes.
70-73
  Also, certain biomarkers 
like matrix metalloproteinase-9 (MMP-9) are shown to play a biphasic role in stroke by 
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disrupting the blood brain barrier during the initial phases of the stroke event and promote 
vascular growth during recovery phases.
74
  Although the exact mechanisms and roles of different 
cells in stroke is still unclear, better investigation of the BBB would pave the way for novel 
therapeutic approaches.  
1.6 Biomarkers for Stroke 
Biomarkers are measurable indicators of any biological processes that may be used to 
diagnose a disease, monitor its activity, predict its course, or assess response to treatment.
75, 76
 
Cells, genes, hormones, enzymes, or changes in biological function can be considered as 
biomarkers.
77
 Development of a proper diagnostic test for stroke through biomarker 
identification has remained a challenge for a variety of reasons, including the complexity of the 
ischemic cascade and presence of the blood-brain barrier; efforts are ongoing in this field of 
study. As discussed in the previous sections, neuroimaging techniques can be used as initial 
evaluation tools depending on their availability in the clinical setting to identify the type of 
stroke. Reaching a clinical decision may sometimes be limited by the experience of the medical 
staff. An adjunctive test along with the neurological assessment becomes important especially in 
cases where brain imaging appears normal. A rapid diagnostic test will, therefore, be extremely 
helpful for pre-hospital screening, and can guide the intervention of thrombolytic treatment.  
Biomarkers have the potential to provide insight into the mechanisms of brain injury and, 
diagnostic information to improve patient management. They are also useful in the investigation 
of prognosis and response to a therapy. The major challenge associated with finding promising 
biomarkers for stroke diagnosis is due to their prolonged release following the event of stroke 
and their inability to perfuse through the BBB.
78
 To date, no molecular diagnostic test exists for 
stroke and no marker has proven to be clinically sensitive and specific to diagnose either 
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ischemic or hemorrhagic stroke. One should note that analytical sensitivity and specificity are 
distinct from clinical sensitivity and specificity. High analytical sensitivity does not always 
guarantee high clinical sensitivity.
35
 
Clinical sensitivity = 
              
                               
 and provides information on the positivity of 
the disease as determined by the assay. Clinical specificity = 
               
                             
 and 
provides information on the negativity of the disease as determined by the assay. Whereas, 
analytical sensitivity refers to the ability of the assay to detect the lowest possible concentration 
of an analyte in a given sample and analytical specificity is assay’s ability to identify a target 
substance.
35
  
There is no individual clinically useful biomarker for stroke, such as troponin or creatinine 
phosphokinase for the diagnosis of coronary syndrome, B-type/brain natriuretic peptide (BNP) 
for congestive heart failure, or D-dimer (DD) for pulmonary embolism, which have been used in 
point-of-care platforms.
79-81
 Detection of ideal biomarkers in the case of neuronal injury is very 
complex compared to heart diseases, due to the physiological differences between the brain and 
the heart, such as cellular heterogeneity in the brain (multiple cell types and cells with 
differentially localized elements such as axons and cell bodies). Also, the BBB limits the access 
of markers in sufficient quantities to the vasculature, but there is direct vasculature access in 
heart. Furthermore, complex biochemical pathways occurring in the ischemic cascade makes 
biomarker isolation difficult. The validity of clinical judgment is also diminished by SMs . While 
a significant amount of research has yet to be conducted on the benefits of single marker vs. 
multi-marker panels, researchers postulate that multi-marker panel testing would increase 
clinical sensitivity for accurate diagnosis.
82
 
 16 
 
Investigations done by the scientific community suggest that an ideal biomarker or a panel of 
biomarkers should be able to address the following diagnostic questions: (i) Does the patient 
have stroke; (ii) Is it IS or HS; (iii) Is there a need for initiation of thrombolytic treatment with 
the observed symptoms; and (iv) Is there a risk of recurrence? These questions can be addressed 
by finding an ideal biomarker that can be released into blood in a fair amount of time in 
detectable quantities, and the concentration levels should correlate with the volume of infarct. 
Some practical considerations in the choice of these biomarkers include cost, factors that affect 
the measurement, and the ease of obtaining the biomarkers. Ideal properties of biomarkers for 
clinical utility are summarized in the Table 1.2 
Table 1.2 Ideal properties of biologic markers. Adapted from Biomarkers Definitions Working 
Group [Reference 76].  
 
 
1.7 Types of Protein Biomarkers for Stroke 
This section highlights the biomarkers relevant to ischemic stroke. Compared to ischemic 
biomarkers, very little research has been carried out on hemorrhagic biomarkers due to fewer 
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cases of HS. Biomarkers can be classified into several categories: (i) Imaging biomarkers that 
measure the changes in the nervous system through brain imaging; (ii) Molecular biomarkers; 
and (iii) Pharamacodynamic biomarkers, indicative of certain pharmacological responses useful 
in drug development.
83
 Biomarkers based on drug development can be described as diagnostic 
(defining the population within a specific disease) and prognostic (correlated with outcome). The 
subsequent sections will focus mainly on molecular biomarkers in which measurements are made 
on biological fluids like blood, plasma, serum, or CSF. The onset of any brain disease triggers 
the release of several biomarkers into CSF and subsequently into the blood stream. Nevertheless, 
not all the biomarkers released may be specific to stroke.  
 
Figure 1.5 Categorization of potential biomarkers according to their role in ischemic cascade. 
Markers for neuronal injury, lipid peroxidation, inflammation and homeostasis are illustrated. 
Reproduced with permission from reference [84].  
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Advances in proteomics and genomics have helped in the identification the potential 
biomarker candidates. Among several current approaches, proteomics has attracted attention as 
proteins are readily available in most of the body fluids and, studies offer an insight into both the 
structure and function of proteins in relevance to stroke. Protein biomarkers are mostly studied 
due to the better understanding of their relation with pathophysiology of ischemic stroke. Some 
of the biomarkers involved in ischemic injury include those associated with glial activation, 
inflammation, oxidative stress; thrombus formation, neuronal injury, and endothelial dysfunction 
(see Figure 1.5).
85, 86
   
1.7.1 Glial Biomarkers 
During the initial events in the ischemic cascade, glial cells are activated, and inflammation 
is generated in response to ischemia. The most extensively studied markers specific to glial 
function are S100B, glial fibrillary acidic protein (GFAP), and myelin basic protein (MBP). 
S100B is an acidic calcium binding protein in astrocytes and glial cells; increased concentrations 
of S100B stimulate the cytokine production. In ischemic stroke, serum levels of S100B are 
elevated within 12 h from  symptom onset with continuous increase even after three days.
87
 Even 
in primary hemorrhagic stroke, higher S100B concentrations have been observed, predicting 
higher morbidity.
88, 89
 It has also been shown that S100B correlates with the volume of 
infarction, neurologic outcome, and its elevated levels in serum are believed to be due to BBB 
dysfunction.
90, 91
 S100B cannot be considered as a stroke-specific biomarker as its levels in 
serum and CSF are found to increase in other neurological disorders (trauma, Alzheimer’s 
disease, and schizophrenia), extracranial malignancies (schwannoma, melanoma and 
neuroblastoma) and also due its delayed release.
92, 93
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GFAP is an immediate filament protein present in astrocytes and to a lesser extent in 
ependymal cells. It is a marker of glial cell lineage and has been reported to increase in stroke 
attacks with peak levels after 3 days.
94, 95
 A study by Foerch et al. showed that GFAP is the 
strongest candidate for detecting hemorrhagic stroke due to its significantly increased levels 
observed in 81% of ICH patients compared to 5% of IS patients. Although increase in serum 
concentration of GFAP is found to be correlated with volume of infarcted brain as well as S100B 
concentration, its delayed release of 6 h after symptom onset limits its use in stroke diagnosis.
96, 
97
 
MBP is a hydrophilic protein that plays an important role in the structure of myelin sheaths.
98
 
Increased levels of this protein are found in CSF are found in cases of stroke and multiple 
sclerosis.
99
 Detectable levels of CSF MBP in IS subjects are observed after one week and levels 
decreased after three weeks.
95
 The increased concentrations of MBP correlated with higher 
NIHSS scores and large lesion volumes.
100
 The limiting factor for the application of MBP as a 
diagnostic marker of stroke is its latency in response to a stroke event. 
1.7.2 Neuronal Biomarkers 
During stroke, certain neuronal markers are upregulated and released into the CSF and blood-
stream as a result of CNS cellular responses. Increased levels of these neuronal isoenzymes 
signal damage to the brain parenchyma.
101
 Several neurobiochemical markers that evaluate 
neuronal injury have been identified and some of them are listed below (see Table 1.3). 
Neuron-specific enolase (NSE) is a glycolytic enzyme specific for neurons. NSE levels are 
detectable between 4-8 h of onset of stroke with peak levels after 24 h.
102
  Some of the 
limitations in using this biomarker include latency in release and less sensitive serum levels to 
brain tissue damage, although the sensitivity is high in CSF.
103
 There is no clear explanation in 
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the literature on the variation of CSF and serum NSE levels but serum NSE levels were  
significantly measured in case of greater injury.
104
 Sensitivity may be the limiting factor for its 
clinical use.  
N-methyl-D-aspartate (NMDA) receptor is an excitatory amino acid receptor and is a 
tetramer of two NR1 and two NR2 subunits.
105
 A pilot study found increased serum levels of 
NMDA NR2 antibodies in patients with transient ischemic attack when compared to controls and 
even higher levels in IS subjects. These elevated levels correlated with NIHSS score and lesion 
volume.
106
 Ongoing research is focusing on measuring NMDA receptor and its utility as a 
potential stroke biomarker.  
Another neuronal biomarker, fatty acid–binding protein (FABP), is a cytosolic protein 
involved in transporting long chains of fatty acids. FABP is expressed in various tissues and 
rapidly released into circulation. In the central nervous system, heart-type FABP is present in 
glia and brain-type FABP is present in neurons at elevated levels within 2-3 h of stroke onset. 
Detection of this marker in a variety of other brain injury conditions does not make it stroke-
specific.
107-109
 FABP is also classified as a glial biomarker in some reports. 
1.7.3 Inflammatory Biomarkers 
One of the factors believed to cause neuronal death during the ischemic cascade is 
inflammation, which causes increased levels of inflammatory markers. These biomarkers are 
associated with increased infiltration of leukocytes. Biomarkers such as tumor necrosis factor-
alpha (TNF-α),110 MMPs,111 vascular cell adhesion molecule 1 (VCAM-1), C-reactive protein 
(CRP),
112
 intercellular adhesion molecule 1 (ICAM-1),
113
 interleukin-6 (IL-6),
114
 (Table 1.3) are 
some proteins involved in inflammation. All of these biomarkers have shown only moderate 
clinical utility, either due to low sensitivity or specificity.
115
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Table 1.3 Summary of all protein stroke biomarkers and their functions 
 
 
 
Glial biomarkers 
Protein Description and Function Ref. 
S100B 
Astrocyte marker; a calcium-binding protein 
involved in cell cycle progression & 
differentiation 
[88,96] 
GFAP 
Astrocyte marker; an intermediate filament 
protein role in cell structure, blood 
brain barrier, communication 
[96] 
 
Inflammatory 
biomarkers 
IL-6 Cytokine involved in acute-phase response  [116] 
CRP 
An acute-phase reactant involved in 
atherothrombosis and ischemic injury [117] 
MMP-9 
Proteolytic enzymes that degrade collagen-
disrupting endothelium and plaque matrix [118, 119] 
VCAM-1 
Immunoglobulin involved in leukocyte–
endothelial cell interaction [120, 121] 
TNF-α 
Cytokine involved in inflammation and acute-
phase response [116] 
ICAM-1 
Immunoglobulin involved in leukocyte–
endothelial cell interaction 
[120] 
ApoC-I 
ApoC-III 
Lipid metabolism [122] 
 
 
Neuronal 
biomarkers 
 
 
NSE 
Neuronal marker; a neuronal glycolytic enzyme 
[90, 123] 
FABP 
Cytosolic protein involved in long chain fatty 
acid transportation 
[107-109] 
NMDA 
Glutamate excitotoxic response 
[106] 
 
Thrombosis 
biomarkers 
vWF 
A glycoprotein involved in coagulation, platelet 
adhesion, and factor VIII binding [124] 
D-dimer 
Marker of acute thrombosis; a breakdown 
product of fibrin blood clot [125] 
Other 
biomarkers 
PARK7 
An RNA-binding protein; elevated in 
neurodegenerative disease [126] 
NDKA Transfers phosphate between nucleosides 
[126] 
BNGF 
A growth factor involved in 
neuronal growth and differentiation [82] 
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1.7.4 Evaluation of Protein Biomarkers for Clinical Utility in Stroke 
Several studies have been conducted to evaluate the clinical utility of various stroke relevant 
protein biomarkers, which involves measuring biomarker performance and its statistical 
association with clinical state of interest to know more about the disease. As mentioned 
previously, due to the heterogeneity of stroke and no individually useful biomarker, researchers 
have evaluated multiple biomarker panels to obtain additional information useful for early 
management.  
The potential utility of five blood-borne marker panel consisting of MMP-9, S100B, B-type 
neurotrophic growth factor (BNGF), von willebrand factor (vWF), and monocyte chemotactic 
protein (MCP) was demonstrated by Reynolds et al. Within 9 h of onset of cerebral ischemia,  
they distinguished IS from healthy controls with a sensitivity of 93% and a specificity of 93% 
based on 75 samples, indicating the use of this marker panel in conjunction with CT imaging.
82
 
A pilot study Lynch et al. used 26 blood-borne biomarkers including MMP-9, VCAM-1, S100B 
to differentiate IS from controls with a  sensitivity and specificity was 90% within 24 h of 
symptom onset.
121
 However, initial control subjects employed in this study were very less (65) 
Identification of high levels of  S100B and  low levels of soluble form of receptor for advanced 
glycation endproducts (sRAGE) blood biomarkers in ICH patients compared to IS patients, 
suggested the use of these two biomarkers to distinguish between IS and HS according to 
Montaner et al.
127
  Within 6 h of symptom onset, the increased levels of plasmatic biomarkers, 
apoliprotein CI (ApoC-I) and apoliprotein CIII (ApoC-III) could distinguish between HS and IS. 
ApoC-I provided 94% sensitivity and 73% specificity and ApoC-III 94% sensitivity with 87% 
specificity. In this study, ApoC-III marker was also used to distinguish stroke (both IS and HS) 
from controls with a specificity and sensitivity of 97% and 58%, respectively.
122
 A recent study 
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compared the performance of a biomarker panel (BNP, D-dimer, MMP-9, and S100B) to the 
cincinnati prehospital stroke scale administered by an emergency room triage nurse in 
diagnosing stroke.
128
 The potential utility of this biomarker panel was supported by additional 
studies demonstrating the adaptability of this panel to point-of-care setting.
129, 130
 
Although, some of the aforementioned studies showed good clinical sensitivity and 
specificity; reliability, validity and ease of obtaining results still remains an issue. Moreover, 
comparison between patient and healthy controls, typically results in overestimation of 
sensitivity and specificity of these protein biomarkers.
131
 
1.8 Gene Expression Profiling of Peripheral Blood 
Quantitative assessment of genes expressed in cells or blood samples is known as gene 
expression profiling. Gene expression profiling has been applied to various disease states like 
inflammatory disease,
132
 toxic exposure,
133
 multiple sclerosis,
134
 and renal carcinoma.
135
  These 
studies demonstrated a promising approach and formed the basis for gene expression profiles of 
white blood cells for finding diagnostic and prognostic biomarkers and providing mechanistic 
insights into stroke. A disease can be identified by grouping clusters of up-regulated and/or 
down-regulated genes and monitoring the changes in mRNA expression levels of the cells as a 
response to the injury.  
Biomarkers based on mRNA levels, especially in blood, are an emerging and exciting area of 
research in medicine. mRNA biomarkers offers several advantages when compared to protein 
biomarkers. mRNA levels are chosen to be monitored as they can detect genes with a low 
expression level in protein.
136
 Currently known coding RNAs have been well described and 
available on a single platform rather than identifying for best candidate biomarkers using 
proteomic approaches.
137
 Moreover, mRNA is induced more quickly in response to injury when 
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compared to protein expression. Also, mRNA expression analysis offers high throughput as tens 
of thousands of genes can be analyzed at the same time.
138
 
One of the challenges of biomarker use is obtaining samples from the appropriate tissue. 
Peripheral blood, therefore is a good source of mRNA for use in clinical trials, as plentitude of 
information can be obtained from expression profiling by studying thousands of genes 
simultaneously.
139
 Blood, being a biological fluid circulating through every part of the body, has 
the potential to reflect any physiological changes during a disease state. It is also an easily 
accessible source of tissue to identify the biomarkers for any disease, especially in a clinical 
setting, as tissue biopsy is practically infeasible for neurological disorders.
139
   
 
Figure 1.6 Leukocyte interactions with intravascular elements relevant for stroke in humans. 
Leukocytes (neutrophils, lymphocytes, and monocytes), platelets, red blood cells, and other cells 
interact with each other and with endothelial cells in normal vessels. Leukocyte interactions with 
endothelial cells, platelets, atherosclerotic plaque, blood clots, and intravascular molecules 
(cytokines, chemokines, hormones, others) account for some changes of gene expression 
following stroke. Leukocytes also signal to these other cell types, which also account for changes 
of gene expression. Reproduced with permission from reference [143].  
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 Cell types involved with disease specific responses are mostly blood derived-mononuclear 
cells (lymphocytes and monocytes); hence, peripheral blood mononuclear cells (PBMCs) are 
highly significant in stroke.
140
 As discussed previously, there is an infiltration of leukocytes 
during stroke that generates an inflammatory response. Each cell type has a unique gene 
expression profile, and the change in their expression as a result of any physiological or 
pathological change(s) can be studied from peripheral blood.
141
 Although the exact role of 
leukocytes in brain injury is yet to be clearly understood, it is hypothesized that leukocytes 
interact with cells from every tissue, endothelial cells of the vasculature, foreign organisms or 
cells, injured cells and every element within blood (see Figure 1.6).
142
 In addition, leukocytes 
have a complement of expressed RNAs that reflect a combination of the genetics of these cells as 
well as the interactions of those cells with their environment. 
Two approaches that can be adopted for expression profiling are: (i) Extraction of RNA from 
isolated pure fractions of PBMCs; and (ii) Stabilization of whole blood and extraction of RNA 
from the whole blood cell lysate. Advancements in microarray technology utilizing porous glass 
and plastic membranes facilitated the study of thousands of genes obtained from a single RNA 
sample simultaneously.
144, 145
 The verification of gene regulation is most commonly performed 
using real time/quantitative polymerase chain reaction (qPCR). Strict methods of RNA isolation 
are very critical specially when comparing ischemic and healthy subjects. PAXgene based tubes 
(for blood collection) are used for stabilization of whole blood, and the additive contained in 
them prevents any RNA degradation and further alteration in transcriptional profile. However, 
sensitivities less than 50% were reported using this approach.
146
  
A pilot study of gene expression in humans using peripheral blood was first conducted by 
Moore et al. They identified a 22 gene-panel which distinguished ischemic stroke from controls 
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with 78% sensitivity and 80% specificity.
140
 Further studies with whole blood using an 18 gene-
panel showed a change in gene expression of monocytes and neutrophils.
147
 Prior to this, studies 
by the same group suggested that differences in gene expression observed in white blood cells of 
rat subjected to various brain specific stimuli might serve as a genomic fingerprint for various 
diseases.
148
 Barr et al. identified a panel of 9 genes from 64 samples using whole blood to 
distinguish stroke subjects from controls.
149
 These studies demonstrated a proof-of-concept and 
open the possibility for gene expression studies to identify the genes as biomarkers for 
differentiating stroke subtypes. 
1.8.1 MicroRNA Biomarkers 
MicroRNAs (miRNAs) are a class of small, noncoding RNAs that target and regulate the 
expression of complementary mRNAs. miRNA-based diagnostic assays were developed for 
diseases such as lung cancer and pancreatic adenocarcinoma.
150, 151
 Emerging studies on 
circulating micro RNAs (miRNAs) in several cardiovascular and other diseases demonstrate the 
potential of miRNAs as biomarkers. Some of the attractive features of miRNA include; i) 
detectable levels of miRNAs in plasma and serum; ii) ability to withstand freezing and thawing 
cycles; iii) stability at high pH and temperatures; and iv) reproducible detection in healthy 
individuals and expression levels are tissue specific.
152-154
  
Initial studies in IS rat models have demonstrated the elevation of miR-124 in plasma with 
peak levels at 24 h. Furthermore, miR-210 decreased levels in IS were believed to be an 
indication of severity of brain damage, which were further confirmed in a rat model.
155
 A recent 
study also revealed that elevated expression of circulatory miR-145 expression in peripheral 
blood of IS patients compared to controls, but the source of miR-145 could not be identified.
156
 
However, there remains a need for standardized quantification procedures and validation studies 
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for miRNA profiling, but it would be interesting to explore the role of circulating miRNAs in 
diagnosis and prognosis of stroke.
157
 
1.9 Approaches for Stroke Biomarker Detection and Validation 
Major components of successful biomarker development include discovery, qualification, 
verification, clinical validation and use in clinical trials (Figure 1.7). In the discovery phase of 
development, large sets of biomarker candidates are identified based on knowledge of the 
pathophysiology of the disease and differential expression between diseased and normal states.
75
 
In the verification phase, the potential for success of a marker is determined by its clinical 
specificity and sensitivity. Surviving biomarkers from the verification phase are then considered 
for validation in a clinical environment. Validation is a lengthy process requiring a large cohort 
of patients and robust clinical evidence obtained from several independent studies.
158
 The major 
challenge during this phase is recruitment of properly matched controls (age, gender, 
demographics etc.) for comparison with the patient samples.
159
 
Advancements in -omic approaches (proteomics, genomics, metabolomics) have made it 
possible to identify the expressional or functional changes of a protein, DNA or mRNA 
expression during a diseased state and screen for useful biomarkers.
160
 Proteomic approaches 
have been used for the identification of potential biomarkers because the phenotypic diversity 
among common genes can be determined by bioenzymatic functions of proteins.
161
 Whereas, 
genomic approaches like DNA or RNA microarray technology measures genome-wide mRNA 
expression changes or DNA sequence changes (i.e., mutations), variations in biological/clinical 
samples during developmental stages, drug treatments, and disease states.
162
  
Ideal biomarker detection strategies should be able to detect biomarkers present in limited 
quantities in complex biological/clinical samples. Multiplexed immunoassays and quantitative 
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mass spectrometry are two broader analytical platforms for the identification of biomarkers. 
These techniques have radically improved the speed and precision of biomarker identification 
and measurement in biological fluids and other samples. The type of analytical technique chosen 
depends on the question to be addressed and availability of biological fluid for study. After the 
discovery and verification, robust immunoassays must be developed and optimized to evaluate 
their potential clinical utility. Some of the most widely used, label-based and label-free 
approaches and their usefulness in identification and validation of stroke biomarkers will be 
discussed here. 
 
 
Figure 1.7 Representation of biomarker pipeline. Hypothesis-driven approaches and other high 
throughput technologies suggest thousands of candidate biomarkers from which a set of putative 
markers undergo systematic testing to establish the consistency of the association between 
marker and disease (qualification) and to study the sensitivity and specificity of the indicator in a 
larger number and a broader range of samples (verification). Few candidates after verification 
process undergo a lengthy and rigorous clinical validation. Reproduced with permission from 
reference [163].  
 
 29 
 
1.9.1 Immunoassays 
1.9.1.1 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA is the most routinely employed technique for quantification and identification of 
proteins, peptides, antibodies and hormones. This plate-based immunoassay detects binding of 
the antigen and antibody is using an enzyme linked to a secondary antibody, which turns the 
colorless antigen-antibody complex into a colored product when enzyme substrate is added (see 
Figure 1.8). 
 
Figure 1.8 Schematic representation of the sandwich ELISA in which the target molecule is 
anchored to the substrate by capture antibodies and recognized by primary antibodies. The 
enzyme is linked to the immunocomplex through interactions between enzyme-decorated 
streptavidin and biotinylated secondary antibodies Enzymatic biocatalysis generates a coloured 
compound. P – product S – substrate. Reproduced with permission from reference [164].  
 
In the direct ELISA, antigen is detected using an enzyme-conjugated primary antibody 
whereas; unlabeled primary and conjugated secondary antibodies are used in indirect detection. 
The most sensitive and robust format of ELISA is the sandwich assay. In this assay, the analyte 
to be measured is bound between the capture and detection antibodies. (see Figure 1.8). The 
most commonly used enzyme labels are horseradish peroxidase and alkaline phosphastase. These 
 30 
 
enzymatic labels produce a detectable signal that is directly correlated to the binding of antibody 
to an antigen and the colorimetric output is usually measured by spectrophotometer. ELISA can 
be used for testing a few samples as well as high throughput screening with automated 
procedures. 
A pilot study by Stejskal et al. used sandwich ELISA method to evaluate clinical utility of 
the visinin-like protein (VILIP-1), a CNS-abundant protein biomarker for brain injury and 
several neurogenerative diseases, released into the circulation as a consequence of neuronal 
destruction.
12
 Serum and CSF levels of VILIP-1 were found to be elevated in IS patients within 3 
h of stroke onset, compared to healthy subjects. This study was able to achieve 100% clinical 
sensitivity and specificity for stroke diagnosis. However, it cannot be completely assumed that 
this protein will serve as a single biomarker for stroke as it still needs a larger cohort of patient 
samples for further validation.
165
 Another ELISA-based study using organ samples of mouse 
models enabled the measurement of VILIP-1 concentrations <100 ng/L and identified it as 
potential candidate for an acute blood-borne biomarker of IS.
161
   
Further ELISA studies, in a large cohort of European and American populations, for stroke 
biomarker detection have shown increased concentrations of PARK7 (also called DJ-1) and 
nucleotide diphosphate kinase A (NDKA) in plasma samples after 3 h onset of a stroke event 
compared to a control population and remained increased up to 5 days after the initiation of the 
event. The authors hypothesized that the possible reason for overexpression of both PARK7 and 
VILIP-1 in plasma could be due to soluble protein produced by the injured neurons reaching the 
blood at the site of the lesion.
126
 Zimmerman et al. used ELISA to detect heart-FABP in the 
serum of stroke patients and healthy controls. Clinical sensitivity and specificity were reported to 
be 68% and 100%, respectively.
166
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A new type of immunoassay, elongated oligonucleotide-linked immunosorbent assay 
(EOLISA), for protein biomarker detection has been reported by Han et al. This method utilized 
elongated DNA nucleotides (80-mer), a complementary RNA oligonucleotide and RNase H for 
signal amplification (see Figure 1.9). This assay was evaluated for detection of FABP spiked into 
healthy human serum samples. When compared to conventional ELISA, EOLISA showed 10-
fold higher detection sensitivity (0–1 ng mL-1 range.).167 Due to the improved sensitivity, this 
proposed immunoassay is expected to be potentially useful in clinical analysis of biomarkers.  
 
Figure 1.9 Illustration of EOLISA, a sandwich format which utilizes the biotinylated DNA strand 
and the fluorogenic RNA probes appended with a fluorophore and a quencher at each. At the 
signal amplification step, RNase H cleaves only the RNA part after forming RNA/DNA 
heteroduplexes, resulting in fluorescence recovery due to the release of fluorophore from the 
quencher. The iterative cycle of DNA/RNA duplexation and degradation of RNA by RNase H 
leads to the fluorescence signal amplification. Reproduced with permission from reference [167].   
 
Newer ELISA-based technologies like Searchlight® and Fastquant® allow for operation 
with low final volumes, decreased analysis time and simultaneous analysis of multiple samples 
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unlike conventional ELISA-based methods.
168
 Although ELISA is still considered as a gold 
standard method for biomarker detection, some challenges still exist. Diagnostic assay 
development using ELISA is limited due to the lower concentrations (lower than detection limit 
of ELISA) of biomarkers in biological samples at the early of the disease
169
 and the availability 
of high-quality capture molecules, e.g., antibodies.  
1.9.1.2 Microarray-based Assays 
Microarray technologies have been extensively used to evaluate changes in gene expression 
associated with onset and progression of a disease.
170
 They permit simultaneous screening of 
thousands of genes and allow i) in-depth understanding of genome-wide expression changes in 
health and disease ii) prediction of clinical outcome iii) identification of diagnostic or prognostic 
biomarkers.
144, 171
  
In microarray studies, the term “probe” describes the nucleotide sequence attached to the 
microarray surface; typically employed probes are DNA, antibodies or aptamers. Target refers to 
what is hybridized to the probes.
172
  Based on the length of the probe utilized, DNA microarrays 
are classified into i) cDNA microarrays (500-2500 bp double-strand cDNAs) and ii) 
oligonucleotide microarrays (20-90 single-strand nucleotide molecules). For these microarrays to 
be reliable tools, they must possess probe sequences that hybridize with high sensitivity and 
specificity, thereby allowing precise detection of their intended targets. Gene expression 
profiling using microarrays is performed according to the following steps described.  mRNA 
samples extracted from biological samples and reverse transcribed.
173
 Targets are then prepared 
by labeling mRNA samples with fluorescent dyes on the array. At the hybridization step, each 
labeled nucleotide molecule (mRNA, cRNA, or cDNA) in targets hybridizes with a probe 
complementary to its sequence on the array surface and forms a probe-target hybrid. An image is 
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then using laser-induced fluorescent imaging. The principle behind the quantification of 
expression levels is that the amount of fluorescence measured at each sequence specific location 
is directly proportional to the amount of mRNA with complementary sequence present in the 
sample analyzed. Signal intensities stored in image files can be transformed to numerical 
intensity values for every probe on the array by appropriate algorithms.  
Using peripheral blood mononuclear cells, a panel of 22 genes were found to be 80% 
sensitive and specific for the diagnosis of stroke. The gene list was generated from a starting 
number of 22,283 gene probes, and reproducible gene expression was found within 24 h after IS 
and validated using qPCR.
140, 174
  Barr et al. recruited 67 stroke patients and 25 control subjects 
and performed gene expression profiling of peripheral blood. They identified 9 genes based on 
the 2-fold expression differences between stroke and healthy subjects as determined by the 
statistical analysis. Significant changes on mRNA expression four genes were then validated 
using qPCR which revealed the up-regulation of arginase 1, lymphocyte antigen 96, MMP-9 and 
down-regulation of chemokine receptor 7.
149
 However, the exact role of all these genes in 
ischemic stroke has not been specified. 
Gene expression profiling of purified leukocyte populations (obtained from healthy donors) 
using DNA microarrays containing 18,000 genes enabled the identification of cell-type-specific 
gene patterns. Clustering analysis of these leukocytes revealed global expression levels of T-
cells, B-cells and neutrophils from healthy donors and also variation of gene expression between 
cell types within an individual. This finding suggested that subtle variations of gene expression 
in peripheral blood cells can help in gaining an insight into any type of disease to develop 
diagnostic biomarkers.
175
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In order to circumvent the problems of translating a qualitative microarray approach into a 
clinical setting, Adamski et al. used a new approach, high-throughput reverse transcription qPCR 
which offers high throughput diagnosis, reduced background noise, this high sensitivity, allows 
simultaneous screening of 96 transcripts from nL sample volumes for detecting complementary 
DNA (cDNA) copies. Whereas, traditional qPCR is time consuming and offers low throughput. 
As specific leukocytes are involved in pathogen recognition, innate, adaptive, cellular, and 
humoral immune responses and tissue repair,
141, 147, 176
 gene expression among leukocytes 
subsets were measured by extracting mRNA. Stroke related genes associated with white blood 
cell differentiation activation and differentiation,
139
 IL1R2, S100A9, F5, ETS2, C3AR1 were 
shown to up-regulate their expression in stroke patients relative to healthy controls. (see Figure 
1.10).
177
  
 
Figure 1.10 Comparison of cell count–based and control gene analytic methods by two 
independent approaches. The first was absolute, based on the cell count and normalized to the Cq 
value of the corresponding transcript for the commercial complementary DNA. The second was 
relative, measured relative to the average of the three selected control genes (FDFT1, FUT4, and 
CD3E). Reproduced with permission from reference [177]. 
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Data analysis was performed based using cell counts and also control genes. Both the results 
were in agreement with each other but cell count method was chosen to overcome the expression 
alterations in control genes in different leukocyte subsets or in different disease states. 
Furthermore, expression level of each gene can be assessed independently using cell count 
method instead of relying upon standard control gene expression 
1.9.2 Mass Spectrometry (MS) Techniques 
MS is a label-free analytical technique used to measure the mass-to-charge ratio (m/z) of ions 
and serves as a means of generating semi-quantitative data for measuring abundant proteins. 
These technologies usually combine one or more means of high-resolution protein separation 
techniques. Regularly used techniques for the expression analysis of proteins are matrix assisted 
laser desorption ionization time-of-flight (MALDI-TOF) MS, Surface-enhanced laser desorption 
time-of-flight (SELDI-TOF) MS, and liquid chromatography combined with tandem MS (LC–
MS–MS). Three basic analysis steps are involved in these approaches: (i) Sample preparation; 
(ii) sample separation and analysis; and (iii) data analysis, which include protein identification, 
quantification, and statistical analysis. Some studies for identification of stroke biomarkers are 
outlined below. 
Capillary electrophoresis (CE) is used to separate molecular species by their mass to charge 
ratio in a small capillary filled with an electrolyte. This separation technique has high resolution 
and is used to fractionate and analyze samples before MS. Stroke-specific peptides were 
identified by performing CE-MS from 4,453 urinary proteins and peptides.
178
  Dawson et al. 
developed a 35 biomarker model, consisting of proteins such as FXYD domain-containing ion 
transport regulator 4 (regulator of Na-K-ATPase), polymeric-immunoglobulin receptor (protein 
transport across BBB) and several other proteins related to stroke severity. This panel showed a 
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clinical sensitivity of 56% and specificity of 93%. Although their results show association of the 
biomarkers with stroke, the study can been improved further and by also comparing TIA and 
healthy controls instead of TIA and those having cardiovascular risk factors.
178
  
 MALDI-TOF-MS is a powerful tool for the analysis of proteins and peptides and a sensitive 
technique for the detection of compounds of interest below sub-femtomole (<10
-15
 mol) 
levels.
179, 180
 In MALDI, a matrix absorbs energy from a laser, often a 337 nm N2 laser, and 
causes ionization of the matrix followed by proton transfer to the analyte.
181
 TOF analyzers are 
commonly associated with MALDI due to their robustness, high data acquisition rate and 
sensitivity and a great mass range (1-300 kDa).
182
 MALDI-TOF analysis was previously used to 
identify biomarkers for accurate diagnosis of myocardial infarction.
183
  
 
Figure 1.11 MALDI-TOF spectra of serum samples collected from ischemic stroke patients and 
healthy controls. Serum-free Hb peaks (α and β chains, 15.1 kDa and 15.8 kDa are labeled.186 
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A pilot study by Huang et al. suggested the use of serum free hemoglobin (Hb) as a novel 
biomarker for stroke due to the differential expression of Hb (α-chain and β-chain) in sera of IS 
patients compared to controls (see Figure 1.11). Serum free Hb is a marker of hemolysis 
associated with stroke and atherosclerosis.
184, 185  
MALDI-TOF-MS analysis showed that the 
clinical sensitivity of diagnosing IS with this approach was 70.2% and specificity was 85.3%. 
However, clinical utility of this marker will be better understood by studying its correlation with 
outcome and severity.
186
 
SELDI-TOF-MS is a variant of MALDI-TOF-MS and particularly used for analyzing low 
molecular weight proteins.
187
  SELDI is an affinity-based MS method in which the sample is 
applied to a chromatographic surface so that it selectively binds to a subset of molecules from a 
crude preparation whereas in MALDI the sample has to be purified before application to the 
plate.
188
 SELDI-TOF analysis was used to correlate overexpression of 6.63 kDa protein, ApoC 
III in plasma samples of stroke patients. ApoC III is a protein expressed in the liver and is known 
to inhibit lipoprotein lipase on the surface of vascular endothelial cells.
189, 190
. Summary and 
figures of merit for all biomarker studies using immunoassays and MS approaches is listed in 
Table 1.4.Some challenges associated with SELDI-TOF-MS and MALDI-TOF-MS concern 
reproducibility, which is critical for reliable differential diagnosis, their inability to detect high 
molecular weight proteins (>100 kDa).  
Other approaches documented for the detection and validation of biomarkers for stroke 
included the use of a chemiluminiscence immunoassay and micellar electrokinetic 
chromatography coupled to laser induced fluorescence (MEKC-LIF). The presence of the most 
studied proteins in stroke, NSE and S100B, were detected using chemiluminiscence duplex 
immunoassay technique. It involved the detection of S100B, NSE with alkaline phosphatase and 
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horseradish peroxidase labels respectively; capture antibodies against markers coupled to 
magnetic beads. Detection limit for S100B was found to be 0.005 ng/mL, and NSE was 0.20 
ng/mL achieved in a single experiment without any crosstalk.
191
  
Table 1.4 Summary of biomarker studies of stroke using various immunoassays and mass 
spectrometric analysis 
 
Technique Biomarker Sample 
Type 
Sensitivity 
(%) 
Specificity 
(%) 
Ref. 
Sandwich ELISA PARK 7 
NDKA 
Plasma 84.9 
72.6 
96.7 
96.7 
[126] 
Sandwich ELISA VILIP-1 Serum 100 100 [1] 
ELISA H-FABP Plasma 68 100 [166] 
CE-MS 35 
Biomarkers 
Urine 56 93 [178] 
MALDI-TOF-MS Serum free 
hemoglobin 
Serum 70.2 85.3 [186] 
 
MEKC-LIF method based on the derivatization with 3-(2-furoyl)quinoline-2-carboxaldehyde 
was optimized to separate and detect primary amines from plasma. MEKC-LIF was used to 
simultaneously detect five amine biomarkers, homocysteine, excitatory amino acid 
neurotransmitters principally including glutamic acid, polyamines such as putrescine, spermine, 
and spermidine, from plasma samples of neuroimaged ischemic stroke patients with limits of 
detection 0.2–2.1 nM (at S/N=3), showing about 800 fold higher sensitivity compared with the 
usual concentration levels of these analyses in human plasma under normal or 
pathophysiological conditions.
192
 
1.9.3 Nanotechnology and Lab-on-a-Chip (LOC) Approaches 
An analytical platform integrating proteomics and nanotechniques is termed as 
“nanoproteomics”. The advent of several new nanomaterials has enabled the detection of novel 
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biomarkers for various diseases like cancer, cardio vascular diseases, infectious, and autoimmune 
diseases using nanoproteomic approaches.
193
 Detection strategies such as gold nanoparticles,
194-
196
 silicon nanowires and nanoparticles,
197, 198
 carbon nanotubes,
199, 200
 nanomechanical 
resonators,
201
 quantum dots
202, 203
 have been extensively applied to cancer biomarker detection 
but none of these methods have been applied for stroke biomarker studies so far due to the lack 
of promising biomarkers specific only to stroke. 
   
Figure 1.12 Design of the LOC detection area (left panel) consisting of magnetoresistive 
spinvalve sensors and each sensor is  made up of multiple alternating magnetic and nonmagnetic 
metal layers of 1 to 10 nm each. The resistance of the spinvalve sensor changes in response to an 
external magnetic field which can be measured as output voltage change. (A) detection area 
consists of two rows of 12 sensors (B, D) each sensor is made of 9 spinvalves that are electrically 
connected in parallel (C) sensing area is covered with gold on which magneto-sandwich assay is 
build up (E) scheme of magneto-sandwich assay on the spin valve sensing area; coated with a 
self-assembling monolayer of alkane thiols, onto which the primary antibody is immobilized. 
Secondary antibody binds to the proteins added and forms a link with magnetic beads added in 
the final stage. 
205
 
 
The study for stroke diagnosis using LOC has been conducted by Belgian researchers. They 
built a magnetoresistive spin valve based detection platform (see Figure 1.12) for detecting low 
abundant stroke diagnostic marker like S100BB (a subtype of S100B and a ββ-homodimer).  
E) 
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S100BB is a glial protein which is released into CSF and blood between 48-72 h of stroke 
onset.
88
 This protein predicts BBB disruption.
204
 The concentration of S100BB is 1-100 pg/mL 
in blood and this LOC platform was able to achieve a detection of upto  27 pg/mL.
205
 However, 
details about target analyte and sample processing have not been mentioned.  
1.10 Point-of-Care Testing (POCT) 
POCT refers to the diagnostic testing outside the central lab, without the need for trained 
personnel and lot of laboratory processing. The main objective of POCT is to provide immediate 
results and render better patient management by minimizing the time between testing to 
diagnosis and treatment.
206
 The analytical targets for POC testing include proteins, nucleic acids, 
metabolites, drugs, human cells, and microbes from samples such as blood, saliva, urine, or other 
bodily fluids or (semi) solids.  
Table 1.5 Desirable characteristics of point-of-care assay 
 
For time sensitive medical conditions like stroke, developing a POC diagnostic device offers 
possibilities to accelerate stroke management by reducing times for transport, analyses, or 
transmission of results further reducing the healthcare costs. The need for easy-to-use medical 
technologies in low resource settings can be addressed by developing POC diagnostic tools. Two 
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types of POCT formats in use are benchtop analyzers and handheld portable devices. They 
require only basic instructions to use and provide easily interpretable results.
207
 The desirable 
characteristics for such a device are outlined in Table 1.5 (Adapted from Cardiac markers: point 
of care testing [Reference 206]). 
Triage stroke panel is a currently existing POC testing strategy based on a panel of 
biomarkers associated with IS to provide diagnostic information in patients with suspected 
stroke. It is a rapid, point-of-care fluorescence immunoassay used with the triage meters for the 
rapid, quantitative measurement of BNP, D-dimer, MMP-9, and S100B in whole blood or 
plasma specimens. The Triage meter plus (Biosite Incorporated, San Diego, CA) is a battery 
powered portable fluorometer that display digital results in a turn-around-time of 20 min, by 
conversion of fluorescence measurements into electrical signals.208  
To eliminate the confusions in interpretation of clinical data due to multiple markers, 
Biosite® has developed an algorithm called MultiMarker Index™ (MMX). The MMX value, 
derived from individual analyte values, function like an analyte that is sensitive and specific to 
the disease. It has a receiver operating characteristic curve, and the MMX value cutoff can be 
chosen based on clinical needs. The clinical performance of this triage stroke panel assay has 
been assessed in few studies
128, 130, 209, 210
 and it has been shown that utility and diagnostic of this 
marker panel when combined with other diagnostic methods. However, further validation studies 
are required before their use in clinics. 
1.11 Conclusions 
Advances in stroke research have clearly demonstrated that “time is brain” and immediate 
medical intervention is necessary due to the narrow time window (3 h). With the existing 
diagnostic methods, time required to perform neuro-imaging and the limited availability of 
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neuro-imaging instruments prompt the need for a rapid diagnostic test that is capable of 
providing results within a few hours of stroke onset.  
 Identification of clinically relevant markers is a challenge as not all biomarkers are 
legitimate therapeutic targets. A single biomarker however, cannot be ideal for use as a 
standalone diagnostic test due to the complexity in etiology of stroke. Substantial efforts are 
ongoing to identify different biomarkers associated with stroke. In order to improve clinical 
outcome, development of a multi-biomarker panel, which can indicate the brain damage by 
correlating to the volume of infarction and quick release into the blood/biological fluids upon 
stroke onset adds valuable and time-sensitive diagnostic information in the early evaluation of 
stroke. 
Pilot studies conducted, identified protein biomarkers that distinguished stroke from controls 
and HS from IS suggesting their potential to provide rapid assessment and personalized patient 
care in acute stroke. It is very important to realize that a direct comparison cannot be made 
between clinical sensitivities and specificities obtained from different biomarker studies. This is 
because of large variance in factors such as the recruitment of control subjects, samples obtained 
within various time windows from symptom onset and total number of samples analyzed. 
Therefore, further validation studies in large cohort of patients are required for determining their 
clinical utility and cost effectiveness. Compared to the use of protein biomarkers, mRNA 
profiling of peripheral blood has the potential to improvement of accuracy of stroke diagnoses 
and to accommodate stroke therapy as the recent studies by Baird et al,
139
 Tang et al
147
 and 
Moore et al
140
 provide an evidence on the reproducibility of peripheral blood gene expression 
signatures and also constant gene expression levels for atleast a week.  
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Also, the absence of a widely available and rapid diagnostic test for stroke remains a 
significant limitation in the evaluation and treatment of this disease. Therefore, stroke biomarker 
detection could benefit immeasurably from the application of microfluidic based technology for 
mRNA expression profiling and detection of stroke biomarkers to further create a portable and 
fully automated POC diagnostic tool for rapid blood-based diagnostic testing. This would reduce 
turn-around-time to assist physicians in making proper diagnostic decisions. 
1.12 Outline of the Dissertation 
This work consists of 5 chapters focusing on microfluidics and nanofluidics. A summary of the 
contents of each chapter is presented below.   
The major focus of this work is to develop a portable, automated instrument which would 
serve as a near patient technology for the diagnosis of ischemic and/or hemorrhagic stroke using 
mRNA expression profiling directly from whole blood within a processing time <20 min to 
accommodate effective therapeutic treatment of this disease. This will be achieved by developing 
a fluidic bio-processor fabricated in polymers via micro-replication technology and integrating 
task specific modules on a fluidic motherboard. Chapters 2, 3, 5 provide an indepth elucidation 
of this project. 
In chapter 2, cell isolation module is described in detail. This microfluidic cell isolation module 
enabled the isolation the multiple leukocyte subsets (T-cells and neutrophils) relevant for stroke 
diagnosis based on the differential expression of several genes in these cell types. Cell recoveries 
and purities of isolated cells were reported. Fluid dynamics and microfluidic design architectures 
were emphasized. Solid phase extraction (SPE) module for purification of RNA extracted from 
the isolated T-cells and neutrophils (as discussed in chapter 2) using photoactivated 
polycarbonate SPE bed remains the focus of chapter 3. RNA purification results in a single step 
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by serially connecting the cell isolation and SPE modules were also discussed. Finally in chapter 
5 details on the proposed integration of aforementioned modules in addition to some other 
modules are discussed as the future work. 
Chapter 4 describes the investigation of surface charge density, zeta potential and 
electroosmotic flow in surface modified nanofluidic systems (nanoslits and nanochannels). 
Surface modification of these nanofluidic devices via plasma modification and amination and 
relevant surface characterization studies were elucidated in this chapter. 
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CHAPTER 2. PARALLEL AFFINITY-BASED ISOLATION OF  
LEUKOCYTE SUBSETS USING MICROFLUIDICS: APPLICATION FOR 
STROKE DIAGNOSIS* 
 
 Introduction 2.1
Isolation of pure leukocyte subsets and their molecular analysis from whole blood is 
challenged by the presence of numerous interfering cells.
1
 The use of conventional isolation 
methods such as density gradient centrifugation, sedimentation, and fluorescence assisted cell 
sorting (FACS) are typically time consuming, require large volumes of blood and employ 
sophisticated equipment. Microfluidics, however, are extremely attractive for blood analysis 
because of the potentially short assay turnaround times and the ability to scale devices for point-
of-care applications.
2, 3
  
The use of microfluidics to isolate a certain type of leukocyte has attracted wide interest. For 
example, Cheng et al. reported a two-stage microfluidic for the isolation of CD4+ T-cells; a 
purity of ~90% was achieved.
4-6
 Lee and coworkers constructed a functionalized silicon and 
quartz nanowire array to separate CD4+ T-cells from mouse splenocytes.
7, 8
 Thorslund et al. 
fabricated a glass/PDMS/anti-CD4 microfluidic chip containing different architectural features 
for CD4+ T-cell isolation.
9
 Warner et al. reported a microfluidic neutrophil-capture device 
followed by gene expression analysis to observe changes after trauma injury.
10
 They obtained 
purities of 95% by processing 150 µL of whole blood through the chip that isolated ~25,000 cells 
and yielded 69 ng of RNA. Common to these elegant examples was that only a single cell type 
was isolated from the sample. 
Stroke is the third leading cause of disability and death in the United States.
11
 There are two  
 *Reproduced with permission from Analytical Chemistry 
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types of stroke: (i) Ischemic stroke caused by vessel occlusion and occurs at a frequency of 80-
85%; and (ii) hemorrhagic stroke resulting from vessel rupture and is identified in 15-20% of all 
stroke-related cases. Unfortunately, these two conditions cannot be differentiated using existing 
clinical tests, which typically employ CT or MRI. Additionally, a third of all patients presenting 
stroke-like symptoms actually suffer from non-vascular disease.
12
 It is imperative that stroke 
diagnosis be made quickly and accurately because treatments for ischemic and hemorrhagic 
stroke differ and there is a short time window (~3 h) for effective treatment.
13-17
  
Because head-related trauma or stroke tissue is not easily acquired, researchers have looked 
for markers in the peripheral blood due to its accessibility,
18-20
 and there have been ongoing 
efforts to find reliable blood-based stroke biomarkers that afford high clinical sensitivity and 
specificity.
21
 Several potential biomarker candidates that can be measured in serum or plasma 
have been identified with their role in the underlying pathophysiology investigated.
22
  
Reports have shown that T-lymphocyte mediated anti-inflammatory responses in ischemic 
brain injury
23-26
 and the expression of nearly 5,700 genes related to T-cell function change in 
cases of head trauma.
27
 mRNA can be harvested from specific types of blood cells and used as 
biomarkers that reflect the systemic changes in stroke.
28
 Transcripts of promise for detecting and 
differentiating between ischemic and hemorrhagic stroke include S100A9 and IL1R2.
29-32
 Gene 
expression studies conducted by Adamski et al. identified differential expression across different 
leukocyte subsets, such as CD4 T-cells and neutrophils.
33
 These cells are known to express genes 
found in stroke-related expression profiles.
34
 Therefore, the ability to rapidly isolate these 
leukocyte subsets and secure their mRNA expression profile without interference from other 
leukocyte subsets could provide a viable test for diagnosing various types of stroke.
35-38
 Isolation 
of pure fractions of these subsets is critical to provide unbiased expression data. 
 70 
 
In this study, we report a microfluidic device that can simultaneously isolate different types 
of cells using affinity agents. As an example, we show the positive selection of CD4+ T-cells and 
CD66b+ neutrophils from minute amounts of unprocessed and unfractionated blood. The device 
design allowed for simultaneous isolation of up to four types of cells. The device architecture 
and flow parameters allowed for the isolation of very pure subsets (>90%). Total RNA (TRNA) 
was extracted from the isolated cells and reverse transcribed to monitor mRNA expression 
changes from the isolated cells. To the best of our knowledge, this is the first report on the 
simultaneous isolation of multiple leukocyte subsets. The selected subsets were used to 
expression profile certain genes that possess diagnostic value for stroke. The figures-of-merit for 
two device geometries were evaluated as well as the applicability of two different polymers, 
poly(methyl methacrylate), PMMA, and cyclic olefin copolymer, COC, for optimizing antibody 
load and cell recovery. We also introduce a chemical–based polymer surface activation method 
that utilized sodium hydroxide and isopropanol, which provided efficient and simple polymer 
surface activation resulting in high antibody loads.
 
 Materials and Methods 2.2
 Buffers and Reagents 2.2.1
PMMA (cover plates and substrates), 6013S-04 COC cover plates and 5013L-10 COC 
substrates were purchased from Plaskolite (Columbus, OH) and TOPAS Advanced Polymers 
(Florence, KY). Reagent-grade isopropyl alcohol (IPA), 1-ethyl-3-[3-dimethylaminopropyl] 
carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 2-(4-morpholino)-ethane 
sulfonic acid (MES), bovine serum albumin (BSA), Triton X-100, and paraformaldehyde (PFA) 
were obtained from Sigma-Aldrich (St. Louis, MO). Phosphate buffered saline (PBS, pH = 7.4) 
was purchased from Life Technologies (Grand Island, NY). Sodium dodecyl sulfate (SDS), 
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Micro-90, sodium hydroxide (NaOH) and histological and laboratory grade IPA were received 
from Fisher Scientific (Houston, TX) and toluidine blue O (TBO) from Carolina Biological 
Supply (Burlington, NC). Cy3-labeled oligonucleotides (5ʹNH2-C6-TTT-TTT-TTT-TTC-CGA-
CAC-TTA-CGT-TTT-TTT-T-Cy3-3ʹ) were purchased from Integrated DNA Technology 
(Coralville, IA). Low endotoxin anti-human CD4 antibodies (clone RPA-T4), FITC-conjugated 
anti-human CD20 antibodies (clone AT80), and PE-conjugated anti-human CD14 antibodies 
(clone TÜK4) were purchased from AbD Serotec (Raleigh, NC). FITC-conjugated anti-CD66b 
(clone CLB-B13.9) antibody was obtained from Abcam (Cambridge, MA). Anti-human CD66b 
antibodies (clone- G10F5) and 4ʹ, 6-diamidino-2-phenylindole (DAPI) were obtained from BD 
Biosciences (San Jose, CA).  
 Microfluidic Device Fabrication and Assembly 2.2.2
Microfluidic devices were hot embossed into COC or PMMA substrates via micro-
replication from a metal mold master as previously reported.
39
 Two architectures (Figure 2.1) 
were tested in these studies, both possessing four independent cell isolation beds comprised of 
parallel arrays of curvilinear cell isolation channels with an 8 x 13 mm
2
 footprint.
40
 Prior to 
device assembly, inlet and outlet reservoirs (d = 0.85 mm) were drilled into both chip designs 
followed by cleaning with 10% Micro-90 and IPA and then drying at 60ºC. A 250 µm thick 
cover plate and the device substrate were activated for 15 min in a home-built UV chamber 
equipped with a low pressure Hg lamp (22 mW/cm
2
 at 254 nm) to generate carboxylic acid 
scaffolds on the microchannel surfaces.
41
 Thermal fusion bonding of the cover plate to the 
substrate was performed at 132ºC and 100ºC (~25 min) for UV-modified COC and PMMA 
devices, respectively. PEEK tubing of 175/335 µm id/od (IDEX Health & Science LLC) was 
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inserted into the reservoirs and glued in place with epoxy. A constant flow programmable 
syringe pump (Harvard Instruments) was used to introduce fluids into the devices. 
The architectures for the 2 devices evaluated herein differed in terms of their addressing of 
the selection beds (4 per device) employing either a bifurcation network or Z-configuration 
(Figures 2.1A,C and Figure 2.5). In the Z-configuration device (Figure 2.1C), each cell isolation 
unit consisted of 64 curvilinear channels that were 9,000 x 25 x 80 µm (l x w x h) with a center-
to-center spacing of 200 µm. Two 150 µm wide inlet and outlet channels poised orthogonally to 
the isolation channels addressed the selection bed. The surface area of a single bed including 
inlet and outlet channel was 132.3 mm
2 
(1.9 mm
2
, 1.15 µL per channel). 
 
Figure 2.1 An autoCAD drawing of (A) the bifurcated device with the cell isolation bed 
containing 16 curvilinear channels spaced by 330 µm. (C) Z-configuration isolation bed 
containing 64 curvilinear channels spaced by 200 µm. All curvilinear channel dimensions were 
25 × 80 µm (w × h). (B, D) SEM’s of the isolation beds bifurcated and Z devices respectively.  
The bifurcated device contained isolation beds with 16 curvilinear channels that were 11,000 
x 25 x 80 µm (l x w x h) with a center-to-center spacing of 330 µm between channels (Figure 
2.1A). Each isolation bed’s surface area was 36.8 mm2 (2.3 mm2/channel) with a volume of 352 
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nL. Addressing each bed required four bifurcations with an additional two bifurcations for the 
four independent isolation units. All four isolation beds shared a common inlet port with 
different outlet ports for each cell isolation unit (Figures 2.1B). The total surface area, including 
the bifurcation network, was 43.4 mm
2
.  
 Antibody (Ab) Immobilization to Activated Polymer Surfaces 2.2.3
 Ab immobilization was a two-step process. In the first step, 50 mg/mL EDC and 5 mg/mL 
NHS in 100 mM MES (pH = 4.8) was introduced into the device and incubated for 15 min at 
room temperature followed by flushing with PBS. Then, a 15 µL aliquot of 0.5 mg/mL mouse 
anti-human CD4 or anti-human CD66b monoclonal antibody (mAb) was introduced into the 
device and incubated overnight at 4ºC. The selection bed was then rinsed with 1 mL PBS (pH = 
7.4).  
 Fluorescence Staining of MOLT-3 Cells and Flow Cytometry Analysis 2.2.4
MOLT-3 cells (human acute lymphoblastic leukemia) were cultured as a suspension in 25 
cm
2 
culture flasks (Cell Treat Scientific, Shirley, MA) containing RPMI 1640 Medium (Life 
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Life 
Technologies, Grand Island, NY). FC was performed using a Beckman-Coulter CyAn instrument 
equipped with a 25 mW, 488 nm Coherent sapphire (blue) laser.  
Prior to staining of the MOLT-3 cells for determining CD4 expression, Fc receptors were 
blocked with 5 µL of 1 mg/mL human IgG-Fc blocker (R&D Systems, Minneapolis, MN) and 
incubated at 4ºC for 15 min. The following samples were prepared for analysis: (i) Unstained 
cells serving as an autofluorescence control; (ii) cells stained with 10 µL of 0.1 mg/mL isotype 
control, IgG1-FITC mAbs ( R&D Systems, Minneapolis, MN) and incubated in the dark at 4ºC 
for 30 min; and (iii) cells stained with 10 µL of 0.1 mg/mL CD4-FITC Abs (BD Biosciences, 
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Franklin Lakes, NJ) and incubated in the dark at 4ºC for 30 min. Cells were then washed three 
times: One mL of cold PBS-0.5% BSA was added; the cells were centrifuged for 4 min at 350x 
g; supernatants were decanted and resuspended in 1 mL PBS. Propidium iodide staining (1 
µg/mL) was performed on all the samples (except for the autofluorescence control) just prior to 
the analysis for the determination of cell viability as detected by red fluorescence. Samples were 
then analyzed on a CyAn flow cytometer (Beckman-Coulter) equipped with 25 mW 488 nm 
laser within 2 h after staining. Gain and amplitude settings were set and kept constant throughout 
the analysis. Ten thousand events were counted for all samples. Data acquisition and analysis 
was performed using Summit software (Dako, Carpineteria, CA). 
 Cell Isolation from Whole Blood, Staining and Enumeration 2.2.5
 Whole blood samples were obtained from anonymous healthy donors at the UNC Blood 
Bank in accordance with UNC Institutional Review Board (IRB) procedures. Peripheral blood 
samples were collected by venipuncture in Vacutainer tubes containing EDTA (7.5% in 0.06 
mL; Tyco Health Care). Samples were processed within 4 h following collection. 
The microfluidic device was connected to the syringe pump with PEEK tubing via a luer lock 
syringe connector (Hamilton, Reno, NV). A pre-isolation rinse of the chip was performed using 
PBS/0.5% BSA at 4 mm/s. Fifty µL of whole blood was infused at 3.8 µL/min and 15.3 µL/min 
for the bifurcation and Z-configuration devices, respectively, yielding nominal linear velocities 
of 2 mm/s in the isolation beds. A post-isolation rinse was performed at 4 mm/s with 100-200 µL 
PBS/0.5% BSA to remove blood and unbounded cells. Affinity-bound cells were fixed on-chip 
with 4% PFA/PBS for 15 min and then rinsed with 50 µL PBS/0.5% BSA. Surface antigens of 
fixed T-cells and neutrophils were stained with anti-CD3-FITC Abs and anti-CD66b-FITC Abs, 
respectively, in the dark for 1 h. Then, the chip was rinsed with PBS/0.5% BSA for 10 min (8 
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µL/min). Cells were permeabilized with 0.1% Triton-X for 5 min and nuclei stained with 1 
µg/mL DAPI in PBS for 5 min followed by a rinse with 50 µL PBS/0.5% BSA at 8 µL/min. 
Finally, cells were identified based on staining results with the total number of isolated cells 
determined by scanning across the cell selection regions using a fluorescence confocal 
microscope.  
Cell characterization was performed by acquiring images on an Olympus IX71-DSU 
Spinning Disk Confocal inverted microscope with  DAPI, FITC, and Texas Red filter sets, a 
mercury burner arc lamp and a high sensitivity Hamamatsu EMCCD and high resolution 
Hamamatsu ORCA-03G CCD cameras. Metamorph software was used for analyzing and 
processing images. Exposure times for DAPI, FITC and Texas Red were 10, 300, and 500 ms, 
respectively. 
 Evaluation and Quantification of Carboxylic acid Surface Densities 2.2.6
 Cy3-modified oligonucleotides containing a 5ʹ pendant amino group served as fluorescent 
reporters by covalently labeling surface confined carboxylic acids. Carboxylic acid surface 
densities were also quantified by a colorimetric assay using TBO.  
An incubation chamber (BioRad) was glued to the substrate’s surface and filled with 0.1% 
(w/v) toluidine blue O (TBO) in carbonate buffer (50 mM, pH = 10.5). After 15 min, the 
substrate was submersed in the same buffer for 15 min and air dried. TBO was desorbed using 
40% acetic acid (d = 1.0196 g mL
-1
), collected in a pre-weighed microfuge tube and analyzed 
with an Ultrospec 4000 UV/Vis spectrophotometer (Pharmacia Biotech) against a 40% acetic 
acid blank. 
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 Contact Angle Measurements  2.2.7
Changes in surface hydrophobicity were measured via sessile drop water contact angle 
measurements performed using a VCA 2000 contact angle system (AST Products). Two µL of 
18 MΩ·cm deionized water was dispensed onto substrates, images were collected and contact 
angles were measured using the manufacturer’s software. Five measurements were averaged for 
all reported values. 
 Fluorescence Imaging 2.2.8
Cy3-labeled oligonucleotides (40 µM) modified with an amino group at their 5ʹ end were 
suspended in PBS buffer (100 mM, pH = 7.4) containing EDC (20 mg/mL) and incubated 
overnight at 4
o
C within the appropriately activated microfluidic device. The chip was then rinsed 
with ~2 mL of 0.1% SDS and PBS to remove unreacted molecules. All images were acquired 
(230 ms acquisition time) with a 200M inverted microscope (Zeiss) that contained an XBO 75 
Xe arc lamp, a single band filter set (Omega Optical), and a Cascade 1 K EMCCD camera 
(Photometrics). Images were analyzed using Image-J software. 
 Chemical Surface Modification 2.2.9
 Assembled devices were filled with a mixture of 5:1 (v/v) 2 M NaOH/100% IPA using 
input/output tubing sealed to the chip. Once filled, the chips were incubated with the activating 
solution in a hybridization oven (Boekel Scientific) for 12 h at 65ºC for COC and 30 min at room 
temperature for PMMA unless otherwise noted. Chips were rinsed with 1 mL nanopure water. 
 Reverse Transcription (RT) and Polymerase Chain Reaction (PCR) 2.2.10
 CD4+ T-cells and neutrophils isolated on-chip were lysed by infusing ~20 µL lysis solution 
(GenElute Mammalian Total RNA Miniprep Kit, Sigma, St. Louis, MO) through the cell 
selection bed. The effluent was collected into a microfuge tube and purified using a total RNA 
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miniprep kit (Sigma) according to the manufacturer’s protocol with DNase treatment (On-
Column DNase I, Sigma, St. Louis, MO). After purification of TRNA, reverse transcription (RT) 
was accomplished using a ProtoScript II First Strand cDNA Synthesis Kit (New England 
BioLabs, Ipswich, MA). Samples were prepared by mixing 10 µL reaction mix, 2 µL poly-T 
primer, 2 µL enzyme (no enzyme, 2 µL of water for RT) and 6 µL of TRNA. The samples were 
then incubated at 42˚C for 1 h and heated to 80˚C for 5 min to deactivate the RT enzyme. 
 Polymerase Chain Reaction (PCR) 2.2.11
 PCR was performed with cDNA in a total volume of 20 µL using Taq 2X Master Mix (New 
England Biolabs, Ipswich, MA). PCR cocktails consisted of 2 µL of primers (final concentration 
500 nM), 10 µL Taq 2X Master Mix, 6 µL nuclease free water and 2 µL cDNA. PCR was carried 
out in a commercial thermal cycler (MJ Research Inc., Waltham, MA) with the following steps: 
Initial denaturation at 94˚C for 2.5 min followed by 40 cycles of denaturation at 94˚C for 15 s; 
annealing for 30 s at 63˚C for GAPDH primers and 55˚C for S100 primers; and extension at 
72˚C for 30 s. A final extension at 72˚C for 7 min was followed by a cooling step at 4˚C. All 
primers were obtained from Integrated DNA Technologies, Inc. The sequences (5ʹ-3ʹ) were 
GAPDH: forward (F) – CTTTTGCGTCGCCAGCCGAG; reverse (R) – 
TGACCTTGGCCAGGGGTGCT
42
; S100A9 F – CTCGGCTTTGACAGAGTGCAAGAC; R – 
TCCCCGAGGCCTGGCTTATGG
42
; TCRB F – GTTTTCTTTCAGACTGTGGCTTC; R – 
CACGGCATACAAGGTGGC; and FPR1  F – TTTGCCTGTAACGCCAC; R – 
ATGCTCTATGTC TTCATGGG (www.ncbi.nih.gov). 
PCR products were electrophoresed at 4.8 V/cm in 1X TBE (Tris–boric acid/EDTA, Bio-Rad 
Laboratories) on a 4% agarose gel with ethidium bromide (Lonza) staining. Amplicons were 
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indexed against a DNA sizing ladder 50 – 766 bp (New England Biolabs, Ipswich, MA). Images 
were collected using a Logic Gel imaging system (Eastman Kodak Company). 
 Statistical Analysis and Computational Methods 2.2.12
Data were analyzed using a student’s two-tailed T-test (ANOVA). Statistical significance 
was assigned where p < 0.0500. Shear stress and flow uniformity through the bifurcated device 
was evaluated using COMSOL Multiphysics 4.3b.
43
  Flow distribution analysis in the Z-
configuration device employed a custom numerical algorithm detailed elsewhere.
44
   
 Results and Discussion 2.3
 Polymer Surface Activation for Ab Attachment 2.3.1
 Stable attachment of Abs to the surfaces of the selection bed, which were made from a 
polymer, is critical for efficient recovery and purity of the target cells. Ab density and uniformity 
throughout the selection channel is dependent on the activation protocol employed in cases 
where the Ab concentration exceeds the surface functional group number (see Figure 2.6). 
We have reported that activating microchannel surfaces via UV/ozone irradiation causes two 
effects: (i) Optical absorption by the bulk polymer with transmission decreasing with higher dose 
levels, which can cause functional group surface densities to become increasingly non-uniform 
as the aspect ratio of the channel is increased; and (ii) fragmentation of the polymer during 
irradiation reducing functional group surface density, especially during thermal fusion bonding. 
UV and thermally treated COC devices were less susceptible to these artifacts compared to 
PMMA.
43
 
We sought to avoid these effects by filling assembled devices with an activating chemical 
solution. Therefore, we investigated the use of a chemical modification protocol following 
thermal assembly of the device as this could potentially produce more uniform modification 
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throughout the channel cross-section and avoid thermal effects that would bury the surface 
functional groups for UV-activated surfaces.
43
  
Microchannels were chemically activated via incubation in 5:1 (v:v) 2 M NaOH:IPA. In the 
case of PMMA, it has been reported that it’s ester groups can be hydrolyzed to carboxy groups 
by incubation with 10M NaOH at 40ºC for 16 h.
45
 However, the covalent attachment of Cy3-
labeled oligonucleotides containing a pendant amino group serving as a fluorescent reporter of 
surface-confined carboxylic acids did not indicate the carboxylic acid group formation using this 
procedure. We hypothesized that the addition of IPA (similar to methanol by Patel et al.
46
) would 
encourage interaction with the hydrophobic polymer (water contact angle of PMMA = 76.4 
±1.4º) and/or solvation of methoxide byproducts.
46, 47
 Treatment of PMMA microfluidic 
channels with 1/1 (v/v) 2M NaOH/IPA for 3 min at 60ºC and 10 min at room temperature 
resulted in some channel roughening and deformation (Figures 2.2C, D). However, it was found 
that channel integrity was preserved up to 30 min at 65ºC in 5:1 (v:v) 2M NaOH:IPA (Figure 
2.2E). Thus we restricted PMMA modification using the aforementioned conditions to 30 min 
using 5:1 NaOH:IPA. 
Chemical activation of PMMA did not change the water contact angle or carboxylic acid 
surface density as determined by a TBO assay relative to the pristine surface; this was likely due 
to poor sensitivity of the TBO assay in comparison to fluorescence assays using Cy3-labeled 
oligonucleotides containing a pendant amino group that served as a fluorescent reporter of 
surface-confined carboxylic acids. Chemically activated PMMA microchannels derivatized with 
Cy3-labeled oligonucleotides showed 232 ±47 cps compared to 503 ±72 cps for UV-activated 
and thermally treated PMMA microchannels (Figures 2.2A, E). 
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Figure 2.2 Line plots created from 20X fluorescence images for (A) PMMA and (B) COC 
curvilinear channels modified with 40 μM 3ʹ-Cy3-labeled, 5ʹ-amino modified oligonucleotides 
that were covalently bound to surface-confined carboxylic acids generated by UV (grey lines) or 
chemical activation (black lines) of the polymer surface. For controls (dotted lines colored 
corresponding to their treatments), fluorescently-labeled oligonucleotides were immobilized to 
identical surfaces without EDC coupling reagents to measure nonspecific adsorption and 
autofluorescence. UV activation was identical for the two polymers, but chemical activation 
protocols differed in incubation times, where a 5/1 (v/v) 2 M NaOH/IPA solution was incubated 
at 65
o
C for 30 min for PMMA devices and 12 h for COC devices. Fluorescence images of 
oligonucleotides immobilized to PMMA devices that were chemically treated with (C) 1/1 (v/v) 
2 M NaOH/IPA for 3 min at 60
o
C and (D) 1/1 (v/v) 2 M NaOH/IPA for 10 min at room 
temperature, and (E) 5/1 (v/v) 2M NaOH/IPA for 5 min at 60
o
C 
 
COC microchannels were subjected to a similar treatment (5:1 (v:v); 2 M NaOH:IPA) 
Chemical activation decreased COC’s water contact angle from 95.5 ±1.8º (pristine) to 63.3 
±3.2º and increased the carboxyl surface density to 0.6 ±0.2 nmol/cm
2
 as determined by the TBO 
assay, which approached a theoretical monolayer (0.83 nmol/cm
2
). Carboxyl formation was also 
evident by fluorescence analysis, where the surface fluorescence intensity (4369 ±437 cps) for 
chemical modification was significantly greater than that observed for the UV activated and 
thermally treated COC microchannels (2357 ±218 cps, see Figure 2.2B). The mechanism for 
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carboxyl formation for COC using these chemical conditions is currently unknown; literature 
precedence necessitates a radical-forming catalyst, such as Cu, Fe or other heavy metals to 
convert alkanes, such as those found in COC, directly to carboxylic acid groups.
48
 We suspect 
that additives incorporated into the COC polymer during manufacturing assist in forming the 
surface carboxylic acids. Based on covalent labeling of surface-confined carboxylic acid, 
chemical treatment of COC resulted in the highest production of these functional groups.  
 Flow Uniformity in Bifurcated and Z-configuration Microfluidic Devices 2.3.2
 The uniformity of flow in the two devices, which consisted of four selection units, with each 
unit containing an array of parallel, curvilinear isolation channels addressed by either a 
bifurcation or Z-configuration, were studied using fluid dynamic simulations and video 
microscopy. COMSOL Multiphysics 4.3a was utilized
49
 to confirm uniform flow distribution 
within the devices. The velocity field in Figure 2.3A indicated that flow was uniformly 
distributed within each bifurcated, cell isolation bed (Figure 2.3B) and also between the four 
beds. Furthermore, because the Z-configuration device employed the same addressing 
architecture for the four isolation beds as the bifurcation device, the flow was uniformly 
distributed between the four Z-configuration cell isolation beds, but the flow was slightly non-
uniform within each bed (Figure 2.3B). 
The flow distribution simulations were compared to empirical observations acquired by 
filling the devices with red dye.
44
 Time lapse images were extracted from the videos (Figure 2.4). 
As shown in images depicted in Figure 2.4A-D, the dye front was nearly linear across the four 
bifurcation beds, indicating uniform flow between and within the bifurcation beds, which agreed 
with the simulation results (Figures 2.3A and 2.3B). Flow was uniform between the Z-
configuration isolation beds, but showed a parabolic profile within each bed (Figure 2.3B). As 
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shown in the images depicted in Figure 2.4E-G, dye filled more rapidly in the outer channels 
than the central channels, similar to that depicted in Figure 2.3B. Similar flow profiles were 
observed for filling devices with blood. These data agreed with previous results using a similar 
type of device, but consisting of a single cell isolation bed.
44
 
 
Figure 2.3 (A) COMSOL simulation showing the velocity field of buffer through the bifurcated 
cell isolation device. (B) Linear velocities normalized to an average of 2 mm/s acquired by 
(filled bars) 14 groups of the parallel channels in the Z-configuration device based on the results 
depicted in Figure. 2.4E-H and (solid line) compared to theoretical predictions via numerical 
simulation (solid black line).Dashed line indicates the distribution of linear flow velocities 
through all four beds of the simulated in bifurcation device in Figure 2.3A. 
 
Figure 2.4 Time-lapse images of dye filling the (A-D) bifurcated device and (E-H) Z-
configuration device. Images A-D and E-H were taken at 0, 15, 30, and 60 s, respectively.  
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 Microfluidic Architectures and Performance Evaluation  2.3.3
Two microfluidic devices were fabricated both of which contained four separate isolation 
beds to facilitate the simultaneous positive selection of multiple types of cells. We chose to target 
T-cells using CD4 and neutrophils were selected using anti-CD66b mAbs. In all cases, the 
concentration of mAb used to optimize recovery was 0.5 mg/mL (see Figure 2.6). To facilitate 
simultaneous isolation of T-cells within two beds and neutrophils in the remaining two beds from 
a blood sample (Figures 2.5A, B), the beds were modified by introducing the EDC/NHS solution 
through the common inlet followed by mAbs infusion through the individual isolation bed 
outlets so that beds could be functionalized with different antibodies. This design also enabled 
the lysis of each subset contained within a bed for downstream analysis, such as mRNA 
expression, by infusing a lysis solution through the common inlet and lysate collection from the 
four separate outlets. 
 
Figure 2.5 Photograph of the four isolation beds filled with red dye in A) bifurcated B) Z-
configuration devices 
 
The two microfluidic devices differed in how the parallel channels were addressed. In the 
first device (Figure 2.5A), a bifurcation network was utilized to address 16 channels, thereby 
requiring four bifurcations per isolation unit. The second device (Figure 2.5B) employed a Z-
configuration, where inlet and outlet channels were poised orthogonal to the cell selection 
channels (64 per device).
43, 44
  Due to the larger number of channels within the Z-configuration, 
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this device had a higher throughput; 50 µL of blood could be processed in 3 min maintaining a 2 
mm/s linear velocity to optimize recovery
40
 compared to 13 min for the bifurcated design. Using 
a previously reported and experimentally validated numerical algorithm,
44
 we calculated the flow 
distribution through the Z-configuration and found that the linear velocity ranged between 1.7 
and 2.5 mm/s for each isolation bed in the parallel arrangement (Figure 2.3B). For the bifurcation 
device (Figures 2.3A and 2.4), the fluid velocity within each isolation bed was uniform. The 
variability in the flow velocity seen within each isolation bed of the Z-configuration can result in 
variable cell recoveries. 
To evaluate the performance of the two microfluidic designs and surface activation 
chemistry, T-cells and neutrophils were isolated from blood and their recoveries determined. All 
cell counts and purities are summarized in Table 2.1. In this discussion, we differentiate the UV 
and chemical activation modalities by UV- and CH-, respectively. For COC chips and the 
bifurcated or Z-configuration, these were designated as UV-COCbif and UV-COCZ, respectively, 
when UV activated and CH-COCbif and CH-COCZ when chemically activated. 
To ensure Ab concentration was not a limiting factor and cell recovery results reflected the 
number density of the generated surface-confined carboxylic acids, we quantified cell recovery 
as a function of the antibody concentration in the COC bifurcated devices. The concentration of 
anti-CD4 Abs was varied at 0.1, 0.25, 0.5, and 1 mg/mL. Figure 2.6 suggested reduction in 
recoveries when Ab concentrations were set <0.5 mg/mL and comparable recoveries between 0.5 
and 1 mg/mL. Therefore, 0.5 mg/mL was selected to be the optimal concentration for Ab 
immobilization for all subsequent experiments. 
Initial testing of the bifurcated design indicated that with either activation protocol, COC out 
performed PMMA devices. UV-COCbif isolated 798 ±167 CD4+ T-cells cells compared to 325 
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±85 cells for UV-PMMAbif from a 50 µL blood sample (Table 2.1). These agree with our 
previous results, which indicated efficient and uniform activation in COC microchannels 
providing a higher Ab load and thus, higher recoveries.
43
 CH-PMMAbif devices demonstrated 
extremely poor performance (7 ±3 cells), which reflected the inability to chemically activate 
PMMA without degrading microstructures (see Figure 2.2). Results for CH-COCbif devices (702 
±386 cells) showed no statistical difference (p = 0.631) to UV-COCbif devices (798 ±167) 
(Figure 2.7). Chemical activation was as efficient as UV activation for the bifurcated COC 
devices as well.  
 
Figure 2.6 T-cell recoveries from healthy donor blood using UV-COCbif devices modified with 
anti-human CD4 Abs at different concentrations. 
Both UV-COC devices produced nearly equal recovered T-cells; 798 ±167 and 596 ±154 
using UV-COCbif and UV-COCZ devices, respectively. Considering nearly the same cell 
recovery and more rapid blood sample processing, the Z-type architecture was determined to be 
the most efficient from a throughput perspective. Hence, Z-configuration devices were used for 
simultaneously isolating T-cells and neutrophils. 
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Figure 2.7 Box plot comparing CD4+ T-cell recoveries from 50 µL healthy human blood in UV 
and chemically modified PMMA and COC devices utilizing either bifurcated or Z-configuration. 
(*) indicates statistically significant difference (student’s two tailed t-test p< 0.0500), while (**) 
implies no statistically different results. Solid lines in the boxes represent median; the dotted line 
represents mean; the upper and lower edges of the boxes indicate third and first quartiles, 
respectively; and error bars show maximum and minimum values. 
 
We observed higher cell recovery using CH-COCZ devices; absolute cell counts increased 
from 596 ±25 for UV-COCZ to 2565 ±1194 for the CH-COCZ devices for T-cell isolation. In the 
case of neutrophils, 1096 ±537 cells were selected for the UV-COCZ device compared to 2949 
±901 for the CH-COCZ device. However, we observed no difference between the activation 
modalities for bifurcated COC devices, which can be explained by shear stress considerations.
50
 
In bifurcated devices, ~40% of cells were isolated in the bifurcation regions (Figure 2.8B-E), 
whereas only 4% were observed in the inlet and outlet addressing channels of the Z-
configuration. Inspection of the bifurcation network showed that fluidic shear stress was reduced 
from 11 dynes/cm
2
 in the parallel channels to 6-7 dynes/cm
2
 through the bifurcation network, 
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where ~17.7% of the device’s surface area accounted for ~40% of cell isolation. Conversely, 
shear stress through the Z-configuration inlet and outlet channels ranged between ~1 and 38 
dynes/cm
2
 along the channel’s length and was <11 dynes/cm2 in ~19% of the length of the inlet 
and outlet channels. 
For the Z-configuration, recovery occurred predominantly in the cell isolation channels, 
where optical absorption of the activating UV radiation may lead to reduced Ab loads; activating 
polymer surfaces using chemical modification is not sensitive to device aspect ratio. These 
effects may be precluded in bifurcated devices due to cell isolation in the low aspect ratio 
bifurcation regions (Figure 2.8A).  
 
Figure 2.8 (A) Computational simulations showing the shear stresses in the parallel channels of 
the bifurcated device. (B- E) T-cells isolated from blood from the left in the 3, 2, 1, and 0 
bifurcation levels of the bifurcated microchip. All curvilinear channel dimensions are 25 × 80 
µm (w × h) and the SEM scale bars are 1 mm for all micrographs. 
 
 Determination of CD4 Expression of MOLT-3 Cells by Flow Cytometry 2.3.4
Expression of CD4 antigen on MOLT-3 cells was measured after subtracting isotype control-
FITC and CD4-FITC double positive events as shown in the histograms in Figure 2.9.  
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Figure 2.9 (A) Overlay of histograms generated by integration of negative isotype control 
(vertical lines), CD4- MOLT-3 cells (diagonal lines), and CD4+ MOLT-3 cells (hatched lines). 
The histogram for the CD4+ MOLT-3 cells was generated by the Overton subtraction method. 
(B) Visualization of CD4-FITC labelled MOLT-3 cells on a microscope.   
 
The low fluorescence signal observed for CD4+ MOLT-3 cells in flow cytometry (Figure 
2.9A) indicated these cells have much lower CD4 expression than T-cells (46,000-202,000 CD4 
molecules/cell; mean = 100,000 molecules/cell).
51-53
 
 Recovery of Different Leukocyte Subsets 2.3.5
Initial recovery tests were performed with MOLT-3 cells (average cell diameter 9.3 ±2.4 µm) 
using isolation beds modified with anti-CD4. However, we observed very poor recovery of these 
cells; 0.36 ±0.3% for UV-COCbif, 0.13 ±0.1% for CH-COCbif and 0.52 ±0.1% for CH-COCZ. 
After correcting for the CD4-MOLT-3 expression from the flow cytometry analysis (see Figure 
2.9), the recoveries were 1.4 ±0.3 %, 0.5 ±0.1% and 2.0 ±0.1%, for the UV-COCbif, CH-COCbif 
and CH-COCZ devices, respectively. These efficiencies were lower than that observed for the 
human T-cells (~10%), but exhibited similar patterns between the activation modality and device 
design; chemically activated COCZ devices isolated the highest absolute number of cells. 
The two primary factors contributing to the low recovery of MOLT-3 cells were likely the 
small cell size relative to the channel width and the low CD4 expression levels for these cells. 
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Because the 9.3 ±2.4 µm diameter MOLT-3 cells were isolated in 25 µm wide channels, we 
would expect low recovery as there is a low probability of cell/surface-confined Ab interactions. 
Reduction in channel width to slightly larger than the MOLT-3 cell diameter should improve 
their recovery.
40
 However, the use of much narrower channels may be problematic for blood 
processing due to the risk of device failure arising from clogging because of the presence of large 
leukocytes (~15 µm). If the Ag expression level is low, shear forces in the channel may also 
remove isolated cells from the selection bed due to the small adhesion force and thus, produce 
lower recovery. These considerations were also true for human T-cell isolation from whole 
blood; in spite of their smaller size (~7 µm average diameter) compared to MOLT-3 cells, these 
cells showed higher recovery most likely because of the higher expression of CD4 producing 
better cell/surface adhesion forces.  
We observed higher recoveries for CD4 T-cells (10.3 ±0.5%) compared to CD66b 
neutrophils (1.5 ±0.1%) in the CH-COCZ devices, assuming relative abundances of 25,000 and 
200,000 cells/50 µL of blood for T-cells and neutrophils, respectively.
54
 This difference in 
recovery may be related to the number of Ab molecules immobilized to the surface. With the 
size of anti-CD4 and anti-CD66b being 150 kDa IgG1 and 900 kDa IgM, respectively, they will 
form monolayers where IgM is ~36x less abundant than a monolayer of IgG, possibly leading to 
lower neutrophil recovery.
43, 55
  
Flow cytometric analysis was performed on T-cells and neutrophils isolated from a buffy 
coat as described previously. For T-cells, CD4-FITC fluorescence intensity was 5.3 times greater 
than the IgG isotype control and for neutrophils, CD66b-FITC showed 4.6 times greater intensity 
compared to its IgM control. However, due to the surface area of neutrophils (~707 µm
2
) 
compared to smaller T-cells (113 µm
2
), antigen density (  ) of CD4 on T-cells is roughly 7 
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times denser than CD66b on neutrophils. Consequently, the rate of adhesion (   ) of T-cells to 
surface antibodies is ~7 times greater than for neutrophils as stipulated by Chang and Hammer;
55
 
                              (1) 
where (  ) is the effective antibody-antigen binding rate and (  ) is the antibody number. 
Thus, the ~10 times lower recovery observed for neutrophils could be attributed to lower surface 
density of the IgM anti-CD66b selection antibody and/or reduced surface densities of CD66b on 
neutrophil cells.  
 
Figure 2.10 (A) Distribution of T-cells and neutrophils in Z-configuration parallel channels, 
which have varying linear velocities. (B) Scatter plot of the data in (A) showing strong, negative 
correlation between the percentage of cells isolated in a parallel channel with the linear velocity 
in that channel.  
 
We also inspected the distribution of isolated cells throughout the parallel channels of the Z-
configuration device to relate cell counts to linear velocity (Figure 2.10A). To discern the effects 
of varying linear velocity on absolute recovery, we normalized the recovered cell counts to the 
total input cell counts and plotted these results as a function of linear velocity (Figure 2.10B). A 
strong, negative correlation between linear velocity and cell recovery was observed for both T-
cells (Pearson’s correlation r = -0.65) and neutrophils (r = -0.72). However, the magnitude of the 
slope suggests that neutrophils (m = -10.03 cells/mm/s) are more sensitive to linear velocity and 
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fluidic shear stress than T-cells (m = -5.17 cells/mm/s) due to the effects of lower CD66b antigen 
surface density as noted by Eq. (1). 
 Purity of Isolated Leukocytes 2.3.6
 When designing systems for mRNA expression analysis of cell subsets isolated from blood, 
it is critical to isolate pure fractions of the targets. For T-cell isolation via CD4 positive selection, 
this is challenged by the fact that CD4 is also expressed on the surface of monocytes, 
macrophages, and dendritic cells at a frequency of 3-8% of the total leukocyte population in 
blood, albeit, CD4 expression is lower compared to T-cells (46,000-202,000 molecules/cell) and 
thus, their kad lower as noted by Eq. (1).
4, 51-53
  This means that fluidic shear stress can be used to 
remove from the selection surface cells with low kad values.  
Purity of isolated CD4+ T-lymphocytes was assessed by immunostaining with CD66b, 
CD14, and CD20 Abs to identify neutrophils (comprising 40-66% of total leukocyte population), 
monocytes (4-8%), and B-cells (8-12%), respectively.
3
 Purity was defined as the ratio of DAPI+, 
CD14-, CD66b-, and CD20- cells to the total number of nucleated cells. Fluorescence images 
(Figures 2.11A-C) showed the absence of cells labeled with CD14/66b/20 Abs. Isolated cells 
showed intact structures without an obvious change in morphology. It was also observed that T-
cells and neutrophils were distributed randomly within the channel (outer and inner curvatures of 
the curvilinear channels, Figure 2.8A) unlike circulating tumor cells, which we have reported to 
be predominantly isolated along the inner curvature.
40
 To confirm proper identification of T-
cells, an anti-CD3 marker was chosen because 87% of T-cells are CD3+ and CD4+ (Figures 
2.11D-F).
56
 For the UV-COCbif devices, purities were 97 ±1%, and CH-COCbif purities were 92 
±5% (Table 2.1). The lack of contaminating cells most likely resulted from their low CD4 
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expression and the application of a shear stress between 6 to 11 dynes/cm
2
.
51, 52, 57, 58
 The purity 
for the CH-COCZ for the CD4+ T-cells was found to be 98 ±1%. 
 
Figure 2.11 (A-F) Fluorescence microscopy images of CD4+ T-cells isolated from whole blood 
using a bifurcated microfluidic device immobilized with anti-CD4 Ab and stained with (A, D) 
DAPI (nuclear stain); (B) CD20/CD66b-FITC specific for B-lymphocytes and neutrophils, 
respectively; (C) CD14-PE specific for monocytes; (E) CD3-FITC specific for T-cells; and (F) 
no antibody used. Purity of CD4+ T cells was defined as positive for DAPI and negative for PE 
and FITC stains in (A-C), while specificity was demonstrated by dual staining of cells with CD3-
FITC and DAPI (D-F). (G-I) Fluorescence microscopic images of isolated neutrophils: (G) DAPI 
stained; (H) CD66b-FITC stained; (I) no Ab used; and (J-L) a neutrophil that was (J) DAPI 
stained with neutrophil morphology, (K) showed lack of CD66b-FITC signal, and (L) no Ab 
used. Neutrophils were identified only if positive for both DAPI and CD66b 
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Lastly, we assessed neutrophil purity by counting double positive DAPI and CD66b-FITC 
cells (Figure 2.11G-I). We observed that some cells were DAPI+ but very faint for CD66b-FITC, 
but the dimensions and morphology of these cells were consistent with neutrophils (Figure 2.11J-
L).
59
 These cells were counted as neutrophils and it is plausible that some neutrophils possessed 
very low CD66b expression and thus, could not be detected thereby artificially lowering purity 
levels. Neutrophil counts isolated from 50 μL of blood using the UV-COCbif devices averaged 
918 ±91 with a purity of 94 ±3 % and CH-COCZ yielded purities of 97 ±2% (see Table 2.1) 
Table 2.1 Enumeration values for isolated T-cells and neutrophils from whole blood using COC 
and PMMA microfluidic devices with different geometries and activation protocols. 
 
Cell type Chip Design 
Modification
-substrate 
Cell count (n= 4)  
Mean ± SD (Median) 
Negative 
control 
Purity  
T-Cells Bifurcated 
UV-PMMA 325 ±85 (342) --- --- 
UV-COC 798 ±168(723) 19 ±5 97 ±1 
CH-PMMA 7 ±3 (8) --- --- 
CH-COC 703 ±386 (846) 16 ±3 92 ±5 
Neutrophils Bifurcated UV-COC 918 ±91 (888) --- 94 ±3 
Neutrophils 
Z-
configuration 
UV- COC 1096 ±537 (1112) --- --- 
CH-COC 2949 ±901 --- 97 ±2 
T-cells 
Z-
configuration 
UV-COC 596 ±154 (585) 7 ±1 --- 
CH-COC 2565 ±1194 (2139) 30 ±9 98 ±1 
 
 Reverse Transcription –Polymerase Chain Reaction (RT-PCR) 2.3.7
The total number of isolated cells in the CH-COCZ devices ranged from 500 to 2,000 CD4+ 
T-cells and CD66b+ neutrophils. Considering an average of 10 pg of TRNA per leukocyte, we 
expected to obtain 5 – 20 ng TRNA (0.25-1 ng of mRNA) per bed, which should provide 
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sufficient material for cDNA synthesis and gene expression analysis. To make sure that 
sufficient mRNA was harvested from the T-cells and neutrophils, two beds were used for each 
cell type. T-cells and neutrophils were isolated from the same blood sample using the CH-COCZ 
chip and because of the high purity of isolated fractions, cell lysis was performed directly on 
chip. Following lysis and TRNA isolation, an RT reaction was performed. cDNA was then used 
for PCR with expression analysis of 4 genes; S100A9, which has been shown to be 
overexpressed following stroke
38
 and plays a prominent role in the regulation of inflammatory 
processes and immune response,
60-62
 TCRB and FPR1 genes, which are specific to T-cells and 
neutrophils,
63-65
 respectively, and GAPDH, a housekeeping gene used as a reference. Figure 
2.12A shows fluorescence images of the amplicons. Although the expression of GAPDH can 
vary between different types of cells,
66
 for these initial results we normalized the amplicon 
intensities to the intensity of the GAPDH product.  
As shown in Figure 4B for the T-cell population, we observed significantly lower expression 
(22x) of S100A9 than in the neutrophil subset for the same healthy donor.T-cells showed a higher 
expression of the TCRB gene compared to neutrophils as supported from the literature. However, 
some studies demonstrated neutrophils populations also expressing TCRB mRNA as well.
67
 
FPR1 gene was 7x higher expressed in neutrophils, similar to that reported in the literature.
68
 It is 
important to emphasize that in the case of mRNA profiling, it is imperative that cell perturbation 
and handling is reduced to eliminate any phenotypic changes.
69, 70
 By using microfluidics, we 
obtained pure populations of cells and cell lysate within 12 min from the time of blood sample 
introduction into the microfluidic device. Fast processing allows for securing high quality 
mRNA (data not shown), lack of centrifugation, and unnecessary storage of blood specimens.  
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Figure 2.12 (A) Gel electrophoresis inverted image of amplicons generated from cDNA reverse 
transcribed from TRNA extracted from isolated neutrophils. Negative control (-) and positive (+) 
amplification reactions for tested genes were performed with products from negative (-) RT 
(without RT enzyme) and positive (+) RT.  Amplicon lengths are shown in the figure. Separation 
performed at 4.8 V/cm in a TBE buffer. (B) Normalized to GAPDH gene signals (n=3) from the 
amplicons identified on an agarose gel stained with ethidium bromide for T-cells and 
neutrophils.  
 
 Conclusions 2.4
We have demonstrated an affinity-based microfluidic system capable of isolating highly pure 
subsets of leukocytes from whole blood. Processing 50 µL of whole blood within 6.6 min 
provided sufficient genetic material for gene expression profiling.  Special emphasis was placed 
on the fluid dynamics and design architecture of the device for T-cell and neutrophil isolation to 
obtain high purity leukocytes fractions using a single step. The isolation of two types of cells 
from whole blood was accomplished with purity >90%. 
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 We assessed the effects of polymeric substrate and surface activation modalities on cell 
isolation and discovered a chemical activation method for COC, which can be useful for ultra-
high aspect ratio microfluidic devices. The demonstrated results are not limited only to CD4+ T-
cells and CD66b+ neutrophils but can be expanded to analyze other cell types simply by 
choosing different affinity agents for the cells of interest. Furthermore, our microfluidic device 
contains four individually addressable beds, permitting simultaneous isolation of four individual 
cell sub-populations from the same blood sample with sufficient material to perform mRNA 
expression analysis on the isolated cells. 
 References 2.5
1. Feezor, R. J.; Baker, H. V.; Mindrinos, M.; Hayden, D.; Tannahill, C. L.; Brownstein, B. 
H.; Fay, A.; MacMillan, S.; Laramie, J.; Xiao, W.; Moldawer, L. L.; Cobb, J. P.; 
Laudanski, K.; Miller-Graziano, C. L.; Maier, R. V.; Schoenfeld, D.; Davis, R. W.; 
Tompkins, R. G. Whole Blood and Leukocyte Rna Isolation for Gene Expression 
Analyses. Physiol Genomics 2004, 19, 247-54. 
 
 
2. Gao, Y.; Li, W.; Pappas, D. Recent Advances in Microfluidic Cell Separations. Analyst 
(Cambridge, U. K.) 2013, 138, 4714-4721. 
 
 
3. Toner, M.; Irimia, D. Blood-on-a-Chip. Annu. Rev. Biomed. Eng. 2005, 7, 77-103, 3 
plates. 
 
 
4. Cheng, X.; Irimia, D.; Dixon, M.; Sekine, K.; Demirci, U.; Zamir, L.; Tompkins, R. G.; 
Rodriguez, W.; Toner, M. A Microfluidic Device for Practical Label-Free Cd4+ T Cell 
Counting of Hiv-Infected Subjects. Lab Chip 2007, 7, 170-178. 
 
 
5. Cheng, X.; Liu, Y.-s.; Irimia, D.; Demirci, U.; Yang, L.; Zamir, L.; Rodriguez, W. R.; 
Toner, M.; Bashir, R. Cell Detection and Counting through Cell Lysate Impedance 
Spectroscopy in Microfluidic Devices. Lab Chip 2007, 7, 746-755. 
 
 
6. Rodriguez, W. R.; Christodoulides, N.; Floriano, P. N.; Graham, S.; Mohanty, S.; Dixon, 
M.; Hsiang, M.; Peter, T.; Zavahir, S.; Thior, I.; Romanovicz, D.; Bernard, B.; Goodey, 
 97 
 
A. P.; Walker, B. D.; McDevitt, J. T. A Microchip Cd4 Counting Method for Hiv 
Monitoring in Resource-Poor Settings. PLoS Med. 2005, 2, 663-672. 
 
 
7. Kim, S. T.; Kim, D.-J.; Kim, T.-J.; Seo, D.-W.; Kim, T.-H.; Lee, S.-Y.; Kim, K.; Lee, K.-
M.; Lee, S.-K. Novel Streptavidin-Functionalized Silicon Nanowire Arrays for Cd4+ T 
Lymphocyte Separation. Nano Lett. 2010, 10, 2877-2883. 
 
 
8. Kim, D.-J.; Seol, J.-K.; Wu, Y.; Ji, S.; Kim, G.-S.; Hyung, J.-H.; Lee, S.-Y.; Lim, H.; 
Fan, R.; Lee, S.-K. A Quartz Nanopillar Hemocytometer for High-Yield Separation and 
Counting of Cd4+ T Lymphocytes. Nanoscale 2012, 4, 2500-2507. 
 
 
9. Thorslund, S.; Larsson, R.; Bergquist, J.; Nikolajeff, F.; Sanchez, J. A Pdms-Based 
Disposable Microfluidic Sensor for Cd4+ Lymphocyte Counting. Biomed Microdevices 
2008, 10, 851-7. 
 
 
10. Warner, E. A.; Kotz, K. T.; Ungaro, R. F.; Abouhamze, A. S.; Lopez, M. C.; Cuenca, A. 
G.; Kelly-Scumpia, K. M.; Moreno, C.; O'Malley, K. A.; Lanz, J. D.; Baker, H. V.; 
Martin, L. C.; Toner, M.; Tompkins, R. G.; Efron, P. A.; Moldawer, L. L. Microfluidics-
Based Capture of Human Neutrophils for Expression Analysis in Blood and 
Bronchoalveolar Lavage. Lab. Invest. 2011, 91, 1787-1795. 
 
 
11. Feigin, V. L.; Lawes, C. M. M.; Bennett, D. A.; Barker-Collo, S. L.; Parag, V. 
Worldwide Stroke Incidence and Early Case Fatality Reported in 56 Population-Based 
Studies: A Systematic Review. The Lancet Neurology 2009, 8, 355-369. 
 
 
12. Hand, P. J.; Kwan, J.; Lindley, R. I.; Dennis, M. S.; Wardlaw, J. M. Distinguishing 
between Stroke and Mimic at the Bedside: The Brain Attack Study. Stroke 2006, 37, 769-
75. 
 
 
13. Norris, J. W.; Hachinski, V. C. Misdiagnosis of Stroke. Lancet 1982, 1, 328-31. 
 
 
14. Goldstein, L. B.; Simel, D. L. Is This Patient Having a Stroke? JAMA, J. Am. Med. Assoc. 
2005, 293, 2391-2402. 
 
 
15. Furlan, A.; Higashida, R.; Wechsler, L.; Gent, M.; Rowley, H.; Kase, C.; Pessin, M.; 
Ahuja, A.; Callahan, F.; Clark, W. M.; Silver, F.; Rivera, F. Intra-Arterial Prourokinase 
 98 
 
for Acute Ischemic Stroke. The Proact Ii Study: A Randomized Controlled Trial. JAMA, 
J. Am. Med. Assoc. 1999, 282, 2003-2011. 
 
 
16. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Dvalos, A.; Guidetti, D.; Larrue, V.; 
Lees, K. R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von, K. R.; Wahlgren, N.; Toni, 
D. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N. Engl. J. 
Med. 2008, 359, 1317-1329. 
 
 
17. Goldstein, L. B. Improving the Clinical Diagnosis of Stroke. Stroke 2006, 37, 754-5. 
 
 
18. Whiteley, W.; Tseng, M.-C.; Sandercock, P. Blood Biomarkers in the Diagnosis of 
Ischemic Stroke: A Systematic Review. Stroke 2008, 39, 2902-9. 
 
 
19. Hasan, N.; McColgan, P.; Bentley, P.; Edwards, R. J.; Sharma, P. Towards the 
Identification of Blood Biomarkers for Acute Stroke in Humans: A Comprehensive 
Systematic Review. Br. J. Clin. Pharmacol. 2012, 74, 230-240. 
 
 
20. Jickling, G. C.; Sharp, F. R. Blood Biomarkers of Ischemic Stroke. Neurotherapeutics 
2011, 8, 349-360. 
 
 
21. Saah, A. J.; Hoover, D. R. “Sensitivity” and “Specificity” Reconsidered: The Meaning of 
These Terms in Analytical and Diagnostic Settings. Annals of Internal Medicine 1997, 
126, 91-94. 
 
 
22. Maas, M. B.; Furie, K. L. Molecular Biomarkers in Stroke Diagnosis and Prognosis. 
Biomarkers Med. 2009, 3, 363-383. 
 
 
23. Yilmaz, G.; Arumugam, T. V.; Stokes, K. Y.; Granger, D. N. Role of T Lymphocytes and 
Interferon-Gamma in Ischemic Stroke. Circulation 2006, 113, 2105-12. 
 
 
24. Marsh, B. J.; Williams-Karnesky, R. L.; Stenzel-Poore, M. P. Toll-Like Receptor 
Signaling in Endogenous Neuroprotection and Stroke. Neuroscience (Amsterdam, Neth.) 
2009, 158, 1007-1020. 
 
 
25. Tang, S.-C.; Arumugam, T. V.; Xu, X.; Cheng, A.; Mughal, M. R.; Jo, D. G.; Lathia, J. 
D.; Siler, D. A.; Chigurupati, S.; Ouyang, X.; Magnus, T.; Camandola, S.; Mattson, M. P. 
 99 
 
Pivotal Role for Neuronal Toll-Like Receptors in Ischemic Brain Injury and Functional 
Deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 13798-13803. 
 
 
26. Gee, J. M.; Kalil, A.; Shea, C.; Becker, K. J. Lymphocytes: Potential Mediators of 
Postischemic Injury and Neuroprotection. Stroke 2007, 38, 783-8. 
 
 
27. Laudanski, K.; Miller-Graziano, C.; Xiao, W.; Mindrinos, M. N.; Richards, D. R.; De, A.; 
Moldawer, L. L.; Maier, R. V.; Bankey, P.; Baker, H. V.; Brownstein, B. H.; Cobb, J. P.; 
Calvano, S. E.; Davis, R. W.; Tompkins, R. G. Cell-Specific Expression and Pathway 
Analyses Reveal Alterations in Trauma-Related Human T Cell and Monocyte Pathways. 
Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15564-15569. 
 
 
28. Baird, A. E. Blood Biologic Markers of Stroke: Improved Management, Reduced Cost? 
Curr Atheroscler Rep 2006, 8, 267-75. 
 
 
29. Moore, D. F.; Goldin, R.; Violet, W. Using Peripheral Blood Mononuclear Cells to 
Determine a Gene Expression Profile of Intra-Cerebral Hemorrhage. Annals of Neurology 
2007, 62, S8. 
 
 
30. Moore, D. F.; Li, H.; Jeffries, N.; Wright, V.; Cooper, R. A.; Elkahloun, A.; Gelderman, 
M. P.; Zudaire, E.; Blevins, G.; Yu, H.; Goldin, E.; Baird, A. E. Using Peripheral Blood 
Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke. 
Circulation 2005, 111, 212-221. 
 
 
31. Oh, S.-H.; Kim, O.-J.; Shin, D.-A.; Song, J.; Yoo, H.; Kim, Y.-K.; Kim, J.-K. Alteration 
of Immunologic Responses on Peripheral Blood in the Acute Phase of Ischemic Stroke: 
Blood Genomic Profiling Study. Journal of Neuroimmunology 2012, 249, 60-65. 
 
 
32. Tang, Y.; Xu, H.; Du, X.; Lit, L.; Walker, W.; Lu, A.; Ran, R.; Gregg, J. P.; Reilly, M.; 
Pancioli, A.; Khoury, J. C.; Sauerbeck, L. R.; Carrozzella, J. A.; Spilker, J.; Clark, J.; 
Wagner, K. R.; Jauch, E. C.; Chang, D. J.; Verro, P.; Broderick, J. P.; Sharp, F. R. Gene 
Expression in Blood Changes Rapidly in Neutrophils and Monocytes after Ischemic 
Stroke in Humans: A Microarray Study. J Cereb. Blood Flow Metab. 2006, 26, 1089-
1102. 
 
 
33. Mateusz G. Adamski, Y. L., Erin Wagner, Hua Yu, Chloe Seales-Bailey,  Steven A. 
Soper, Michael Murphy, Alison E. Baird. J Biomolecular Screening 2013, submitted for 
publication. 
 100 
 
34. Du, X.; Tang, Y.; Xu, H.; Lit, L.; Walker, W.; Ashwood, P.; Gregg, J. P.; Sharp, F. R. 
Genomic Profiles for Human Peripheral Blood T Cells, B Cells, Natural Killer Cells, 
Monocytes, and Polymorphonuclear Cells: Comparisons to Ischemic Stroke, Migraine, 
and Tourette Syndrome. Genomics 2006, 87, 693-703. 
 
 
35. Siliciano, R. F.; Lawton, T.; Knall, C.; Karr, R. W.; Berman, P.; Gregory, T.; Reinherz, 
E. L. Analysis of Host-Virus Interactions in Aids with Anti-Gp120 T Cell Clones: Effect 
of Hiv Sequence Variation and a Mechanism for Cd4+ Cell Depletion. Cell (Cambridge, 
Mass.) 1988, 54, 561-75. 
 
 
36. O'Brien, W. A.; Hartigan, P. M.; Daar, E. S.; Simberkoff, M. S.; Hamilton, J. D. Changes 
in Plasma Hiv Rna Levels and Cd4+ Lymphocyte Counts Predict Both Response to 
Antiretroviral Therapy and Therapeutic Failure. Va Cooperative Study Group on Aids. 
Ann Intern Med 1997, 126, 939-45. 
 
 
37. Yarchoan, R.; Tosato, G.; Little, R. F. Therapy Insight: Aids-Related Malignancies-the 
Influence of Antiviral Therapy on Pathogenesis and Management. Nat. Clin. Pract. 
Oncol. 2005, 2, 406-415. 
 
 
38. Adamski, M. G.; Li, Y.; Wagner, E.; Yu, H.; Seales-Bailey, C.; Soper, S. A.; Murphy, 
M.; Baird, A. E. Next-Generation Qpcr for the High-Throughput Measurement of Gene 
Expression in Multiple Leukocyte Subsets. J Biomol Screen 2013, 18, 1008-1017. 
 
 
39. Hupert, M. L.; Guy, W. J.; Llopis, S. D.; Shadpour, H.; Rani, S.; Nikitopoulos, D. E.; 
Soper, S. A. Evaluation of Micromilled Metal Mold Masters for the Replication of 
Microchip Electrophoresis Devices. Microfluid. Nanofluid. 2007, 3, 1-11. 
 
 
40. Adams, A. A.; Okagbare, P. I.; Feng, J.; Hupert, M. L.; Patterson, D.; Gottert, J.; 
McCarley, R. L.; Nikitopoulos, D.; Murphy, M. C.; Soper, S. A. Highly Efficient 
Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using 
Polymer-Based Microfluidics with an Integrated Conductivity Sensor. J. Am. Chem. Soc. 
2008, 130, 8633-8641. 
 
 
41. Wei, S.; Vaidya, B.; Patel, A. B.; Soper, S. A.; McCarley, R. L. Photochemically 
Patterned Poly(Methyl Methacrylate) Surfaces Used in the Fabrication of Microanalytical 
Devices. J. Phys. Chem. B 2005, 109, 16988-16996. 
 
 
 101 
 
42. Adamski, M. G.; Li, Y.; Wagner, E.; Yu, H.; Seales-Bailey, C.; Soper, S. A.; Murphy, 
M.; Baird, A. E. Next-Generation Qpcr for the High-Throughput Measurement of Gene 
Expression in Multiple Leukocyte Subsets. J Biomol Screen 2013. 
 
 
43. Jackson, J. M.; Witek, M. A.; Hupert, M. L.; Brady, C.; Pullagurla, S.; Kamande, J.; 
Aufforth, R. D.; Tignanelli, C. J.; Torphy, R. J.; Yeh, J. J.; Soper, S. A. Uv Activation of 
Polymeric High Aspect Ratio Microstructures: Ramifications in Antibody Surface 
Loading for Circulating Tumor Cell Selection. Lab on a Chip 2014. 
 
 
44. Kamande, J. W.; Hupert, M. L.; Witek, M. A.; Wang, H.; Torphy, R. J.; Dharmasiri, U.; 
Njoroge, S. K.; Jackson, J. M.; Aufforth, R. D.; Snavely, A.; Yeh, J. J.; Soper, S. A. 
Modular Microsystem for the Isolation, Enumeration, and Phenotyping of Circulating 
Tumor Cells in Patients with Pancreatic Cancer. Analytical Chemistry 2013. 
 
 
45. Holmberg, K.; Hyden, H. Methods of Immobilization of Proteins to 
Polymethylmethacrylate. Prep. Biochem. 1985, 15, 309-19. 
 
 
46. Patel, S.; Thakar, R. G.; Wong, J.; McLeod, S. D.; Li, S. Control of Cell Adhesion on 
Poly(Methyl Methacrylate). Biomaterials 2006, 27, 2890-2897. 
 
 
47. Holmberg, K.; Hyden, H. Methods of Immobilization of Proteins to 
Polymethylmethacrylate. Preparative biochemistry 1985, 15, 309-19. 
 
 
48. Kirillova, M. V.; Kirillov, A. M.; Kuznetsov, M. L.; Silva, J. A. L.; da Silva, J. J. R. F.; 
Pombeiro, A. J. L. Alkanes to Carboxylic Acids in Aqueous Medium: Metal-Free and 
Metal-Promoted Highly Efficient and Mild Conversions. Chem Commun 2009, 2353-
2355. 
 
 
49. Soper, S. A.; Battle, K.; Jackson, J. M.; Witek, M. A.; Hupert, M.; Hunsucker, S.; 
Armistead, P. Solid-Phase Extraction and Purification of Membrane Proteins Using a Uv-
Modified Pmma Microfluidic Bioaffinity [Small Micro]Spe Device. Analyst 2014. 
 
 
50. Murthy, S. K.; Sin, A.; Tompkins, R. G.; Toner, M. Effect of Flow and Surface 
Conditions on Human Lymphocyte Isolation Using Microfluidic Chambers. Langmuir 
2004, 20, 11649-11655. 
 
 
 102 
 
51. Beck, M.; Brockhuis, S.; van, d. V. N.; Breukers, C.; Greve, J.; Terstappen, L. W. M. M. 
On-Chip Sample Preparation by Controlled Release of Antibodies for Simple Cd4 
Counting. Lab Chip 2012, 12, 167-173. 
 
 
52. Davis, K. A.; Abrams, B.; Iyer, S. B.; Hoffman, R. A.; Bishop, J. E. Determination of 
Cd4 Antigen Density on Cells: Role of Antibody Valency, Avidity, Clones, and 
Conjugation. Cytometry 1998, 33, 197-205. 
 
 
53. Denny, T. N.; Stein, D.; Mui, T.; Scolpino, A.; Holland, B. Quantitative Determination of 
Surface Antibody Binding Capacities of Immune Subsets Present in Peripheral Blood of 
Healthy Adult Donors. Cytometry 1996, 26, 265-274. 
 
 
54. Toner, M.; Irimia, D. Blood-on-a-Chip. Annual Review of Biomedical Engineering 2005, 
7, 77-103. 
 
 
55. Chang, K.-C.; Hammer, D. A. The Forward Rate of Binding of Surface-Tethered 
Reactants: Effect of Relative Motion between Two Surfaces. Biophysical journal 1999, 
76, 1280-1292. 
 
 
56. Egerton, M.; Scollay, R.; Shortman, K. Kinetics of Mature T-Cell Development in the 
Thymus. Proceedings of the National Academy of Sciences 1990, 87, 2579-2582. 
 
 
57. Hultin, L. E.; Matud, J. L.; Giorgi, J. V. Quantitation of Cd38 Activation Antigen 
Expression on Cd8+ T Cells in Hiv-1 Infection Using Cd4 Expression on Cd4+ T 
Lymphocytes as a Biological Calibrator. Cytometry 1998, 33, 123-132. 
 
 
58. Lee, B.; Sharron, M.; Montaner, L. J.; Weissman, D.; Doms, R. W. Quantification of 
Cd4, Ccr5, and Cxcr4 Levels on Lymphocyte Subsets, Dendritic Cells, and Differentially 
Conditioned Monocyte-Derived Macrophages. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 
5215-5220. 
 
 
59. Bainton, D. F.; Ullyot, J. L.; Farquhar, M. G. The Development of Neutrophilic 
Polymorphonuclear Leukocytes in Human Bone Marrow: Origin and Content of 
Azurophil and Specific Granules. The Journal of Experimental Medicine 1971, 134, 907-
934. 
 
 
 103 
 
60. Srikrishna, G. S100a8 and S100a9: New Insights into Their Roles in Malignancy. J. 
Innate Immun. 2012, 4, 31-40. 
 
 
61. Brennan, R. M.; Petersen, J.; Neller, M. A.; Miles, J. J.; Burrows, J. M.; Smith, C.; 
McCluskey, J.; Khanna, R.; Rossjohn, J.; Burrows, S. R. The Impact of a Large and 
Frequent Deletion in the Human Tcr Β Locus on Antiviral Immunity. J. Immunol. 2012, 
188, 2742-2748. 
 
 
62. Marrack, P.; Rubtsova, K.; Scott-Browne, J.; Kappler, J. W. T Cell Receptor Specificity 
for Major Histocompatibility Complex Proteins. Curr. Opin. Immunol. 2008, 20, 203-
207. 
 
 
63. Murphy, P. M.; Tiffany, H. L.; McDermott, D.; Ahuja, S. K. Sequence and Organization 
of the Human N-Formyl Peptide Receptor-Encoding Gene. Gene 1993, 133, 285-90. 
 
 
64. Devosse, T.; Guillabert, A.; D'Haene, N.; Berton, A.; De Nadai, P.; Noel, S.; Brait, M.; 
Franssen, J.-D.; Sozzani, S.; Salmon, I.; Parmentier, M. Formyl Peptide Receptor-Like 2 
Is Expressed and Functional in Plasmacytoid Dendritic Cells, Tissue-Specific 
Macrophage Subpopulations, and Eosinophils. J. Immunol. 2009, 182, 4974-4984. 
 
 
65. Tunnacliffe, A.; Kefford, R.; Milstein, C.; Forster, A.; Rabbitts, T. H. Sequence and 
Evolution of the Human T-Cell Antigen Receptor Β-Chain Genes. Proc. Natl. Acad. Sci. 
U. S. A. 1985, 82, 5068-72. 
 
 
66. Reiter, M.; Kirchner, B.; Mueller, H.; Holzhauer, C.; Mann, W.; Pfaffl, M. W. 
Quantification Noise in Single Cell Experiments. Nucleic Acids Res. 2011, 39, e124. 
 
 
67. Puellmann, K.; Kaminski, W. E.; Vogel, M.; Nebe, C. T.; Schroeder, J.; Wolf, H.; 
Beham, A. W. A Variable Immunoreceptor in a Subpopulation of Human Neutrophils. 
Chir. Forum Exp. Klin. Forsch. 2007, 247-249. 
 
 
68. Whitney, A. R.; Diehn, M.; Popper, S. J.; Alizadeh, A. A.; Boldrick, J. C.; Relman, D. 
A.; Brown, P. O. Individuality and Variation in Gene Expression Patterns in Human 
Blood. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1896-1901. 
 
 
 104 
 
69. Eggleton, P.; Gargan, R.; Fisher, D. Rapid Method for the Isolation of Neutrophils in 
High Yield without the Use of Dextran or Density Gradient Polymers. J Immunol 
Methods 1989, 121, 105-13. 
 
 
70. Watson, F.; Robinson, J. J.; Edwards, S. W. Neutrophil Function in Whole Blood and 
after Purification: Changes in Receptor Expression, Oxidase Activity and Responsiveness 
to Cytokines. Biosci. Rep. 1992, 12, 123-33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
 
CHAPTER 3. SOLID PHASE EXTRACTION OF RNA FROM ISOLATED 
T-CELLS AND NEUTROPHILS USING COMBINED MICROFLUIDIC 
MODULES 
 
3.1 Introduction 
Advancements in the field of genomics have allowed better understanding of gene expression 
changes and provide accurate means of disease diagnosis by potential biomarker measurement.
1
 
Genomic profiling of peripheral blood samples could be of great value in identifying biomarkers 
for various complex diseases, including stroke, as evident from the studies which utilized white 
blood cells to identify discrete patterns of expression associated with the disease states.
2, 3
 
Therefore, growing interest continues in isolation of pure population of relevant white blood cell 
subsets and extraction of nucleic acids for applications in clinical diagnostics and forensics. In 
addition to that, development of small footprint, self-contained, disposable, fast, and inexpensive 
devices for cell isolation and nucleic acid isolation play a key role in the point-of-care testing 
specially in resource-poor settings. Greatest areas of potential impact for these miniaturized 
devices is in molecular diagnostics to facilitate fast diagnostics, low cost, operation by minimally 
trained personnel, and low contamination risk.  
Some of the previously reported cell separation strategies include density gradient methods,
4
 
magnetic activated cell separation (MACS),
5
 micro-fabricated fluorescence activated cell 
sorting,
6
 ultrasonic particle separation,
7
 mammalian cells sorted by optical force switching,
8
 cell 
separation by dielectrophoresis chip.
9
 However some of the limitations associated with 
aforementioned techniques are alteration in immunophenotype of leukocytes due to excessive 
manipulation of sample such as repeating pipetting or centrifugation. Cells are prone to apoptosis 
as they are very sensitive to the changes in the environment.
10
 Although FACS and MACS offer 
high throughput, however high cost and complexity of these systems limits their implementation 
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in a clinical setting. Strong polarization charges in non-uniform electric field may cause damage 
to the cells in dielectrophoresis methods which limits its wide clinical use.  
A suitable sample preparation for molecular diagnostics consists of an efficient target 
recovery, from a biologically relevant sample, preserving the integrity of the nucleic acid (NA) 
molecules at the same time. Nucleic acid-based assays have been successfully implemented in 
recent years in many fields exploiting their rapid and accurate analysis (e.g., medical diagnostics, 
forensics, environmental analysis, and biodefense).
11-14
 These assays typically involve cell lysis 
to release the small amount of NAs (DNA/RNA) present in the sample, purification of these 
moieties followed by amplification to achieve detectable concentration, and detection using 
hybridization or electrophoretic methods.
15
 The sensitivity of these analyses, among other things 
depends on the purity and yield of NA obtained that can be transferred into amplification 
reaction. 
Earlier methods of DNA purification, CsCl gradient extraction method,
16
 phenol-chloroform 
phase separation
17
 were replaced by solid phase extraction (SPE) methods wherein analytes are 
retained on a solid support and are subsequently eluted in a concentrated form,
18
  thus eliminating 
the need for the use of toxic chemicals and lengthy centrifuge times. Most of these methods rely on 
adsorption of DNA with a solid surface, either via hydrogen bonding or via electrostatic 
interactions.
19
 Commercially available NA binding columns require several centrifugation steps 
and pipetting. Therefore, transition to micro-domain is more amenable to miniaturization than 
the traditional extraction processes and the use of microfluidic SPE allows for more rapid and 
straightforward on-chip sample preparation as demonstrated by Tian et al., who established a 
capillary-based micro-SPE (iSPE).
20
 Microchip-based DNA purification was first demonstrated 
by Christel et al. using pillars created in a microchannel using reactive ion etching to increase the 
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silica surface area available for DNA adsorption but limited by the complexity of the fabrication 
procedure.
21
 Various techniques of microfluidic SPE involved the use of functionalized 
microparticles, filters, silica gels and beads, and micro- and nano-engineered surfaces.
22
 
Microfluidic extraction systems are mostly designed for DNA sample preparation and 
relatively less research has been reported on the RNA isolation and specifically using 
microfluidics. This is due to difficulty in isolation and purification of RNA because of significant 
chemical and biological lability and instability of RNA when compared to DNA. RNases are 
extremely active enzymes present in human skin, body fluids, lab surfaces, and environment. 
RNase contamination makes the isolation of RNA from common clinical and forensic samples 
challenging. Also, RNA derived from complicated matrix like blood may be contaminated with 
inhibitors of downstream molecular analyses. Therefore, the choice of RNA purification methods 
is important for successful isolation of high quality of RNA for consistent performance in 
downstream applications like reverse transcription RT quantitative PCR (RT-qPCR), microarray 
analyses.  
RNA has multiple advantages over DNA in some applications as a biological target material 
since it is more closely related to cell’s machinery. To carry out a gene expression analysis, RNA 
must be first isolated and purified from biological source of interest. Detection of RNA and 
mRNA expression can be used for clinical diagnostics, as the increased/decreased levels of 
expression of specific genes can be indicative of the disease. These methods are based on the 
inherently variable mRNA expression from different cell types, producing gene-specific patterns 
which can be verified by the presence of a unique mRNA expression pattern.
23
 However, it is 
known that, within minutes of collection, peripheral blood gene expression profiles change 
significantly due to transcript degradation, and these purification processes further introduce 
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changes in expressed transcripts.
24
 The correct interpretation of transcript abundance requires 
stabilization of the transcriptome at the point of sample collection, through storage and transport, 
in order for gene expression to be detected in a reproducible manner.
25
 Traditional assays involve 
multiple steps involving sample transfer which can cause the degradation of the sample by 
exposure to outside environment. Microchip based extraction hence offers advantages by 
providing a contamination free environment because material is isolated in enclosed 
architectures with minute amount of the sample needed. Examples of microfluidic chips for the 
SPE of RNA using silica beads as a solid phase, chitosan-coated silica, porous polymer monolith 
have been demonstrated.
26-29
 
To address some of the issues of the aforementioned methods and their applicability for the 
purification of NAs in clinical settings such as 1) cost of device fabrication and substrate 
material required for the device; (2) lengthy and labor intensive procedures for SPE bed 
preparation and; (3) sample recovery, we have demonstrated the use of photoactivated 
polycarbonate (PPC) devices containing micropillars. SPE active surface on these PC devices is 
produced by simple UV-photoactivation protocol which generates high density of carboxylic 
acids on the PC surface that serves as the affinity surface for NA.
30, 31
 The advantages of this 
method include: (1) inexpensive device fabrication through micro-replication into PC; (2) quick 
and simple bed activation procedure using UV irradiation; (3) scalability of the fabrication 
process to high volume mass production; (4) versatility – various NAs can be selectively purified 
by using the proper composition of immobilization buffer and; (5) very high target recoveries 
with good removal of endogenous proteins.30-32 
In this study, we present a reliable and fast method using combined microfluidic modules 
that serve purpose of cell isolation, cell lysis and TRNA isolation. The strategy employed here is 
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to capture target cells on cell isolation module and following lysis on microchip to isolate RNA 
using SPE module. RNA extracted using this method was reverse transcribed and resulting 
cDNA was amplified via PCR. Incorporation of cell isolation, lysis and RNA purification steps 
into one platform has a potential for development of an on-site setting and reduces the potential 
for contamination. These integrated modules can be adapted for automation to enable high 
throughput and can be implemented into microfluidic systems that interface with downstream 
components. 
3.2 Materials and Methods 
3.2.1 Surface Characterization Techniques 
Surface characterization studies were performed on clean planar polymer substrates. For XPS 
measurements, C 1s and O 1s photoelectron signals were acquired using an Axis Ultra DLD X-
ray photoelectron spectrometer (Kratos Analytical) under ultra-high vacuum conditions (10
-8
 to 
10
-10 Torr) with a monochromatic Al Kα X-ray source, 20 eV pass energy, 370 s acquisition 
time, 1,600 ms dwell time, and 20° electron take-off angle. Given an inelastic mean free path of 
3-4 nm, ~95% of the resultant signal originated 9-12 nm from the surface. ATR-FTIR spectra 
were scanned from 375-4000 cm
-1 
using an ALPHA FTIR spectrometer and a Platinum ATR 
module (Bruker Optics).  
3.2.2 Chemicals and Reagents 
Polyethylene glycol (PEG, Mw 8000), NaCl, ethanol, 2-propanol, were all purchased from 
Sigma Aldrich. Ethanol was purchased from Fisher Scientific (Houston, TX). The lysis solution, 
DNase used was from GenElute mammalian genomic RNA Miniprep Kit (Sigma-Aldrich, St. 
Louis, MO) and used as received. A stock solution of immobilization buffer (IB) was prepared 
with nuclease-free water to yield an optimal buffer composition of 0.5 M NaCl, 5% PEG, 63% 
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EtOH. RNA containing samples were suspended in the IB and processed using the SPE 
microchip as described below. All the primers used in this work were purchased from Integrated 
DNA Technologies, Coralville, IA. 
3.2.3 Design and Fabrication of Microfluidic Modules 
The microfluidic device fabrication involved three major steps: (1) Mold insert fabrication 
using a micro-milling machine (Kern MMP, Kern Micro- and Feinwerktechnik, Murnau-
Westried, Germany); (2) hot embossing of the microfluidic structures (HEX02, JenOptik 
Mikrotechnik, Jena, Germany) on 3 mm thick PMMA/PC substrates (Goodfellow, United 
Kingdom); and (3) post-processing of the microfluidic device including drilling of sample 
reservoirs, UV modification of the immobilization beds and cover plate assembly.  
The microfluidic devices for cell isolation were hot embossed into cycloolefin copolymer 
(COC) substrates, via micro replication from a metal mold master as reported earlier.
33
 The Z-
configuration device, consisted of 64 curvilinear channels (see Figure 3.3A) that were 9,000 x 25 
x 80 µm (l x w x h) with a center-to-center spacing of 200 µm. Each isolation bed’s surface area 
was 132.3 mm
2
. Addressing each bed required four bifurcations, with an additional two 
bifurcations for the four individual isolation units. All four capture beds shared a common inlet 
port, with different outlet ports for each capture bed (Figure 3.3 B). 
SPE module for isolation and purification of RNA, was embossed into PC substrate in a 
single step. This device consisted of six, 24 mm long and 1.4 mm wide channels with 
microposts. The channel (capture bed) dimensions were 100 μm height, 100 μm diameter, a 50 
μm spacing. The extraction bed consisted of series of ~3600 microposts (see Figure 3.2 C, D) 
which provided a high surface area allowing high mass load of RNA. Each affinity bed had a 
surface area of 110 mm
2
 and volume 260 nL. 
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3.2.4 Assembly of the Microfluidic Modules 
For the device assembly, both COC and PC, inlet and outlet reservoirs were drilled (d=0.85 
mm) in both microchip devices, followed by cleaning and then drying at 60ºC. A 250 µm thick 
coverslips and devices were modified for 15 min in a home built UV chamber equipped with a 
low pressure Hg lamp (1.5cm from light source, 22 mW/cm
2
 measured at 254 nm) to generate 
carboxylic acid scaffolds on microchannel surfaces.
34
 In order to enclose the microfluidic 
structures, thermal fusion bonding was performed at 132˚C and 144oC (~25 min) for UV-
modified COC and PC microdevices, respectively. PEEK tubing, IDEX Health & Science LLC 
(175/335 µm id/od) was inserted into the drilled reservoirs and glued with epoxy resin to 
facilitate sealed junction. Constant flow programmable syringe pump (Harvard Instruments) with 
attached syringe introduced fluids into the device. 
3.2.5 Cell Isolation on COC Microfluidic Devices 
Following device assembly, Ab immobilization was carried out in two-step process. In the 
first step, 50 mg/mL EDC and 5 mg/mL NHS in 100 mM MES (pH= 4.8) was introduced into 
the freshly fabricated device and incubated for 15 min at room temperature to obtain the 
succinimidyl ester intermediate. EDC/NHS solution was then removed from the device by 
flushing with PBS, and a 15 µL aliquot of 0.5 mg/mL (unless stated otherwise) mouse anti-
human CD4 (T-cell isolation) or mouse anti-human CD66b (neutrophil isolation) was introduced 
into the device and incubated overnight at 4˚C. The capture bed was then rinsed with 1 mL PBS 
(pH = 7.4) to remove unreacted molecules. 
Whole blood samples were obtained from anonymous healthy donors at UNC Cancer 
Hospital Blood Bank in accordance with the UNC Institutional Review Board (IRB) procedures. 
Peripheral blood samples were collected by venipuncture technique in Vacutainer tubes 
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containing EDTA (K3) 7.5%, 0.06 mL, (Tyco Health Care). Collected samples were processed 
within 4 h. 
The microfluidic device was connected to the syringe pump with PEEK tubing via a luer lock 
tuberculin syringe connector (Hamilton, Reno, NV). A precapture rinse of the chip was 
performed using PBS/0.5% BSA at 4 mm/s. 200 µL of whole blood was infused through the 
common inlet, at 3.8 µL/min which yielded nominal linear velocities of 2 mm/s in the isolation 
bed. A post capture rinse was performed at 4 mm/s with 100-200 µL PBS/0.5% BSA to remove 
blood and unbounded cells. 
3.2.6 Cell Lysis 
T-cells and neutrophils isolated in the bifurcated COC chip. Numbers of isolated cells were 
enumerated using bright field microscopy. 200 µl of lysis solution was then introduced through 
the common inlet of the bifurcated device and the lysate is collected into four different 
microfuge tubes from the outlets. The cell lysate was then suspended in the appropriate IB ready 
to be introduced to the SPE module. 
3.2.7 Operation of Microchip Solid Phase Extraction  
The extraction procedure consisted of load, wash, and elution steps. In the load step a 
cocktail of 50 μL of IB buffer (0.5 M NaCl, 5% PEG, 63 % Ethanol) , 50 µl  cell lysate (T-
cells/neutrophils) and 170 µl of ethanol (63%), was infused through the SPE bed using a 
programmable syringe pump at 5 µL/min followed by a 200 µL of wash buffer (85% ethanol) at 
5 μL/min.  This washing step ensures complete removal of any proteins or possible PCR 
inhibitors that were adsorbed onto the SPE bed during the load step. Air was drawn through the 
other end of the SPE bed to remove ethanol and dry the bed. Ethanol removal is critical, because 
residual amounts of ethanol may serve as a PCR inhibitor. Finally, the RNA was eluted with ~20 
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μL H2O pumped through the SPE bed at 5 μL/min and was collected from the SPE bed into PCR 
tubes. Then, isolation of pure RNA was achieved by a secondary enrichment, through enzymatic 
removal of genomic DNA (DNase treatment), using DNase 1 digestion set (Sigma Aldrich, St. 
Louis, MO. The DNase cocktail was prepared by addition of DNase I (10% of the total eluted 
volume) and buffer (10% of the total eluted buffer). After incubation at room temperature for 15 
minutes, the same volume of EDTA stop solution was added and the mixture was incubated at 
70˚C for 10 minutes. This solution was then used for subsequent reverse transcription and PCR 
analysis. 
3.2.8 Reverse Transcription 
After the purification of total RNA (TRNA), using SPE unit, reverse transcription (RT) of 
RNA was accomplished using a ProtoScript II First Strand cDNA Synthesis Kit (New England 
BioLabs, Ipswich, MA). Samples were prepared by mixing 10 µL reaction mix, 2 µL poly-T 
primer, 2 µL enzyme (no enzyme, 2 µL of water for RT-) and 6 µL of TRNA. The samples were 
then incubated at 42˚C for 1 h and heated to 80˚C for 5 min to deactivate the RT enzyme.  
3.2.9 Polymerase Chain Reactions (PCR) 
PCR was performed with synthesized cDNA in a total volume of 20 µL using Taq 2X Master 
Mix (New England Biolabs, Ipswich, MA). PCR cocktails consisted of 2 µL of primers mix 
(final concentration 500 nM), 10 µL Taq 2X Master Mix, 6 µL nuclease free water and 2 µL 
cDNA. PCR was carried out in a commercial thermal cycler (MJ Research Inc., Waltham, MA) 
with following steps: an initial denaturation at 94˚C for 2.5 min followed by 40 cycles of 
denaturation at 94˚C for 15 s, annealing for 30 s at 63˚C for GAPDH primers, 55˚C for S100A9 
and GUSB primers, 58˚C for TCRB primers, and 54˚C for FPR1 primers, and elongation at 72˚C 
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for 30 s. A final extension at 72˚C for 7 min was followed by a cooling step at 4˚C. The list of 
primers used is tabulated below.  
Table 3.1 List of primers used for amplification of cDNA. 
 
3.2.10 Gel Electrophoresis 
PCR products were electrophoresed at 8.3 V/cm in 1X TBE (Tris–boric acid/EDTA) (Bio-
Rad Laboratories) on a 4% agarose gel with ethidium bromide (Lonza). Amplicons were indexed 
against a DNA sizing ladder 50–766 bp (New England Biolabs, Ipswich, MA). Images were 
collected using a Logic Gel imaging system (Eastman Kodak Company). 
3.2.11 Fluorescence Spectroscopy 
Following the SPE protocol described above with known total RNA concentrations of 50, 20, 
4, 0.5, 0.3, 0.2 ng, quantification was done with RiboGreen Reagent (excitation 480 nm/ 
emission 520 nm, Molecular Probes). The emission spectra were acquired using FLUOROLOG-
3 spectrofluorometer (Jobin Yvon Inc., Edison, NJ) equipped with a 450 W xenon lamp and a 
cooled Hamamatsu R928 photomultiplier (Bridgewater, NJ) operated at 900 V in a photon163 
counting mode with the resulting emission spectra used for determining the RNA concentration 
in the samples. A calibration curve was constructed using RiboGreen stained RNAs of 
concentrations ranging from 1 ng/ μL to 1 µg/μL for RNA standards and correlation coefficient 
for RNA standards were determined. 
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3.3 Results and Discussion  
3.3.1  Surface Characterization of UV Activated Polycarbonate 
To identify the photo-products generated on the UV modified PC surface, we employed both 
XPS and ATR-FTIR spectroscopies. After UV-activation, a 0.33-fold increase in the O/C ratio 
was observed due to the appearance of several oxidized carbon species, which were 
deconvoluted based on previously published functional group binding energies.
35-37
 
Pristine PC’s C 1s spectrum was deconvoluted into the following peaks: (1) 284.5 eV 
aromatic C-C and C-H; (2) 285.0 eV aliphatic C-C and C-H; (3) 290.4 eV carbonate C=O; (4) 
291.8 π-π* shake-up satellite; and (5) 286.2 eV aromatic C-O. The ratio of peak areas of C 1s 
(1):(2):(3):(5) was 8.42:2.85:1.00:1.99, and matches reasonably well with the theoretical ratio of 
10:3:1:2.  
UV modified PC spectra were deconvoluted by calibrating the C 1s (2) peak to 285.0 eV, 
fixing the C 1s (3) and C 1s (4) peaks at their pristine positions, adjusting the C 1s (1) peak 
within ±0.2 eV of its pristine position, and adding C 1s (5), C 1s (6), and C 1s (7) peaks 
corresponding to phenols, alcohols, or ethers, aldehyde or ketone carbonyls, and ester or 
carboxylic acid carbonyls, respectively. 
ATR-FTIR peak areas indicated the presence of several new oxidized functionalities, 
such as an increase of 0.5 au·cm
-1
 and 6.3 au·cm
-1
 for the C=O (1650-1850 cm
-1
) and O-H 
(3200-3700) regions, respectively. More specifically, using the work of Rivaton, et al., we were 
able to identify several photo-products shown in Figure 3.1 along with their corresponding 
carbonyl stretching energies, which are matched to the pristine-subtracted UV-PC. 
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Figure 3.1 Structures and carbonyl stretching frequencies of PC’s photo-Fries rearrangement and 
photo-oxidation products. Reproduced with permission from [39]. 
 
Despite being convoluted, we were able to identify several peaks in addition to the pristine 
carbonate stretch (1767 cm
-1
) that were generated by UV-activation. The photo-Fries 
rearrangement products, 2,2’-dihydroxybenzophenone (1627 cm-1) and phenylsalicylate (1687 
cm
-1
), were apparent along with their associated O-H ring substitutions (1617 and 1585 cm
-1
) and 
H-bonded carbonate groups (1748 cm
-1
).
35 The constant level of atomic oxygen and ozone in the 
UV modification chamber may have also led to photo-oxidation of the gem dimethyl side chains, 
producing aliphatic carboxylic acids (1713 cm
-1
) and benzoic acids (1696 cm
-1
). There was also a 
very small peak at 1840 cm
-1
, which could have originated from ring scissions producing 
aliphatic carboxylic acids that can rearrange to form cyclic anhydrides at the elevated 
temperatures present in our system. Rivaton, et al. observed this rearrangement from 45°C to 
75°C , and these conditions occurred within the modification chamber, which was heated to 
50°C after a 15 min UV exposure time.
35
 However, this peak is small enough that it could be an 
artifact of background subtraction.  
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3.3.2 Operation of Serially-connected Micromodules 
The combined fluidic system presented here consists of two task-specific modules connected 
in series to facilitate leukocyte subset isolation, cell lysis and RNA isolation. As demonstrated 
recently by Wang et. al.,
38
 the modular design approach offers some appealing advantages 
compared to monolithic designs, including: (1) flexibility in materials used for designing 
individual modules to optimize performance of each processing step imposed on that module; (2) 
the ability to reconfigure the assay format without requiring re-engineering; (3) the ability to use 
different fabrication schemes optimized for each module; and (4) high production yields of 
integrated systems, because each module is fabricated and tested separately.  Modules fabricated 
in different thermoplastic materials with desired structures can be custom-designed.  
We have demonstrated COC’s superb ability to generate COOH functionalities upon 
exposure to UV light.
39
 Probability of COOH functional group generation on COC microchannel 
surfaces do not decrease with the increase in microchannel’s aspect ratio unlike PMMA. 
Furthermore, COC microdevices were less susceptible to photo-fragmentation upon irradiation. 
These factors are critical for accessibility and covalent attachment of antibodies to microchannel 
surfaces via carboxylic acid (COOH) scaffolds leading to efficient attachment of antibody and 
therefore efficient cell isolation. The cell isolation data shown in chapter 2 clearly indicates that 
COC devices exhibited superior performance compared to PMMA devices. Chemically modified 
Z-configuration devices immobilized with anti-CD4 and anti-CD66b yielded 2565 ±1194 T-cells 
and 2949 ±901 neutrophils respectively (Figure 3.2 A, B).  
SPE module was constructed using polycarbonate (PC) due to its unique characteristic to 
allow the isolation and purification of nucleic acids.
30, 31
 Generation of polymer phenyl 
salicylates, hydroxybenzophenones and a wide range of carbonyl/carboxyl-containing groups 
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upon UV irradiation (254-300nm) of PC can serve as a capture medium for the isolation, 
purification and preconcentration of a wide range of molecular weight-sized NA’s present in 
complex biological samples. 
 
Figure 3.2 Bright field images of (A) T-cells (60X) and (B) neutrophils (40X) captured within 
the COC microfluidic device immobilized with CD4 and CD66b antibodies respectively.  
 
 
Figure 3.3 (A) SEM image of isolation bed of Z-configuration device with dimensions 25 µm 
wide and 80 µm deep (B) Photograph of Z-configuration device filled with red dye (C), (D) SEM 
images of SPE immobilization capture bed, post diameter =100 µm, center-to-center post 
spacing =50 µm (E) Picture showing the connected micromodules.  
  
A 
B 
C
  B 
D
  B 
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Two modules were connected in series using a glass connector (see Figure 3.3 E). T-cells and 
neutrophils captured on individual cell selection units were lysed by infusing cocktail solution 
containing 50 µl IB, 50 µl lysis solution, 170 µl EtOH through leukocyte isolation module. The 
lysate is directed to the SPE module on which RNA is purified and eluted with water for cDNA 
synthesis and further amplification. 
3.3.3 DNase Treatment of the Lysate.  
A potential problem with RT-PCR is DNA contamination in RNA sample. DNA removal is 
therefore critical especially for RT-PCR applications since DNA can serve as a template during 
the PCR resulting in false positives, background, etc. Therefore, DNase treatment was performed 
on the RNA isolated from SPE, prior to RT for cDNA synthesis. “Minus RT controls” (without 
RT enzyme) were performed to identify erroneous signal due to genomic DNA contamination. 
To demonstrate the effectiveness of SPE in removing the contaminated DNA, we chose to 
perform DNase treatment on TRNA that was isolated from MCF-7 cells, a human breast cancer 
cell line. Following cell lysis and considering 10 pg of TRNA per cell, 2 µl of lysate containing 
8,000 cells i.e. 80 ng of TRNA was used for SPE. A cocktail mixture of 2 µl of this lysate, 50 µl 
IB, 48 µl nuclease-free water, 170 µl of ethanol was infused through SPE bed and the TRNA 
was eluted with 20 µl water. Following elution from SPE bed, DNase treatment for 15 minutes, 
an RT reaction was performed. cDNA was then PCR amplified using GAPDH and GUSB 
primers. 
To eliminate amplification of gDNA, PCR primers can be designed to span introns or bridge 
an exon-exon junction only in cDNA. Primers for GAPDH were designed that way, therefore, 
PCR will not amplify gDNA and thus, any possible DNA contamination could not be identified. 
GUSB primers, however, were not spanning introns and the absence of amplicons clearly 
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indicates the lack of DNA contamination. PCR products separated on gel for GUSB gene (Figure 
3.4) indicate that DNase treatment was shown to efficiently degrade contaminating gDNA, since 
no PCR product was amplified from samples that were DNase-treated but not reverse-transcribed 
(minus RT controls), whereas the DNase treated and reverse transcribed mRNA show the 
products of 528 bp and 122 bp for GAPDH and GUSB, respectively.   
 
Figure 3.4 Gel electrophoresis images showing DNase treatment after SPE.RNA from MCF-7 
cells was DNase treated for 15 min, reverse transcribed and PCR was performed on cDNA with 
(A) GAPDH primers and (B) GUSB primers The absence of product for the negative RT 
controls indicates the absence of DNA contamination. 
 
3.3.4 Evaluation of RNA Extraction Efficiency  
An efficient cell isolation method will not guarantee successful molecular analysis. In order 
to perform an analytical assay, preconcentration of target (i.e., DNA or RNA) must be 
accomplished. Microfluidic chips are especially attractive for cellular-based assays because 
many of the sample processing steps can be integrated into a single module, minimizing the 
dilution of intracellular components following cell lysis. 
Recovery of TRNA after purification on SPE bed was evaluated by examining the mass of 
TRNA before and after purification on the microchip. Samples containing TRNA in a mass 
range of 0.5–180 ng were examined. RNA concentration was determined by staining with 
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RiboGreen (excitation 500 nm/ emission ~525 nm, Molecular Probes). Calibration curves were 
constructed using concentrations ranging from 5 pg/ µL to 1000 pg/µL for RNA standards. 
After TRNA elution, as judged by fluorescence, the efficiency of recovery for 5 ng TRNA 
was estimated to be 57% (Figure 3.5 C). Based on the TRNA mass immobilized on chip surface 
and the available surface area of the capture bed, the surface loading density of TRNA was 
determined to be 2.6 ng/cm
2
. It was observed that the efficiency of recovery decreased as the 
mass load of TRNA introduced on a SPE bed increased. Efficiency of the recovery was less than 
10% for aliquots containing 180 ng of TRNA. This indicates that the amount of TRNA 
introduced onto bed exceeded the load capacity of the capture bed (i.e. available –COOH sites).  
The amount of TRNA captured on previously reported 96-well PPC chip was determined to be 
582 ± 286 ng/cm
2
.
30
 This significant difference in the surface load can be explained by use of a 
different architecture chip. In previous work, SPE bed contained 3,800 20 μm diameter posts 
with 20 μm spacing and 50 μm depth and surface area of 28.4 mm2. Such geometry provides 
advantage for more efficient solid phase extraction because provides higher density of posts and 
reduced inter-post spacing, providing shorter diffusional distance for RNA to reach surface.  
As we could not determine the efficiency of the purification process for samples containing 
less than 5 ng of TRNA, most likely due to instability of the RNA, we chose to test if TRNA is 
present in the effluent of these samples by performing RT-PCR. In a separate experiment, a 
range of different masses of TRNA (0.2-50 ng corresponding to ~10-2,500 cells) was introduced 
on chip and purified. Immediately after purification, RT was performed with collected TRNA, 
followed by amplification of GAPDH gene. Products were separated and these results are 
presented in Figure 3.5A.  
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Figure 3.5 SPE was performed on commercial Jurkat T-cell TRNA and isolated RNA was 
analyzed via RT-PCR with GAPDH PCR primers.  (A) Fluorescence image of ethidium-stained 
4% agarose gel showing decrease in RNA isolated with a decrease in total RNA input. (B) Band 
volumes of product bands in part A were quantified using ImageQuant. (C) Efficiency of RNA 
isolation for different input masses of TRNA evaluated using the RiboGreen assay. 
 
The products were observed for all tested effluents after SPE purification. Even effluent from 
purification of 0.2 ng of TRNA was successfully amplified, suggesting that purification can be 
efficient for minute amount of sample. The integrated intensity of the amplicon bands from 
Figure 3.5A was plotted vs amount of TRNA introduced on SPE bed. The data show linearity for 
lowest mass loads of TRNA while saturation of the signal on the gel is observed for amplicons 
generated from 4-50ng TRNA mass load. Even though the SPE process is less efficient for these 
amounts of TRNA, it can still purify enough material for gene expression analysis in RT-PCR. It 
is clear, that for a given sample and immobilization buffer, the RNA recovery efficiency will 
depend on the extraction bed characteristics, including the active surface area and the inter-post 
distance and post layout. 
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3.3.5 RT-PCR of RNA Extracted from T-cells and Neutrophils 
In previous work we demonstrated that the total number of isolated cells from 50μL blood 
using the same microfluidic device as reported herein ranged from 500 to 2,000 CD4+ T-cells 
and CD66b+ neutrophils. We increased blood volume processed to 200 μL to increase the load 
of isolated cells. If at least 4 times more cells will be isolated, therefore, we expected to obtain 
between 20 and 80 ng TRNA (1-4 ng of mRNA), which should secure enough material after SPE 
purification for cDNA synthesis and gene expression analysis. T-cells and neutrophils were 
isolated from the same blood sample and because of the high purity (94±3%) of isolated 
fractions, cell lysis was performed directly on chip followed by SPE and RT-PCR analysis in 
thermocycler. Figure 3.6 presents agarose gel image showing amplicons from amplified S100A9 
and FPR1 gene. Presence of amplicon products after RT-PCR indicates that high quality TRNA 
(mRNA) was obtained during processing on integrated cell isolation and SPE unit. 
 
Figure 3.6 Fluorescence images of ethidium-stained 4% agarose gels showing RT-PCR products 
of TRNA captured from CD4+ T-Cells or neutrophils isolated from 100 μl whole blood. RNA 
was captured on SPE bed, and reverse transcription was performed. PCR was run with primers 
targeting S100A9 and FPR1 genes. Negative RT controls were performed without RT enzyme.  
We have previously demonstrated high quality of TRNA following SPE microchip 
purification.
30
 We assessed integrity of TRNA by monitoring the electrophoretic band pattern for 
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rRNAs. This method relies on the assumption that rRNA quality and quantity reflect that of the 
underlying mRNA population.
31
 The rRNA species used for this assessment included the 18S 
and 28S rRNAs for mammalian samples. Ratios of these band intensities of ~2 were indicative of 
intact TRNA, while for degraded RNA samples, these bands appeared smeared in the 
electrophoretic bands.  
3.4 Conclusions 
The use of the PPC-SPE devices along with cell isolation unit is advantageous for RNA 
purification requiring disposable and one-time use devices for eliminating potential sample 
contamination and protection of RNA from RNases or other factors that can cause RNA 
hydrolysis.  Chip fabrication method, which use of micro-replication techniques such as hot 
embossing or injection molding can provide high-volume and low-cost production of these 
devices which can allow for wide use of these in clinical applications.
33,34  
We demonstrated that RT-PCRs of the SPE purified mRNAs were successful with the 
amounts of mRNA isolated. The SPE chip showed the ability to provide high quality material 
from whole cell lysate that could be used for a variety of molecular assays i.e., gene expression 
analysis, particularly in detection of stroke markers in subpopulations of leukocytes.   
The incorporation of SPE protocols into microfluidic formats is very appealing because 
microfluidics capture occurs in a closed architecture and, therefore, the potential risk of cross-
contamination is significantly reduced. By combining NA purification with cell isolation on-chip 
processing, fully integrated lab-on-a-chip systems can be realized with a concomitant reduction 
in the time, complexity, and cost of carrying out the analysis. 
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CHAPTER 4. INVESTIGATION OF SURFACE CHARGE AND 
ELECTROSMOTIC FLOW IN POLYMER NANOSLITS AND 
NANOCHANNELS 
 
 Introduction 4.1
Fluidic channels with one or two of its dimensions in the nanometer scale, nanoslits or 
nanochannels, respectively, have recently generated great interest because of unique phenomena 
that occur in nano-confined space such as nanocapillarity,
1
 concentration polarization
2, 3
 and 
electrical double layer (EDL) overlap.
4-7
 These properties arise when the channel size is 
comparable to either the length scales of the range of electrostatic interactions in solution or the 
molecular size of the analytes. Some of the interesting applications that arise from the use of 
nanochannels and nanoslits include single-molecule interrogations,
8-11
 molecular pre-
concentration,
12
 chemical analyses of mass-limited samples,
13, 14
 DNA electrophoresis,
15-17
 
desalination,
18
 nanofluidic diodes,
19
 real-time probing of biomolecules,
20-24
 ionic transport,
25
 and 
entropic trapping for DNA separations.
26 Nanochannels fabricated in a controlled fashion have 
enabled the exploration of charge-related effects such as concentration enhancement and 
depletion and surface-charge-governed transport.27, 28 Hence, nanofluidic channels have become 
a fundamental and essential experimental platform for the study of nanoscale-molecular, -fluidic, 
and -ionic transport properties that offer high throughput with low sample volume requirements.  
As described by Chantiwas et al.,
29
 polymer-based nanoslits/nanochannels have provided an 
attractive alternative to glass or silicon devices due to their diverse range of physiochemical 
properties, low material cost and the availability of a plethora of fabrication techniques to design 
the prerequisite structures. A commonly employed modality for the fabrication of thermoplastic 
nanofluidic devices is nanoimprint lithography (NIL), a specific sub-type of hot embossing.
30-33
 
This technique takes advantage of the deformability of the material at elevated temperatures to 
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produce multi-scale nanostructures in a relatively high production mode over large areas and at 
low-cost.
34
 A distinct benefit of using polymers for the fabrication of nanofluidic devices is the 
diversity in their surface chemistry, which is determined by the identity of the monomer units 
comprising the polymer chains. For example, poly(methylmethacrylate), PMMA, possesses 
functional groups on its backbone that consists of methyl esters while polycarbonate, PC, 
possesses carbonates. In addition, a diverse range of simple activation techniques can be 
employed to generate surface functionalities appropriate for the desired application.
35-39
 
Common surface modification protocols reported for polymer fluidic devices are ultraviolet 
(UV) and plasma oxidation.
40-42
 These activation techniques have been reported to generate a 
host of oxygen-containing species, such as different carbonyls (aldehydes, ketones and 
carboxylic acids) and alcohols on the polymer surface
41, 43
 following a sequence of free-radical 
photo-initiated oxidation reactions. Photochemical activation of polymer substrates possessing 
nanofluidic structures requires careful control of the dose to minimize activation induced 
nanoscale roughness that may affect the operational characteristics of the device.
44
 Plasma 
treatment has been the technique of choice for nanofluidic surface activation and low-
temperature assembly of the device as it induces minimal surface root-mean-square (RMS) 
roughness, lacks diffraction limitations and shadowing effects, as reported for UV activation of 
polymer substrates with microchannels,
38
 and allows for low temperature assembly of the 
nanofluidic device while retaining the surface functionality and minimizing nanostructure 
deformation.
33
 For example, by exposing PMMA to controlled plasma conditions, it is possible 
to generate surface carboxyl functional groups,
41
 which remain accessible for reactions after 
device thermal assembly. 
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In a previous work, we reported the generation of positively charged surface moieties in 
PMMA microchannels following both chemical (N-lithiodiaminoethane reaction)
39
 and 
photochemical (UV - [N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC)] – 
[ethylenediamine (EDA)]) pathways.
37
 To the best of our knowledge, most of the work on 
nanochannel surface modification has involved functionalization of surface silanol groups,
28
 
immobilization of biomolecules on the channel walls
25, 45, 46
 and ion transport studies performed 
in glass-based substrates. Glass possesses well-established surface chemistry, hydrophilicity, 
non-conductivity, rigidity with minimal surface defects, non-deformability at high pressures, 
excellent optical properties and well-established top-down fabrication techniques.
47, 48
 However, 
with the growing interests in elastomeric,
49-52
 thermoplastic
31
 and membrane-based
53, 54
 
nanofluidic devices, it becomes necessary to understand the effects of surface modification on 
the charge density and surface charge governed ion transport in polymer-based nanofluidic 
channels, especially when considering such devices for many of the nanofluidic applications 
discussed previously.
28, 55
  
In this work, we report for the first time the surface modification of polymer nanoslits and 
nanochannels and the investigation of the surface charge density and electroosmotic flow (EOF) 
in these devices. The nanofluidic devices were fabricated in PMMA substrates using a modified 
protocol that we previously reported. Carboxyl groups were generated on the walls of PMMA 
nanoslits and nanochannels under controlled conditions of the plasma exposure time and oxygen 
gas flow rate.
41, 43
 These groups were subsequently aminated by reaction of the surface carboxyl 
groups with a solution of EDC and EDA. The extent of surface roughness induced by surface 
activation was assessed in a nanoslit using atomic force microscopy (AFM). Surface 
conductance plots were generated for the fluidic devices using a range of potassium chloride 
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(KCl) concentrations. In agreement with our measurements, a modified model of ion transport in 
nanofluidic devices, based on Schoch et al.
55 is presented. It revealed the importance of 
geometrical parameters of the nanometer-sized channels and a dominating surface charge density 
inducing a conductance plateau at low ionic strength. In addition, we investigated the effects of 
solution pH on the surface charge density, reported the electroosmotic flow (EOF) in these 
devices. 
 Materials and Methods 4.2
 Reagents and Buffers 4.2.1
PMMA sheets and cover plates used for the device fabrication were purchased from Good 
Fellow (Berwyn, PA). Cycloolefin copolymer backbone (COC 6017) for nanoimprinting was 
purchased from TOPAS Advanced Polymers (Florence KY). Si <100> wafer was purchased 
from University wafers (Boston, MA). Isopropanol, 1-ethyl-3-[dimethylaminopropyl] 
carbodimide hydrochloride (EDC), 2-(4-morpholino)-ethane sulfonic acid (MES), 
Ethylenediamine (EDA), tripropylene glycol diacrylate (TPGA), trimethylolpropane triacrylate 
(TMPA), Irgacure 651 (photo-initiator), 50% potassium hydroxide (KOH) and potassium 
chloride (KCl) were purchased from Sigma-Aldrich (St. Louis, MO). Anti-adhesion monolayer 
of (Tridecafluoro – 1,1,2,2 – Tetrahydrooctyl) Tricholorosilane (T-Silane) was purchased from 
Gelest, Inc. Tris buffer (pH 8.0) was obtained from Fisher Scientific (Houston, TX). Phosphate-
buffered saline (PBS, pH = 7.4) was purchased from Life Technologies (Carlsbad, CA). All 
required dilutions were performed using 18 MΩ/cm milliQ water (Millipore technologies) and 
all measurements were performed at 25°C unless specified otherwise.  
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 Fabrication of Nanofluidic Devices 4.2.2
Previously, we have reported the development of nanoslits and nanochannels in polymer 
substrates following a single step fabrication scheme that is based on nanoimprint lithography 
(NIL).
31, 32
 Briefly, the device fabrication involves four key steps. First, the silicon master was 
developed by initially patterning two V-shaped access microfluidic channels, 55 µm wide, 12 
µm deep 1.5 cm long in Si <100> wafer using standard photolithography followed by anisotropic 
etching with 50% KOH solution. Next, nanofluidic channels were patterned across the 
microchannels by FIB milling using a Helios NanoLab 600 DualBeam instrument (FEI 
Company). The spot size (beam current) and sputtering rate were carefully controlled to ensure 
that the desired channel dimensions were designed.  
Following this, an anti-adhesion monolayer of T-Silane was coated on the Si master from gas 
phase in a desiccator under vacuum for 2 h to facilitate the demolding process. The structures on 
the Si master were then carefully transferred into a UV-curable resin polymeric blend, containing 
68 wt% TPGA as the base, 28 wt% TMPA as the crosslinking agent and 4 wt% Irgacure 651 as 
photo-initiator) coated onto a cyloolefin copolymer (COC) backbone, via UV-NIL to 
produce polymer stamps with protrusive structures. To achieve this, the Si master (mold) was 
initially coated with the UV resin by dispensing with a pipette, followed by gentle pressing of the 
COC backbone on the resin-coated master to ensure complete filling of the resin into mold 
cavities. This was followed by exposure to a 365nm UV light (10 J/m
2
) through the COC 
backbone for 5 min in a CL-100 Ultraviolet Crosslinker. After curing, the UV-curable resin was 
gently demolded from the Si mold to get the negative copy on UV-curable resin. 
Next, the patterned UV-curable resin was used as the stamp to hot emboss into a 3 mm-thick 
PMMA sheet (Lucite CP) with access holes for reservoirs, drilled prior to embossing. The 
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imprinting was performed at a pressure of 1910 kN/m
2
 for 120 s with the top and bottom plates 
maintained at a temperature of 125
º
C using the Hex03 hot-embosser (JenOptik). Pressure was 
applied after 30 s preheating of the stamp and the substrate at the desired molding temperature, 
and was maintained during the imprinting process until the system was cooled down to 45°C. 
Upon cooling, PMMA copy was easily demolded from the UV-resin stamp. A 175µm thick 
PMMA sheet (Goodfellow Corporation) was used as the cover plate. Both the patterned PMMA 
sheet and cover plate were pre-activated with oxygen plasma at 50W for 35 s and 5.5 sccm gas 
flow rate. Thermal assembly was performed immediately at 80°C for 400 s under a 370 kN/m
2
 
pressure. This approach not only helped with achieving a low temperature device assembly with 
the desirable bond strength but also contributed to the effective functionalization of the 
nanochannel surface with carboxyl (hydrophilic) functional groups necessary for amine 
modification.  
 Surface Modification 4.2.3
The reaction was initially tested on pre-cut pieces of PMMA (1 cm x 1 cm) without micro or 
nanostructures. Clean PMMA substrates were exposed to 50 W (5.5 sccm) oxygen plasma for 35 
s to generate the carboxyl functional scaffolds necessary for amination reaction (Scheme 4.1a). 
The plasma modified samples were then soaked in a solution containing 300 mg EDA and 250 
mg EDC in 5 ml of 0.1 M MES buffer (pH 4.8) for 20 min at room temperature. The amide 
linkage between the surface carboxyl group and a terminal –NH2 group from EDA was achieved 
through EDC linker chemistry. EDA attachment onto the surface is possible under the buffer 
conditions described (pH 5 to 9) as the molecule does not contain functional groups susceptible 
to hydrolysis (Scheme 4.1b).
56
 After incubation, samples were thoroughly rinsed with deionized 
water and air dried. These amine modified samples along with the pristine and plasma activated 
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substrates were then subjected to XPS analysis to determine the surface chemical composition 
and AFM analysis to probe changes in surface morphology (roughness) induced by plasma 
etching or chemical swelling/dissolution. The same protocol was adopted for the amination of 
the assembled PMMA devices containing nanoslits and nanochannels. In this case, the plasma 
assembled devices were immediately filled with EDC-EDA and allowed to incubate for 20 min 
in a closed chamber. All devices were rinsed with deionized water prior to experiments.  
 
Scheme 4.1 Protocol for the surface modification of PMMA with (a) carboxyl groups by plasma 
activation, and (b) amine groups by chemical reaction with ethylenediamine through EDC 
coupling chemistry to the plasma activated PMMA.  
 
 Water Contact Angle and Surface Energy 4.2.4
The wettability of the unmodified and surface treated PMMA were assessed by water 
contact-angle measurements using a VCA Optima instrument (AST Products). 3 mm thick 
PMMA sheet was cut to 15 mm x 18 mm dimensions and the surface was modified as described 
above. A volume of 2.0 µL nanopure water (18.2MΩ.cm at 25oC) was dispensed on to the 
substrate and the photograph of each droplet was captured immediately for analysis using the 
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software provided by the manufacturer. The measurements were repeated at least five times at 
separate positions on the substrate, and the values reported as the mean ± one standard deviation.  
 Atomic Force Microscopy (AFM)  4.2.5
The topographies of unmodified, O2-PMMA and NH2-modified flat PMMA surface and the 
bottom of PMMA nanoslits were investigated using the Asylum Research MFP-3D Atomic 
Force Microscope (tip radius ~2nm) in repulsive tapping mode at a rate of 1.0 Hz. The 
Tap300A1-G cantilever tips (Ted Pella) had a frequency of 300 kHz and force constant of 40 
N/m. For the flat surfaces, the scans were taken over a 3.5 µm x 3.5 µm scan size, presented in 
3D and RMS surface roughness computed using manufacturer’s software. In the nanoslit, a scan 
size of 4 µm x 500 nm was taken and the RMS roughness computed for the entire area. 
 Spectroscopies 4.2.6
For XPS measurements, C 1s, O 1s and N 1s photoelectron signals were acquired using an 
Axis Ultra DLD X-ray photoelectron spectrometer (Kratos Analytical) under ultra-high vacuum 
conditions (10
-8
 to 10
-10 Torr) with a monochromatic Al Kα X-ray source, 20 eV pass energy, 
370 s acquisition time, 1,600 ms dwell time, and 20° electron take-off angle. Given an inelastic 
mean free path of 3-4 nm, ~95% of the resultant signal originated 9-12 nm from the surface.
57-59
 
To examine the molecular nature of the treated and untreated surfaces, IR studies were employed 
using pre-cut Silicon wafers coated with 200 nm Au layer (Au wafer). Commercial PMMA sheet 
was dissolved in dichloromethane and serially diluted to yield a solution with final concentration 
of 0.5 mg of PMMA/mL of dichloromethane. This was spin coated on the Au wafer at 2500 rpm 
for 60 s to yield a 5 nm thick polymer layer. The coated Au-wafers were allowed to dry in an 
oven after which they are ready for surface modification and analysis. This approach helped to 
minimize interference from bulk material in the IR spectra. IR spectra were collected at a 
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resolution of 2 cm
−1
 scans on a 670-IR spectrophotometer (Varian, US) using a 
monolayer/grazing-angle specular reflectance accessory. For SEM, COC stamp and PMMA 
substrate were pre-coated with a 2-3 nm layer of Au/Pd and were imaged under high vacuum 
with an FEI Quanta 200 field emission gun at a 10 kV accelerating voltage and an Everhart-
Thornley detector. 
 Surface Charge Measurement 4.2.7
Following each step of surface modification of the nanofluidic vias, electrical conductance of 
the nanochannels was investigated using different dilutions of KCl from 1M to 10
-6
M in Tris 
buffers, pH 7.8 for all devices. The DC electrical conductance of the nanochannels was 
monitored through Ag/AgCl electrodes immersed in the access reservoirs at the ends of 
microchannels using a low noise Axopatch 200B amplifier with real-time control and analysis 
using pClamp10 software. The conductance values were determined by fitting the slope of the 
ionic current as a function of the applied voltage, which was stepped from -1V to 1V with 
100mV step size and 5 s delay time for each data point.  We found that the delay time was 
sufficient for the device to reach a steady state current. The measurement was performed in 
triplicate with the mean conductance plotted against the electrolyte concentration in log-log plot 
and the surface charge was determined from these graphs. This experiment was repeated at pH 
range between 3 and 12 to investigate the pH effects on the surface charge. The solution pH was 
adjusted using hydrochloric acid or potassium chloride. No pressure difference across the 
nanochannel was induced during the measurements.  
To equilibrate the system, the fluidic device was first flushed with a binary mixture 
of methanol/ultrapure water (50% v/v) by capillary force assisted with vacuum from the outlet 
port to ensure complete filling and the elimination of air-bubbles. Next, deionized water (18 
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MΩcm) was used to rinse the previous solution from the fluidic network followed by the 
addition of the chosen electrolyte solution until the resistance of the fluidic channels reached a 
stable minimum. Each rinsing cycle took 5 to 10 min until the flow was stopped and the 
measurements were made. To avoid errors from solution interference, each measurement was 
performed using a new device.  
 Electroosmotic Flow (EOF) Measurement 4.2.8
 The EOF was measured using the Axopatch 200B amplifier. Two devices, one possessing a 
single PMMA nanoslit (138 µm long, 50 nm high, and 1 μm wide) and the other a single 
nanochannel (138 µm long, 120 nm high and 120 nm wide), connecting two opposite V-shaped 
access microchannels, were fabricated as described previously. Fluidic channels were activated 
and the EOF was assessed using the current monitoring method. EOF values were measured 
using 0.1 and 0.05 M KCl solution in 10mM Tris buffer at pH 7.8. First, the entire device was 
primed with 50% v/v water/methanol then drained and flushed with deionized water for 5-10 
min. Next, the device was filled with 0.1 M solution and allowed to equilibrate for 3 min under a 
1V DC bias. Following equilibration, as evident by a constant current trace, one access reservoir 
was emptied and 0.05 M KCl was introduced. Ag/AgCl electrodes were placed in the reservoirs 
across the channels under a 200 mV DC bias. Signals were acquired using pClamp10 software 
and Digidata 1440A digitizer set at 10 kHz sampling frequency. 
 Results and Discussion   4.3
 Device Fabrication 4.3.1
The Silicon (Si) master, which consisted of micron-scale access channels (fabricated using 
photolithography) and an array of connecting nanoslits or nanochannels (fabricated using 
Focused Ion Beam (FIB) milling), was used to fabricate the protrusive polymer stamp, which 
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was made from a UV-curable resin. Thermal imprinting was used to transfer the nanofluidic 
structures into PMMA from the UV-curable resin stamp and the device was sealed with a 
PMMA cover plate using low-temperature plasma assisted bonding to build the enclosed mixed-
scale polymer device. UV-NIL conditions were carefully controlled to ensure that patterns from 
the Si master were transferred with high fidelity and minimum deformations into the resin stamp. 
Figure 4.1 shows scanning electron microscope (SEM) images of the original Si master, cured 
UV-resin stamp and thermally imprinted PMMA substrate with an array of four nanoslits (Figure 
4.1a – 4.1c) and seven nanochannels (Figure 4.1d – 4.1f).  
 
Figure 4.1 Scanning electron micrographs (SEM) of the Si master, resin stamp and PMMA 
substrate for the nanoslits (a, b, c) and nanochannel (d, e, f), respectively. – Inset shows the off–
axis (52
°
) cross section SEM images of the Si masters. The dimensions (l × w × h) were 21 µm x 
1µm x 50 nm for each of the 4 nanoslits and 46 µm × 120 nm × 120 nm for each of the 7 
nanochannels. (Note that the roughness on the SEM image of the stamp and substrate are 
artifacts from coating with 3 nm AuPd for imaging).  
The original channel fabricated by FIB milling into the Si master was purposely designed 
with dimensions (width × depth) of 980 nm × 53 nm and 110 nm × 125 nm for the nanoslit and 
nanochannel, respectively, to account for slight deformation of the UV resin stamp during the 
high pressure and temperature thermal imprinting.
32
 The final PMMA devices had the 
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dimensions of 1 µm × 50 nm and 120 nm × 120 nm, with the same polarity as the structures in 
the Si master. Although we have previously reported the nanochannels in PMMA with the width 
& depth <80 nm but for proof-of-concept, we deliberately chose these channel dimensions. The 
UV resin stamp possessed a thermal expansion coefficient similar to PMMA (6 × 10
−5
/°C) and 
was chosen due to its capability to fabricate micro- and nano-scale patterns via UV-NIL and 
reduce thermal stress following thermal-NIL production of the nanofluidic device.
60,61
 A single 
UV resin stamp was used for thermal imprinting for up to 10 times without any noticeable 
damage to the structures.  
 
Figure 4.2 (a) Photograph of the thermally assembled nanofluidic devices fabricated in PMMA. 
The fluorescence images for the sealed nanoslit (b) and nanochannel (c) devices seeded with 5 
mM FITC in 0.5X TBE buffer. The images shows channel continuity and the absence of 
leakages. (d) IV plot generated between -0.9V to 0.9V for the nanofluidic devices filled with 1 
mM KCl solution revealing an electrical resistance of 266.4 MΩ and 908.5 MΩ for the nanoslits 
and nanochannels, respectively. The measured currents have similar absolute values for the 
respective voltages of opposing polarities; hence, the channels are symmetric (absence of 
rectification) 
 
The PMMA substrates were sealed using plasma assisted low temperature thermal fusion 
bonding (Figure 4.2a). The formation of leak-free fluidic devices or discontinuities due to 
channel collapse during assembly was evaluated by introducing 5 mM fluorescein isothiocyanate 
(FITC) solution in 0.5X TBE buffer into the fluidic network and allowing the channels to be 
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filled by capillarity. As shown in Figure 4.2b and 4.2c, the fluidic channels did not show any 
leakage between the substrate and the cover plate. Current-voltage plots acquired after filling 
with 1 mM KCl as shown in Figure 4.2d revealed that the measured currents for voltages of 
opposite polarity had similar absolute values and showed good linearity (non-rectification). The 
absence of voltage gating and rectification indicated homogeneity in surface charge along the 
walls of the PMMA nanoslits and nanochannels when using symmetrical electrolyte conditions. 
Using low thermal bonding temperatures (~80
o
C) also minimized the amount of surface 
reorganization of the polar functional groups following plasma treatment. (Figure 4.3).   
 Surface Characterization 4.3.2
 Effects of Annealing Temperature on the Wettability of Plasma-activated PMMA 4.3.2.1
Previous reports have shown that thermal annealing for nanofluidic device assembly affects 
the surface wettability/solid surface tension of polymer surfaces.
38
 Here, we investigated the 
effects of temperature on the wettability of PMMA activated under oxygen plasma (50 W, 5.5 
sccm gas flow rate for 35 s) by measuring the water contact angle between 75˚C and 100˚C, the 
typical temperature range reported for thermal assembly of PMMA nanofluidic devices. As 
represented by Chai et al.
41
 the interpretation of contact angles in terms of the solid surface 
tension relies on the validity of Young’s equation, which interrelates the Young’s contact angle, 
θY, with the interfacial tension of the liquid-vapor , γlv, solid-vapor, γsv, and solid-liquid, γsl, 
interface;  
γ
lv
cos θY = γsv - γsl      (1) 
Typically, θY is expected to be a good approximation of the measured contact angle for a 
surface with RMS roughness ≤ 5 nm.62 The solid surface tension (surface energy) γsv can be 
calculated from the water contact angle using;
62
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γ
sl
 =  γ
lv
 + γ
sv
 -  2√γlvγsv(1 - β(γlv -  γsv)
2
)   (2) 
where β is 1.057 x 10-4 (m2/mJ)2 and γlv is the surface tension of water (72.70 mJ/m
2
).  
 
Figure 4.3 Variation of surface energy with annealing temperature for plasma activated PMMA 
substrate. As shown, there was no significant change in the surface energy at temperatures below 
80ºC. At temperatures above 85ºC, the wettability significantly reduced as indicated by an 
increase in the water contact angle. Each reported value represents the average of five values 
measured at different positions on the substrate and the vertical bars represent the error of one 
standard deviation. 
 
As shown in Figure 4.3a, there was a gradual increase in the water contact angle as the 
temperature of the plasma-activated PMMA was increased. Heating the plasma activated 
substrate at temperatures ≤ 80˚C did not result in a significant change in the solid surface 
tension/wettability. However, at temperatures ≥ 85˚C, there was a significant increase in surface 
tension at the solid-liquid interface. As described by Jackson et al.,
38
 this increase arises because 
the functional groups generated after plasma activation (≤ 10 nm from the surface) undergo 
thermally induced rearrangement and are buried into the bulk substrate when heated. To avoid 
this, we performed thermal fusion bonding of the nanofluidic device at 80˚C for 400 s. The 
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wettability was retained at this condition and allowed the devices to be fill easily with aqueous 
solvents by capillary action and low pressure suction.   
The surface wettability and solid surface tensions for the unmodified, plasma and amine-
modified PMMA samples were then assessed using water contact angle measurements (see 
equations 1& 2). Unmodified PMMA showed a contact angle of 78.0 ±1.5°, which corresponds 
to a solid-vapor surface tension (surface energy) of ~36.8 mJ/m
2
. After plasma treatment, the 
contact angle decreased to 50.1 ±1.1° implying an increase in surface energy to ~54.6 mJ/m
2
. 
Amine modification led to an increase in the water contact angle to 62.92 ±2.0° with an 
associated surface energy of 45.8 mJ/m
2
. The observed trends are consistent with literature 
values.
39
 
 XPS Analysis 4.3.2.2
X-ray photoelectron spectra (XPS) was used to analyze the surfaces of the unmodified, 
plasma activated and amine-terminated PMMA sheets for the chemical composition. The O/C 
and N/C ratio was used to assess the extent of surface modification of different tested schemes 
(Figure 4.4c). For convenience, we designate unmodified, plasma activated and amine 
terminated PMMA as u-PMMA, O2-PMMA and NH2-PMMA, respectively. The modification 
scheme employed will determine the type of functional moieties generated. XPS was used to 
monitor the O/C and N/C ratio on plasma-activated and amine-modified PMMA surfaces. In all 
XPS spectra acquired here, a Shirley background was subtracted by averaging at least 10 end 
points associated with the background. As shown in Figure 4.4c, plasma activation of PMMA led 
to an increase in the O/C ratio confirming the addition of oxygen containing functional groups.
41
 
For amination of the plasma activated polymer, several schemes involving EDC or EDC-NHS 
coupling chemistries were tested with concentrations between 0.1 and 1 M EDA; in all cases, 
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there was a decrease in the O/C ratio (Figure 4.4c). However, the amount of nitrogen containing 
groups differed with different conditions. As depicted in Figure 4.4d, the highest N/C ratio (and 
lowest O/C ratio) was observed for animation involving the reaction of O2-PMMA with a 
solution of 1 M EDA in EDC.  
To identify the surface groups generated after treatment of PMMA, the C1s spectra for all 
treated surfaces was deconvoluted based on previously published work.
63
 Pristine PMMA C1s 
spectrum showed the presence of four Gaussian components: (1) 284.6 eV aliphatic C-C and C-
H; (2) 285.2 eV quaternary C-C α to the pristine ester; (3) 286.4 eV methoxy C-O ester; and (4) 
288.7 eV carbonyl C=O ester (Figure 4.4e). The theoretical peak area ratio of the C1s 
components (1) - (4) of 2:1:1:1 was found to be 1.90:1.18:1.20:1.00 in our data. The slight 
deviation may have been attributed to additives and plasticizers introduced into the substrate by 
the manufacturer.
64
 Furthermore, in addition to the peaks listed above for u-PMMA, the 
deconvoluted C1s peak of O2-PMMA showed the presence of a peak at a binding energy of 
289.7 eV (Figure 4.4f). This peak corresponds to the OC=O for a carboxylic acid group. After 
amination, the deconvoluted C1s peak showed the absence of the carboxylic acid peak and the 
presence of two peaks; 285.8 eV, C-N bond of an amine, and 287.9 eV for a O=C-N bond 
associated with an amide (Figure 4.4g). 
The combined survey spectra are shown in Figure 4.4a. The trace for u-PMMA showed the 
presence of only two peaks at 284.8 eV and 532.0 eV, indicative of C1s and O1s core levels, 
respectively. After exposure to 50 W (5.5 sccm) oxygen plasma for 35 s, there were observable 
changes in the individual intensities of the C1s and O1s peaks when compared to the untreated 
samples (red trace in Figure 4.4a). There was an increase in the O/C atomic ratio from 0.331 
±0.006 for u-PMMA to 0.403 ±0.003 for O2-PMMA, indicating the incorporation of oxygen 
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containing polar functional groups onto the surface. The survey spectrum taken from the amine-
terminated PMMA (blue trace) shows the presence of a new peak centered at 399.69 eV in 
addition to the C1s and O1s peaks. This peak is characteristic of surfaces possessing nitrogen-
containing functionalities (N1s core level) and is in agreement with literature values.
39,65
  
 
Figure 4.4 (a) Full XPS survey spectrum of unmodified (black trace), plasma activated (red 
trace) and amine modified (blue trace) PMMA (b) N 1s deconvoluted spectrum showing two 
forms of nitrogen atoms (insert shows the chemical structure of aminated PMMA surface with 
the forms of nitrogen labeled N1 and N2 .Bar graphs showing the (c) O/C ratio and (d) N/C ratio 
for different surface modification schemes C-H tested for both unmodified-PMMA and O2-
PMMA (plasma treated PMMA), obtained from XPS data. Deconvoluted C1s spectra for (e) 
unmodified, (f) O2-PMMA and (g) NH2-PMMA obtained by reacting the plasma activated 
PMMA with 1 M ethylenediamine in the presence of EDC. PMMA peaks are labeled and 
assigned to the polymer’s monomer. Spectra for the plasma activated PMMA contained an 
additional peak for COOH functionalities and the amine modified surface showed the presence 
of two peaks corresponding to the C-N amine and amide carbon atoms. 
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Further analysis of the XPS data revealed that the atomic ratio of the peak area of the O1s 
peak to the C1s peak was 0.309 ±0.006 with the ratio of the O1s to C1s peak areas ~10.9% less 
for NH2-PMMA compared to u-PMMA. This result demonstrated that not only was nitrogen 
successfully incorporated onto the surface of the PMMA but the amount of oxygen present on 
the surface was less than what was present for the u-PMMA or O2-PMMA. The N/C ratio was 
0.025 ±0.001. The N1s peak obtained was deconvoluted as shown in Figure 4.4b. This peak 
consisted of two individual peaks, one centered at 399.1 eV and the other at 400.9 eV. The peak 
at the lower binding energy corresponded to the N1s core level of an amine (N1), while the 
higher energy peak was assigned to an amide (N2).
39
 The deconvoluted C1s peaks for u-PMMA, 
O2-PMMA and NH2- PMMA are presented in Figure 4.4e-g and described in detail.  
The observations in the XPS data were in agreement with the infrared spectra shown in 
Figure 4.6, which indicated the presence of fewer ester groups for the amine-terminated PMMA. 
Collectively, these results indicated successful oxidation and amination reactions of the PMMA 
surface, an outcome that is important for applications requiring surface modification of the 
nanofluidic devices. 
 AFM Imaging 4.3.2.3
Typically, surface modification reactions induce not only chemical changes but also some 
topographical changes. These changes are in the form of nanometer or sub-nanometer random 
surface roughness on solid walls with roughness amplitude ar. Results obtained from previously 
reported molecular dynamic simulations showed that the roughness may dramatically affect the 
wettability of surfaces and EOF in nanofluidic channels depending on the magnitude of ar.
66
  For 
the case where λD/ar << 1, where λD is the Debye length, the EOF can be significantly different 
compared to λD/ar ~ 1; the presence of a rough surface that is comparable to the double layer 
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thickness can alter the electrical double layer near the surface and significantly reduce the EOF
67
 
and streaming potential.
68
 For a homogeneously charged rough channel (such as considered 
here), the EOF is expected to decrease when the roughness is larger than 5% of the channel 
width.
69
 However, this effect becomes insignificant for surfaces with λD/ar > 1.
70,66
 Also, the 
water contact angle (wettability) is expected to be larger for very rough surfaces than a smooth 
surface with identical chemical properties.
71,62
  
First, we investigated the surface topography of PMMA substrates to monitor any changes in 
surface roughness induced by surface treatment. Figure 4.5 a-c shows representative AFM scans 
for unmodified, plasma and amine-modified PMMA nanoslit devices following assembly of the 
cover plate to the substrates. The measured RMS roughness for u-PMMA nanoslit devices was 
1.16 nm, which originated from the Si master due to ion sputtering. The RMS roughness values 
increased to 1.42 nm for O2-PMMA and 1.63 nm for NH2-PMMA nanoslit devices.  
The roughness of PMMA nanoslits was measured by AFM only because the bottom surface 
could be easily profiled without interference due to tip-wall interactions. Figure 4.5d shows a 
representative AFM image of a nanoslit. AFM scans of 4 µm × 500 nm were acquired for the 
bottom surfaces of the unmodified, plasma and amine modified nanoslits. For the u-PMMA 
nanoslit shown in Figure 4.5e, the measured RMS surface roughness was 0.80 nm. This value 
was approximately equal to the measured roughness obtained from the bottom surface of the FIB 
milled nanoslit in the original Si master (data not shown). After surface modification, there was 
an increase in RMS surface roughness to 1.15 nm and 1.23 nm for the plasma and amine-
modified PMMA, respectively. This increase in surface roughness of O2-PMMA is due to 
etching by the oxygen plasma. However, the increase in surface roughness for the aminated 
surface can be attributed to slight swelling and/or dissolution of the PMMA by the EDC/EDA 
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solution and the additional C-C bonds introduced onto the surface from EDA. (see  Figure 4.5 a-
c). Nevertheless, because the experiments were performed at solution ionic strengths producing a 
debye length which is smaller than ten times the channel dimension but larger than the wall 
roughness (λD > 2.0 nm,)
17,72
 we expect the contributions of surface roughness to wettability and 
EOF in our PMMA nanoslit and nanochannel devices to be insignificant relative to contributions 
from changes in surface chemistry and/or charge.  
 
Figure 4.5 AFM images acquired for (a) u-PMMA (b) O2-PMMA and (c) NH2-PMMA. All 
images were scanned over a surface area of 3 µm x 3 µm (d) AFM characterization of the device 
with 1 µm x 50 nm nanoslit. AFM surface scans of (e) unmodified (f) plasma activated and (g) 
amine-terminated nanoslit in PMMA substrate. This was performed in the nanoslit (4 µm x 
500nm scan size) since the bottom surface could be easily profiled without the interference of 
tip-wall interactions. The measured root-mean-square (RMS) surface roughness was 0.80 nm, 
0.95 nm and 1.03 nm, respectively 
 
 Fourier Transform Infra-red (FTIR) Spectroscopy 4.3.2.4
FTIR was employed to characterize the functional groups on pristine, plasma and amine 
modified PMMA. The typical IR spectrum of pristine PMMA with characteristic peaks between 
4000 and 650 cm
-1
 are shown in Figure 4.6a. The most prominent band was ν(C=O), at 1733 cm-1 
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assigned to stretching of esters. The absorption bands at 1270, 1241 cm
−1 and 1195, 1153 
cm
−1
 could be assigned to ν(C–O) and ν(COC) stretching of an ester, respectively. This spectrum 
correlated well with the absorbance spectrum of PMMA documented in the literature.
39
 After 
plasma treatment, bands appeared at 3430 cm
-1
 and at 1700 cm
-1
 assigned to the ν(O-H) and 
ν(C=O) of a carboxylic acid (Figure 4.6b). Amination with EDA led to peaks at 3396 cm-1 and 
1675 cm
-1
 corresponding to the ν(N-H) stretch of a primary amine and ν(C=O) of an amide 
(Figure 4.6c). These support the XPS results and confirm successful surface modification of the 
PMMA devices. 
 
Figure 4.6 ATR-FTIR Spectra for (a) Untreated (b) Plasma activated (c) Amine modified PMMA 
substrates 
 
 Surface Charge and pH Effects  4.3.3
Considering that a solid in contact with a liquid electrolyte will bear a surface charge, which 
may be due to dissociation of surface groups or specific (nonelectric) adsorption of ions in 
solution, one would expect that the contributions of the surface charge to fluid transport 
dynamics and molecular interactions becomes significant in devices possessing high surface-to-
150 
 
volume ratios. Depending on the solution pH and the surface chemistry, the solid can have either 
a positive or negative surface charge density, σs, described as σs= ∑    ⁄ ; where qi = zie and is 
the net charge of ion i, zi is the valency of ion i, e is the electron charge, and A is the surface area. 
This can be used to compute the number of charged sites per unit area Γ in nm-1.  
Due to the fixed surface charge, an oppositely charged region called the electric double layer 
(EDL), which consists of a layer of immobile surface charge and a layer of mobile counterions, 
develops in the liquid to maintain the electroneutrality of the solid/liquid interface.
73
 In 
nanofluidic channels, the EDL can represent a significant fraction of the total channel volume. 
For a channel filled with a symmetrical 1:1 electrolyte like KCl with ionic concentration c, the 
EDL thickness or Debye length, λD, is represented as (ϵ0ϵrRT/2F
2
c)
1/2
, where F is the Faraday 
constant (C·m
-1
), R is the molar gas constant (J·mol
-1
K
-1
), ϵ0 is the permittivity of vacuum (F·m
-
1
), ϵr is the dielectric constant of the medium, and T is the Kelvin temperature. Depending on the 
ionic concentration, λD can vary from less than 1 nm at high ionic strength to a few tens of 
nanometers at low ionic strength.
27
 
Electrical conductance measurements across nanofluidic channels filled with ionic salt 
solutions have been an approach used to deduce the magnitude of the surface charge density. 
Here, we present a modified electrokinetic model based on the report from Stein et al.
28
 for 
deducing σs. When an external electric field is applied across a nanochannel filled with an ionic 
salt solution, the measured electrical conductance (neglecting electroosmotic effects) is a sum of 
the bulk conductance (GB) and the secondary surface conductance (GS); 
                      (3) 
At high salt concentrations, the surface charges in the nanochannel are shielded by the 
mobile ions and have negligible influence on the ion concentration in the nanochannel. In this 
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case, the ionic transport is dominated by the ions in the bulk solution and GT ≈  B. The value of 
GB depends on the nanochannel dimensions and electrolyte concentration according to the 
following expression;
55,72,45
 
     10
3 ( 
K+
    
Cl
-)        
     
 
     (4)  
where w, L and h are the nanochannel width, length and height, respectively, NA is the 
Avogadro constant, c is the electrolyte concentration in mol/L, n  is the number of nanochannels 
and μK+ and µCl
-
 are the ion mobilities of K
+
 and Cl
-
 ions, respectively (μK+ = 7.619 × 10
-8 
m
2
/V s 
and µCl
- 
= 7.912 × 10
-8
 m
2
/V s).  At low salt concentrations, the nanochannels are filled with 
counterions. For electroneutrality inside the nanochannel, excess counterions in the EDL 
compensate for the net surface charge, which governs the excess counterion concentration ce 
(mol/L) inside the channel.
74
 GB becomes negligible and σs governs the total ion conductance in 
the nanochannel (GT ≈  S). Considering that a nanochannel possesses four surfaces in contact 
with the electrolyte solution and by the principle of charge conservation, ce is given by;  
   e  mol L⁄   = 10
-3  
2 σs (     )
        
      (5) 
For 1D nanochannels (i.e., nanoslits), such as reported by Stein et al.,
28
 Schoch et al.,
55
 
Karnik et al.,
46
 and Martins et al.,
45
  h << w; hence (w + h) ≈ w. However, for 2D nanochannels 
with h ≤ w, the channel width also contributes to ce and GS. Therefore,  
    =  2     σs  
(     )
 
      (6)  
Substituting equations (2) and (4) into equation (1) yields the expression; 
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   (7) 
When GB ≈ GS, a transition ion concentration, ct is observed on the log-log plot of GT 
versus the ion concentration.
55
  
152 
 
We investigated the effects of surface modification of polymer nanofluidic devices by 
experimentally measuring the surface charge density of modified PMMA nanoslits and 
nanochannels by monitoring ionic conductance plots performed on nanofluidic devices. Figure 
4.7a and 4.7b show the conductance traces for an array of surface modified nanoslits (22 µm × 1 
µm × 50 nm) and nanochannels (45 µm × 120 nm × 120 nm) measured over the range of 
concentrations between 10
-5
 M and 1 M KCl in Tris buffer (pH 7.8). In both nanofluidic devices, 
the conductance results obtained before and after surface modification differed essentially in the 
low ionic concentration regime. This effect is characterized by a shift of the plateau conductance 
suggesting a change in the surface charge dependent on the nature of the modification.  When the 
modified surfaces were in contact with a KCl solution at pH 7.8, ~99.9 % of the surface –COOH 
groups (pKa = 4.66) would be deprotonated and ~99.0% of the –NH2 groups (pKa = 10.42) 
would be protonated.
75
 At extreme pH values and very low buffer concentrations, the total 
counterions in solution necessary to maintain electroneutrality are H
+
 and K
+
 for the O2-PMMA 
and Cl
-
 and OH
-
 for the NH2-PMMA devices. However, at pH 7.8 and KCl concentration ≥10
-5
 
M, [K
+
] >> [H
+
] and [Cl
-
] >> [OH
-
] ([H
+] ≈ 1.6 × 10-8 M and [OH-] ≈ 6.31 × 10-7 M); hence, GS 
is computed from equation (4) using µK+ and µCl- as µopp for the –COO
-
 and –NH3
+
 surfaces, 
respectively. Nevertheless, due to the different size of the K
+
 (0.27 nm) and Cl
-
 (0.36 nm) and 
the discreteness of the water molecules, we expect differences in surface conductance between 
the positively and the negatively charged channel.
76
 
At a KCl concentration greater than 10
-2
 M (geometry governed region), the measured ionic 
conductance in both the nanoslits and nanochannels fit linearly with the theoretical bulk 
conductance (Fig. 4.7) and was reproducible from one device to another. This confirmed that 
there was no significant change in the dimensions of the fluidic channels during thermal 
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imprinting, device assembly and surface chemical modification with EDC/EDA. However, at 
low electrolyte concentrations (surface charge-governed regime), the nanochannel conductance 
deviated from linearity and plateaued for both the plasma and amine treated PMMA nanoslits 
and nanochannels with the measured surface conductance lower for the –NH3
+ 
terminated 
devices compared to the –COO- terminated devices.  
          
Figure 4.7 Conductance plots obtained from surface modified devices consisting an array of (a) 
four nanoslits (each 1 µm wide, 50 nm deep and 22 µm long), and (b) seven nanochannels (each 
120 nm wide, 120 nm deep and 45 µm long) (square and circle markers represent the data 
obtained for the plasma and amine modified surfaces, respectively. The solid blue line represents 
the trace of the theoretical bulk conductance calculated with equation (2)). Each data point 
represents the average of five measurements with a scatter in the data within 5-8% of the mean 
value. From the graph, the effective surface charge density as calculated from the transition 
concentration, ct, was 38.2 mC/m
2
 for plasma treated nanoslit, 28.4 mC/m
2
 for amine treated 
nanoslit, 40.5 mC/m
2
 for plasma treated nanochannel and 22.9 mC/m
2
 for the amine treated 
nanochannel. 
 
For the nanoslit devices, the average surface conductance at this region was 7.5 × 10
-10
 S for 
the O2-PMMA device. After amination, the conductance dropped to 3.8 × 10
-10
 S, ~50.7 % of its 
original value (Fig. 4.7a). The transition concentration, ct, used to compute σs was approximately 
6.60 mM and 3.52 mM for the plasma and amine modified surfaces, respectively. For plasma 
treated PMMA nanoslits, we obtained |σs| of ~ 38.2 mC/m
2
, which was less than 60 mC/m
2
 
reported by Stein et al.
28
 and 214 mC/m
2
 reported by Schoch et al.
55
 for glass-based nanoslits 
measured at pH 8. For the amine modified nanoslit, |σs| was 28.4 mC/m
2
. In the nanochannels, 
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the conductance in the low ionic strength region for the amine-modified device dropped to 
~67.6% of its plasma modified counterpart. The surface charge densities were 40.5 mC/m
2
 and 
22.9 mC/m
2
 for the plasma and amine devices, respectively.  
We also monitored the effect of pH on the surface charge density of nanoslits and 
nanochannels. As depicted in Figure 4.8 for both the plasma modified nanoslits and 
nanochannels the surface charge gradually increased as the pH of the electrolyte solution 
increased because at low pH (high H
+
 concentration), the surface carboxy groups are converted 
to the protonated form. This leads to a corresponding measurable decrease in the surface 
conductance as less counterions are attracted into the fluidic channel. On the other hand, at high 
pH, the –COOH groups become deprotonated and are converted to the negatively charged –
COO
-
 thereby increasing σs.  
 
Figure 4.8 Plot showing the effect of pH on the surface charge density σs, in plasma and amine 
modified nanoslits and nanochannels 
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For the amine modified surfaces, an opposite trend was observed. The measured surface 
conductance was higher at low pH values and lower at high pH. This is due to the conversion of 
the reactive –NH2 groups to the positively charged –NH3
+
 groups. At pH ≥ 8, the surfaces of the 
O2-PMMA devices were fully deprotonated and the |σs| for the nanochannel was found to be 
greater than the nanoslits. The values were 38.3 mC/m
2
 (Γ ≈ 4.2 nm-2) and 40.5 mC/m2 (Γ ≈ 4.0 
nm
-2
) for the fully deprotonated PMMA nanoslit and nanochannel, respectively. These values 
were found to remain relatively constant at pH > 10. In the nanochannel, the width was 
comparable to the height and the implication is that the surface charge density contribution from 
the vertical walls, which is typically neglected in the nanoslits, also contributed to ion transport 
within the channel.
77
 Surplus counterions would be attracted into the nanochannel and more 
coions will be excluded. Despite the contribution of vertical surfaces on the aminated surfaces, at 
pH ≤ 8, |σ| was greater in the nanoslits than the nanochannels. This is likely due to incomplete 
conversion of the carboxyl functional groups into the amine groups in the nanochannels for the 
reaction conditions reported, a consequence of EDA depletion in the nanochannel with higher 
surface-to-volume ratio when compared to the nanoslit.  
 Electrical Model of a Nanofluidic Device 4.3.4
Figure 4.9a shows the experimental setup of a nanofluidic device setup for conductance 
measurements and the equivalent circuit (Figure 4.9b). The device contained two oppositely 
placed V-shaped access microchannels (with equal dimensions) and two reservoirs placed at both 
ends of the microchannel for introducing fluids into the nanochannels. We represented the total 
voltage applied across reservoirs 1 and 3 as V and the voltage drops across the micro- and 
nanochannel as Vm and Vn, respectively. In this study, it was important that the microchannel 
dimensions were carefully controlled in such a way that most of the voltage drop across the 
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device occurred within the nanochannel. The measured electrical resistance, R, across reservoirs 
1 and 3 for a given electrolyte was expressed as a combination of the resistance of the 
microchannels, Rm, and that of the nanochannel, Rn:  
   
  
 
 2          (8)  
 
Figure 4.9 (a) Schematic showing the experimental setup for measuring the conductance of the 
nanochannels. It shows the nanofluidic device interfaced to an axopatch 200B amplifier 
connected to a Digidata 1440A and computer for readout. (b) Diagram showing the voltage drop 
and resistances across micro- and nanochannels. (c) Current versus time trace showing the 
current generated across the nanoslit arising from the replacement of a low ionic strength buffer 
(0.05 M KCl in 10 mM Tris buffer phosphate buffer) with a higher ionic strength buffer (0.1 M 
KCl in 10 mM Tris buffer) for the O2-PMMA nanoslit. The buffer replacement within the 
nanochannel arises from the electroosmotic flow. 
 
To assess the percent voltage drop across each nanofluidic array, the mixed-scale devices 
were filled with 0.5 M KCl and the values of Rm and R measured using the Axopatch 200B 
current amplifier. From these values, Rn/n was calculated for the nanoslits (n = 4) and 
nanochannels (n = 7) using equation (8) and the voltage drop calculated from;  
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%V  = [(
  
 
)  ⁄ ] ×100       (9) 
The data is summarized in Table 4.1 
Table 4.1. Measured and calculated electrical resistances across the microchannel Rm, 
nanoslit/nanochannel Rn and percent voltage drop. 
 
Device 
Dimensions of 
Nanofluidic device 
(l × w × h) 
 
Rm (kΩ) 
 
R (MΩ) 
 
  
 
 (MΩ) 
Voltage 
drop 
(%V) 
Nanoslit  22 µm × 1 µm × 50 nm 501.7 ± 10.2 19.9 ± 1.2 18.9 ± 1.1 95.2 ± 1.1 
Nanochannel 45 µm × 50 nm × 50 nm 997.2 ± 12.5 60.9 ± 1.8 58.9 ± 1.6 96.7 ± 1.2 
 
 Electroosmotic Flow (EOF) Measurements 4.3.5
The electroosmotic flow is a surface driven fluidic transport that is generated when an 
external electric field E, applied in the direction tangential to the wall of a channel filled with an 
electrolyte solution, induces a fluid drag by motion of ions in the EDL. Because of its scalability 
and ease-of-control, electroosmotic transport has been widely used in many nanofluidic systems. 
The EOF can be described in terms of a mobility, µeof = υeof/E, where υeof is the steady-state bulk 
EOF velocity. It is possible to derive an expression for µeof from the solvent viscosity η, and the 
zeta potential ζ using the Helmholtz-Smoluchowski relation:78  
 
   
 = 
ϵ0 ϵr ζ
η
        (10)  
The Zeta potential depends on σs and λD for different electrolyte solutions as noted by the 
nonlinear Poisson-Boltz-Mann equation:
41, 79
  
ζ  =  
2     T
 
   [ 
2      λ 
ϵr ϵ0    T
  + √1+ [
(
  λ 
ϵr ϵ0    T
⁄ )
2
4
]   ]    (11) 
With ϵ0 and ϵr constants, conditions that cause a change in the σs, ζ, λD, or η will alter the 
magnitude of the EOF.  
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Typically, µeof is measured using the well-established current monitoring method.
80
 In this 
work, 0.1 M and 0.05 M KCl solutions were used for the measurement to allow for the 
generation of a large amount of readable current and measurements at regions with the EDL (see 
Figure 4.9c for a typical current trace). For this investigation, we fabricated PMMA devices 
possessing a single nanofluidic channel, 138 µm long, interfaced across two access 
microchannels as shown in Figure 4.1c and 4.1f. This single channel geometry eliminated errors 
in migration time that may arise due to preferential filling across an array of nanochannels during 
electrolyte replacement. A negative EOF value indicated that the solution flow was from cathode 
to anode and consistent with a positively charged fluidic channel wall. Positive values indicated 
a negatively charged wall and a reverse EOF. 
Previously, we have shown that exposing PMMA to controlled plasma conditions can 
generate carboxylate groups with a surface coverage of 2.7 ± 0.5 × 10
-9
 mol/cm
2
.
43
 We also 
reported the EOF (pH 7.4) for carboxylated and NH2-terminated PMMA microfluidic devices to 
be 4.43 ±0.58 × 10
-4 
cm
2
/ Vs and -1.34 ±0.21 × 10-4 cm2/Vs, respectively.37 As shown in Table 
4.2, we obtained an EOF mobility of 0.93 ±0.03 × 10
-4
 cm
2
/Vs and -0.82 ±0.01 × 10
-4
 cm
2
/Vs for 
plasma activated and NH2-terminated PMMA nanoslits, respectively. For the plasma and NH2-
terminated PMMA nanochannels, the EOF was found to be 1.02 ±0.02 × 10
-4 
cm
2
/Vs and -0.75 
±0.02 × 10
-4
 cm
2
/Vs, respectively. The trend and magnitude of the EOF mobilites observed in the 
PMMA nanofluidic devices scales with the measured surface charge density in the nanochannel 
and was consistent with the molecular dynamic simulation results reported by Qiao et al.
81
 The 
values reported above for the O2-PMMA nanochannels were similar to that reported by Menard 
et al.
17
 for fused silica nanochannels (≤ 100 nm) measured using 2X TBE, with 2% 
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polyvinylpyrrolidone (PVP) (0.79 ±0.01 × 10
-4 
cm
2
/Vs) and ~35.8 ±4.4% lower when compared 
to the value obtained in fused silica measured with only 2X TBE (1.58 ±0.01 × 10
-4
 cm
2
/Vs).  
Table 4.2 Measured and expected EOF mobility values as well as surface charge and zeta 
potentials for the plasma activated and amine terminated devices investigated at pH 7.8. 
 
 
Device 
 
Terminating 
groups 
 
    (mC/m
2
) 
 
ζ (mV) 
µeof (cm
2
/Vs) × 10
-4
 
Expected* Measured 
Nanoslit 
O
2
-PMMA 
NH
2
-PMMA 
- 38.3 
28.4 
- 57.1 
45.8 
4.53 
- 3.63 
0.93 ± 0.025 
- 0.82 ± 0.012 
Nanochannel 
O
2
-PMMA 
NH
2
-PMMA 
- 40.5 
22.9 
- 59.8 
38.3 
4.74 
- 3.04 
1.02 ± 0.017 
- 0.75 ± 0.021 
*Calculated from equation (7) using the values for  s and ζ 
A possible reason for the low EOF observed in the PMMA nanofluidic device is the low ζ 
potential of the surface (at the reported experimental conditions). This conclusion is supported by 
the results from the continuum theory, based on the Poisson–Boltzmann equation for the ion 
distribution and Navier–Stokes equations for the fluid transport,78 and the atomistic 
simulations.
81
 Both models show that the EOF in a nanofluidic channel varies almost linearly 
with the ζ, with the latter model true for surface charge densities ≤ 80 mC/m2.81 As previously 
described, the zeta potential depends on the chemistry of the solid–fluid interface and is related 
to the surface charge density by parameters such as the ionic strength, density of chargeable sites 
on the surface, their pKa values and the solution pH, which modulates the rate of dissociation of 
the surface groups (see Figure 4.8). However, the difference in the EOF values observed for the 
negatively charged O2-PMMA devices when compared to the positively charged NH2-PMMA 
devices is due to the difference in the distribution of counterions in both devices due to the 
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different size of the K
+
 and Cl
-
 ions.
76
  Therefore, at a fixed pH and electrolyte concentration, as 
the surface σs reduces, ζ is lowered resulting in a corresponding lowering effect on the EOF.  
Although the trend of the measured EOF mobilities in the PMMA nanofluidic devices 
presented in Table 4.2 followed the results of the surface charge density, they remained less than 
the expected values, which were similar to that observed in the microchannels. The expected 
values were calculated using λD ≈ 1.5 nm and assuming that the µeof is independent of the size or 
shape of the channels but rather on the charge distribution around several tens of nanometers 
from the surface of the channels. However, recent reports have shown that downsizing the size of 
fluidic channels from the micro- to nano- dimensions can result in reduction of the net flow 
(EOF) within a channel due to the apparent increase in the viscosity of a fluid confined in the 
charged nanochannel resulting from the induced counterflow of the streaming potential to the 
electroosmotic flow.
82-85
 This phenomenon, termed electroviscosity, can cause the ratio apparent 
viscosity to the true viscosity to be as high as 1.3 depending on the material of the channel wall, 
with spatial size and shape of the channel, the ionic concentration, zeta potential, temperature, 
dielectric constant and other properties of the liquid.
84
 In the derivation of equation (6), the 
electroviscous effect was not considered. However, due to relatively higher ζ in glass based 
devices, large streaming potentials are generated resulting in greater electroviscosity in than 
polymer devices. This can explain why the EOF measured in glass nanoslits at pH 8.5 (~1.3 × 10-3 
cm
2
/Vs) was lower than that of fused silica and glass capillaries (5 × 10
-4
 cm
2
/Vs and 1.5 × 10
-3
 
cm
2
/Vs, respectively)
86
 or glass microchannels (4.82 × 10
-4
 cm
2
/Vs).
87
 It also described the 
reason for low EOF observed in a glass microchannel device populated with nanopillars spaced 
by ~700 nm (1 × 10
-5
 cm
2
/Vs).
88
 In PMMA nanoslits and nanochannels, the zeta potential was 
lower for the conditions reported. The implication is that small streaming currents will be 
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generated and the contributions of electroviscosity to the EOF will be minimal; hence, the 
measured EOF will be due majorly due to low surface charge densities.  
In summary, our results reveal that in polymer nanofluidic devices (nanoslit or 
nanochannels), the surface modification scheme adopted, pH and ionic strength of the electrolyte 
play crucial roles in determining the magnitude of the surface charge density and the extent of 
electroviscosity effects on the EOF. Parameters that take predominance will depend upon the 
spatial size of the fluidic device. The effects of Joule heating on the solution viscosity in these 
channels were considered negligible because very small electric currents were generated due to 
the high nanochannel resistance compared to microchannels (see Table 4.1).  
 Conclusions 4.4
In this work, we reported the successful modification of thermoplastic nanoslits and 
nanochannels for the first time to the best of our knowledge. Carboxyl moieties were generated 
by plasma activation and amino groups were introduced by reaction with EDC and covalent 
coupling of EDA molecules. The presence of the surface functional groups was confirmed by 
wettability/surface energy studies and XPS/FTIR analysis. Changes in surface topography 
induced from surface modification were assessed using AFM. The effect of pH on the surface 
charge density σs in the nanofluidic devices was reported and the EOF in the plasma activated 
and amine-terminated devices was measured. The magnitude of σs and ζ for the polymer 
nanofluidic devices were carefully controlled by the choice of substrate, plasma dose and pH of 
the electrolyte solution.  
For the conditions reported in this work, the plasma treated polymer nanoslits and 
nanochannels were observed to possess |σs| of 38.2 mC/m
2
 and 40.5mC/m
2
, respectively, at pH 
7.8. These values were lower than that reported for the glass-based counterpart (60 mC/m
2
) 
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thereby making polymer nanochannels a great prospect in applications involving molecular 
separations. Also, low surface charge densities in fluidic devices help to minimize artifacts of ion 
exclusion from concentration polarization. The ability to generate positively charged –NH3
+
 
moieties in a simple modification scheme with |σs| of 28.4 mC/m
2
 in the nanoslits and 22.9 
mC/m
2
 in the nanochannel offer a unique venue for performing nanochannel chromatography. 
The substrate material can potentially serve as the stationary phase without the need for 
appending different monolayer assemblies to the support and the solute/wall interactions of 
biomolecules traversing through the nanochannels can be investigated.  
The reduced EOF observed in the PMMA devices compared to polymer microchannels and 
glass nanochannels was likely due to lower surface charge density (and zeta potential) for 
polymer devices and electroviscosity effects due to confinement. Generally, low EOF is 
desirable in applications involving DNA analysis for regulation of gene expression, mapping and 
sequencing since it enables the introduction of these biomolecules into the fluidic channels 
without the need of EOF suppressors. Polymer nanofluidic devices can be tuned to possess the 
desired surface functionality and charge density by carefully controlling the modification 
protocol that is employed. We are currently investigating the electrokinetic properties of other 
viable thermoplastic substrates for the fabrication of nanochannels.  
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CHAPTER 5 FUTURE WORK: INTEGRATION OF TASK SPECIFIC 
MODULES TO DEVELOP A MODULAR FLUIDIC BIOPROCESSOR FOR 
POINT-OF-CARE DIAGNOSIS OF STROKE 
  
 Introduction 5.1
Emerging innovations of point-of-care (POC) diagnostic test devices is due to their ability to 
provide rapid results on an ever expanding range of medical tests.
1
 The need for extremely 
simple (in terms of use without need for trained personnel) devices in POC applications has 
fueled an interest in the construction of field deployable instruments using microfluidics.
2
 As 
mentioned earlier in chapter 1, various biomarkers have been reviewed and their role in clinical 
utility has been signified.  The need for a POC device arises from the longer times required for 
clinical distinction of subtypes of stroke with existing neuroimaging methods and shorter time 
window available for treatment and patient management. POC devices also reduce the turn-
around-time (TAT) for the identification of stroke subtype in a prehospital setting as a 
confirmation test for diagnosis. 
Attractive features offered by microfluidics like low consumption of reagents and samples, 
miniaturization, and fast turnaround time for analysis to perform various laboratory functions 
and assessments make them a perfect fit for point-of-care diagnostic devices. These devices are 
fully enclosed due to which a there is a reduction in contaminant carryover, sample dilution and 
losses. In addition, microfluidics is a versatile technology which offer features such as feasibility 
of integrating electronics, reconfigurability, the possibility of automation and high throughput, 
miniaturization of complex fluid handling and integrated detection. Various proof- of-concept 
studies have shown the advantages of lab-on-a-chip (LOC) systems over laboratory testing.
3-6
 
Transformation of microfluidic systems into point-of-care diagnostic systems from a laboratory 
into clinical setting requires automation and also efficient strategies for combining several 
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individually tested modules including pumping, valving, mixing and sample preparation 
obviating the need for moving or spinning components. The ultimate goal is to achieve 
resolution & sensitivity similar to benchtop instruments.  
 Proposed Molecular Processing Strategy 5.2
We focus on developing a portable, automated instrument which would serve as a near patient 
technology for the diagnosis of ischemic and/or hemorrhagic stroke using mRNA expression 
profiling directly from whole blood within a processing time <20 min to accommodate effective 
therapeutic treatment of this disease. This will be achieved by developing a fluidic bio-processor 
fabricated in polymers via micro-replication technology and integrating task specific modules on 
a fluidic motherboard. The material selected for each module will depend selected for each module 
based upon the application needed to produce optimal performance. All the relevant steps required for 
the molecular assay are depicted in Figure 5.1. 
 
Figure 5.1 Processing pipelines using a conventional bench-top strategy for processing mRNAs 
specifically for obtaining expression data and the processing pipeline that will be employed in 
POC system for the rapid reporting of mRNA signatures associated with stroke.  
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This includes i) cell isolation (i.e., positive selection of T-cells and neutrophils), ii) cell lysis of 
isolated cells, extraction/purification of the target material (mRNA), iii) thermal enzymatic 
reactions including reverse transcription (RT) to build cDNAs iv)  Ligase detection reaction 
(LDR) to generate molecular beacons unique to each mRNA biomarker using primers that carry 
reporter sequences for the target and readout of successful ligation events using single pair 
Fluorescence Resonance Energy Transfer (spFRET).The use of spFRET obviates the need for a 
PCR step, which not only reduces processing time, but also produces exquisite analytical 
sensitivity. The most important and notable feature of the molecular processing strategy 
delineated in Figure 5.1, is the TAT. When compared to a conventional approach for mRNA 
expression profiling, TAT is projected to be ~45 min for the proposed strategy compared to the 
conventional approach, which may require nearly 11 h to secure similar information. Next 
sections will provide a description of each processing step and the fluidic device for its 
implementation. Detailed description of each of these modules will be given in the next sections.  
 Fluidic Bioprocessor for mRNA Expression Profiling 5.3
A fully integrated polymer-based fluidic bio-processor for mRNA expression profiling will 
consist of individual or a group of processing steps poised on a single module and systems built 
from modules connected to a fluidic motherboard. All these modules will be combined in plug 
and play like setup.The primary advantages of this design approach include; (1) the ability to 
match the material properties to the processing step(s) situated on the chip; (2) allow individual 
testing of the modules to optimize performance; (3) simplify the fabrication process for 
producing integrated systems; and (4) provide flexibility in assembling modules to accommodate 
different assay strategies. Wang et al. demonstrated this approach for POC detection of 
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Mycobacterium Tuberculosis (Mtb).
7
 This system could determine the multi-drug resistance of 
Mtb resulting from strains that fail to respond to first-line drugs, such as rifampin. 
 
 
Figure 5.2 Fluidic bio-processor for the analysis of mRNAs in PBMCs. The fluidic bio-processor 
has 3 modules that are used for positive cell selection (T-cells and neutrophils), (2) SPE 
isolation/purification of RNA (3) and spFRET readout (4). All these modules will be “plugged” 
into a fluidic motherboard. Also shown are locations of on-chip valves (V) pumps (A-F) and 
high-aspect ratio mixers (M). A – sample input; B – lysing buffer; C – SPE buffer; D – ethanol; 
E – RT cocktail; F – LDR cocktail; G – connection to off-chip vacuum pump. Box in red shows 
the modules which have been described in previous chapters. 
 
The proposed fluidic bio-processor shown schematically in Figure 5.2 consists of different 
modules. In chapters 2 & 3, we have focused our efforts to isolate T-cells and neutrophils. For 
this application, cell sorting module was fabricated in COC due to its high optical transparency 
and uniform modification of high aspect-ratio channels.
8
 We were able successfully isolate the 
cells of interest and isolate TRNA from the lysate of these cells both by commercially available 
silica columns and also by using UV activated PC SPE module. The RNA SPE module and 
fluidic motherboard are made from PC due to its relatively high glass transition temperature to 
allow it to withstand the temperatures required for the thermal reactions and also its unique 
characteristic to allow the SPE of nucleic acids For the initial studies, TRNA was reverse 
transcribed to cDNA and amplified via bench top PCR.
9-11
  Gene expression studies were shown 
for a housekeeping gene (GAPDH), a gene overexpressed in ischemic stroke event (S100A9), T-
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cell specific gene (TCRB) and neutrophil specific gene (FPR1). However, gene expression of 
mRNA’s specific for ischemic and hemorrhagic stroke are yet to be studied. In order to reduce 
the final TAT, gene expression analysis can also be performed by carrying out reverse 
transcription (RT) in a continuous flow mode on a microfluidic chip. An mRNA will be copied 
to cDNA in continuous flow reverse transcription (CFRT) using an oligo dT primer. CFRT’s will 
be used for the RT and LDRs with the devices optimized for processing speed and product yield. 
Reaction time (RT phase) and the number of thermal cycles (LDR phase) required for obtaining 
viable quantitative information from the mRNA transcripts required for the stroke diagnosis will 
be investigated. 
  Fabrication of Microfluidic Modules 5.4
Polymer microchips can be replicated from metal masters using either hot embossing or 
injection molding with the principle advantages of this fabrication protocol being; (1) the ability 
to produce large quantities of microchips at low-cost; (2) once the master is made, a wide 
selection of materials can be used for the final parts without requiring additional lithographic 
processing; (3) mixed-scale, multi-level and double-sided molding can be used to fabricate the 
prerequisite microchips. The metal masters can be made using a variety of techniques, including 
UV-LiGA, X-ray LiGA or high precision micromilling, with the choice predicated on the 
required structures and the stage of development of the microchip; we have developed the 
infrastructure to generate masters using all of these techniques.
10, 12-14
 As the fluidic bio-
processor is to be used for diagnostic applications requiring one-time use operation, it is critical 
to simplify the manufacturing of this fluidic processor to reduce chip cost. 
As seen from Figure 5.2 the fluidic bioprocessor will consist of 3 modules with 1 made in 
PMMA and another in the appropriate waveguiding material (blue, see Figure 5.2) and the third 
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made from PC (light gray). The fluidic motherboard in which the modules will be inserted using 
the appropriate interconnect technology will be made from PC. The modules and motherboard 
will be replicated from metal masters fabricated by lithographic or non-lithographic techniques 
with the selected technique based on the required dimensional features of each. These masters 
will be then used to replicate parts in the appropriate polymeric substrate using hot-embossing.
12, 
14, 15
 The spFRET readout module must be made of a polymeric material that has favorable 
optical properties and also, supports waveguiding. 
For structures possessing lateral dimensions below 20 μm and aspect ratios exceeding 5:1, 
UV-LiGA must be used to make the mold master. For the hemispherical lenses, we will use X-
ray LiGA to fabricate the mold master. Whichever fabrication technique we use, the master is 
used to replicate the appropriate parts via hot embossing (Jenoptik HEX02). Through-holes 
required as the interconnects between modules can be made using excimer laser drilling, which 
can machine holes ~50 μm in diameter through a substrate as thick as 2 mm.10 The exact channel 
lengths and cross-sectional dimensions will be determined from experimental results. As can be 
seen in Figure 5.2, several mixers in the fluidic motherboard are required. Because flow in 
microchannels is laminar (Re << 100), the rate of mixing between two miscible fluids is 
determined by molecular diffusion. To facilitate mixing between sample and reagents and to 
keep the bio-processor operation simple, we will employ a Y-shaped, high-aspect ratio (AR, 
where AR = channel height / channel width) passive micromixer configuration (see Figure 5.2). 
In this type of mixer, input streams are fed into a narrow but deep channel, which effectively 
increases the contact area between the two streams and reduces diffusional distances. The 
increased channel depth also keeps the pressure drop low when feeding liquids into this narrow 
channel.  
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 LDR/spFRET for mRNA Quantitation 5.5
The molecular assay’s foundation is based on the ability to identify unique sequences from 
mRNAs (actually cDNA) using an LDR coupled to spFRET.
16
 In this project, we do not will 
expression profile single cells, but detect single mRNA molecules through their respective 
cDNA surrogates subjected to a LDR (superior sequence specificity for single base variations
17
) 
 to form molecular beacons undergoing spFRET that are digitally counted to provide 
exquisite analytical sensitivity. The major advantages of this single molecule detection in 
molecular analyses include; (1) the ability to alleviate the need for amplifying the target material 
via PCR, which produces potential difficulties in obtaining quantitative information; (2) reduces 
the number of processing steps and; (3) significantly reduces processing time and assay cost. 
 
Figure 5.3 Illustration of LDR-spFRET assay
18
 
LDR involves the use of two primers that recognize a reporter sequence of the target, which 
in this case is a cDNA, and ligates the two primers only if there is complete complementarity 
between the primers and the cDNA. If this condition is met, the primers are successfully ligated, 
179 
 
forming a molecular beacon bringing the donor/acceptor dyes into close proximity to allow for 
spFRET to occur (see Figure 5.3). If the primers are not perfectly matched to the reporter 
sequence of the cDNA, no ligation occurs and consequently, no spFRET results. LDR-spFRET 
provided the necessary specificity and sensitivity to detect single point mutations in as little as 
~600 copies of human genomic DNA without PCR at a level of 1 mutant per 1,000 wild- type 
sequences in less than 5 min.
16
 
 Inter and Intra Modular Assembly 5.6
In this phase of the project, the individual fluidic modules required for each processing 
step of the molecular assay will be integrated to form a fluidic bio-processor consisting of task-
specific modules assembled to a fluidic motherboard using the appropriate interconnect 
technologies. Super hydrophobic seals will be used to prevent “leakage” of fluid at the 
interconnects. Various interconnect geometries and architectures will be evaluated as well. To 
align the modules during assembly, V-grooves and pins (kinematic constraints) will be used. 
Effective thermal isolation between modules will also be investigated and optimized. 
While the proposed system is targeted for field diagnosis of stroke using mRNA biomarkers, 
the system can be envisioned for other applications as well that require quantitative expression 
analysis of mRNA. In the case of stroke diagnoses, the fluidic bio-processor can be configured to 
detect other biomarkers necessary for the diagnoses, such as serum proteins, without hardware 
reconfiguration.  
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